
<html lang="en"     class="pb-page"  data-request-id="22afc87e-2415-4c0b-84fa-a69b40fed971"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01867;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter" /></meta><meta name="dc.Creator" content="José Luis  Díaz" /></meta><meta name="dc.Creator" content="Félix  Cuevas" /></meta><meta name="dc.Creator" content="Gonzalo  Pazos" /></meta><meta name="dc.Creator" content="Paula  Álvarez-Bercedo" /></meta><meta name="dc.Creator" content="Ana I.  Oliva" /></meta><meta name="dc.Creator" content="M. Ángeles  Sarmentero" /></meta><meta name="dc.Creator" content="Daniel  Font" /></meta><meta name="dc.Creator" content="Agustín  Jiménez-Aquino" /></meta><meta name="dc.Creator" content="María  Morón" /></meta><meta name="dc.Creator" content="Adriana  Port" /></meta><meta name="dc.Creator" content="Rosalía  Pascual" /></meta><meta name="dc.Creator" content="Albert  Dordal" /></meta><meta name="dc.Creator" content="Enrique  Portillo-Salido" /></meta><meta name="dc.Creator" content="Raquel F.  Reinoso" /></meta><meta name="dc.Creator" content="José Miguel  Vela" /></meta><meta name="dc.Creator" content="Carmen  Almansa" /></meta><meta name="dc.Description" content="The synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the α2δ-1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine t..." /></meta><meta name="Description" content="The synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the α2δ-1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01867" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01867" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01867" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01867" /></link>
        
    
    

<title>Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01867" /></meta><meta property="og:title" content="Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0016.jpeg" /></meta><meta property="og:description" content="The synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the α2δ-1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET) are reported. Exploration of the positions amenable for substitution on a nonaminoacidic Cavα2δ-1 scaffold allowed the identification of favorable positions for the attachment of NET pharmacophores. Among the patterns explored, attachment of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one framework to the meta-position of the phenyl ring of the 3-methylamino-1-phenylpropoxy and 3-methylamino-1-thiophenylpropoxy moieties provided dual compounds with excellent NET functionality. Alternative bicyclic frameworks were also explored, and some lead molecules were identified, which showed a balanced dual profile and exhibited good ADMET properties." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01867"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01867">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01867&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01867&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01867&amp;href=/doi/10.1021/acs.jmedchem.0c01867" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 2167-2185</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01785" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01967" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">José Luis Díaz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">José Luis Díaz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Luis++D%C3%ADaz">José Luis Díaz</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8812-4689" title="Orcid link">http://orcid.org/0000-0001-8812-4689</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Félix Cuevas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Félix Cuevas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=F%C3%A9lix++Cuevas">Félix Cuevas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gonzalo Pazos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gonzalo Pazos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gonzalo++Pazos">Gonzalo Pazos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paula Álvarez-Bercedo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paula Álvarez-Bercedo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paula++%C3%81lvarez-Bercedo">Paula Álvarez-Bercedo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ana I. Oliva</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana I. Oliva</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana+I.++Oliva">Ana I. Oliva</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">M. Ángeles Sarmentero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">M. Ángeles Sarmentero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M.+%C3%81ngeles++Sarmentero">M. Ángeles Sarmentero</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Font</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Font</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Font">Daniel Font</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Agustín Jiménez-Aquino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Agustín Jiménez-Aquino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Agust%C3%ADn++Jim%C3%A9nez-Aquino">Agustín Jiménez-Aquino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">María Morón</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">María Morón</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa++Mor%C3%B3n">María Morón</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adriana Port</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adriana Port</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adriana++Port">Adriana Port</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rosalía Pascual</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rosalía Pascual</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rosal%C3%ADa++Pascual">Rosalía Pascual</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Albert Dordal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Albert Dordal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Albert++Dordal">Albert Dordal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Enrique Portillo-Salido</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Enrique Portillo-Salido</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Enrique++Portillo-Salido">Enrique Portillo-Salido</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raquel F. Reinoso</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raquel F. Reinoso</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raquel+F.++Reinoso">Raquel F. Reinoso</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">José Miguel Vela</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">José Miguel Vela</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Miguel++Vela">José Miguel Vela</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Carmen Almansa</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carmen Almansa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f291939e9f939c8193b285979e9390dc90938091979e9d9c93"><span class="__cf_email__" data-cfemail="95f6f4f9f8f4fbe6f4d5e2f0f9f4f7bbf7f4e7f6f0f9fafbf4">[email protected]</span></a>. Tel.: 0034650697372.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carmen++Almansa">Carmen Almansa</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5665-4685" title="Orcid link">http://orcid.org/0000-0001-5665-4685</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01867&amp;href=/doi/10.1021%2Facs.jmedchem.0c01867" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 2167–2185</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 October 2020</li><li><span class="item_label"><b>Published</b> online</span>16 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01867" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01867</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2167%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJos%25C3%25A9%2BLuis%2BD%25C3%25ADaz%252C%2BF%25C3%25A9lix%2BCuevas%252C%2BGonzalo%2BPazos%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01867%26title%3DBicyclic%2BDiazepinones%2Bas%2BDual%2BLigands%2Bof%2Bthe%2B%25CE%25B12%25CE%25B4-1%2BSubunit%2Bof%2BVoltage-Gated%2BCalcium%2BChannels%2Band%2Bthe%2BNorepinephrine%2BTransporter%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2185%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01867"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">555</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01867" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Luis Díaz&quot;},{&quot;first_name&quot;:&quot;Félix&quot;,&quot;last_name&quot;:&quot;Cuevas&quot;},{&quot;first_name&quot;:&quot;Gonzalo&quot;,&quot;last_name&quot;:&quot;Pazos&quot;},{&quot;first_name&quot;:&quot;Paula&quot;,&quot;last_name&quot;:&quot;Álvarez-Bercedo&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;I. Oliva&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Ángeles Sarmentero&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Font&quot;},{&quot;first_name&quot;:&quot;Agustín&quot;,&quot;last_name&quot;:&quot;Jiménez-Aquino&quot;},{&quot;first_name&quot;:&quot;María&quot;,&quot;last_name&quot;:&quot;Morón&quot;},{&quot;first_name&quot;:&quot;Adriana&quot;,&quot;last_name&quot;:&quot;Port&quot;},{&quot;first_name&quot;:&quot;Rosalía&quot;,&quot;last_name&quot;:&quot;Pascual&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;Dordal&quot;},{&quot;first_name&quot;:&quot;Enrique&quot;,&quot;last_name&quot;:&quot;Portillo-Salido&quot;},{&quot;first_name&quot;:&quot;Raquel&quot;,&quot;last_name&quot;:&quot;F. Reinoso&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Miguel Vela&quot;},{&quot;first_name&quot;:&quot;Carmen&quot;,&quot;last_name&quot;:&quot;Almansa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2167-2185&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01867&quot;},&quot;abstract&quot;:&quot;The synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the α2δ-1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET) are reported. Exploration of the positions amenable for substitution on a nonaminoacidic Cavα2δ-1 scaffold allowed the identification of favorable positions for the attachment of NET pharmacophores. Among the patterns explored, attachment of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one framework to the meta-position of the phenyl ring of the 3-methylamino-1-phenylpropoxy and 3-methylamino-1-thiophenylpropoxy moieties provided dual compounds with excellent NET functionality. Alternative bicyclic frameworks were also explored, and some lead molecules were identified, which showed a balanced dual profile and exhibited good ADMET properties.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01867&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01867" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01867&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01867" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01867&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01867" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01867&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01867&amp;href=/doi/10.1021/acs.jmedchem.0c01867" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01867" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01867" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01867%26sid%3Dliteratum%253Aachs%26pmid%3D33591743%26genre%3Darticle%26aulast%3DD%25C3%25ADaz%26date%3D2021%26atitle%3DBicyclic%2BDiazepinones%2Bas%2BDual%2BLigands%2Bof%2Bthe%2B%25CE%25B12%25CE%25B4-1%2BSubunit%2Bof%2BVoltage-Gated%2BCalcium%2BChannels%2Band%2Bthe%2BNorepinephrine%2BTransporter%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D2167%26epage%3D2185%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the α2δ-1 subunit of voltage-gated calcium channels (Ca<sub>v</sub>α2δ-1) and the norepinephrine transporter (NET) are reported. Exploration of the positions amenable for substitution on a nonaminoacidic Ca<sub>v</sub>α2δ-1 scaffold allowed the identification of favorable positions for the attachment of NET pharmacophores. Among the patterns explored, attachment of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one framework to the meta-position of the phenyl ring of the 3-methylamino-1-phenylpropoxy and 3-methylamino-1-thiophenylpropoxy moieties provided dual compounds with excellent NET functionality. Alternative bicyclic frameworks were also explored, and some lead molecules were identified, which showed a balanced dual profile and exhibited good ADMET properties.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The treatment of pain constitutes an important challenge since current therapies are suboptimal and hampered by side effects, which contribute to noncompliance or limited efficacy.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Considering that most pain states involve multiple mediators and signaling pathways, both central and peripheral, multimodal analgesic approaches are often used in the clinical practice<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and recommended in management guidelines. Additive or synergistic effects between interventions can enhance analgesia, and efficacy may be achieved at lower doses, potentially reducing the risk of adverse effects.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Combinations of available drugs are often used in the clinic,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> but developing single compounds with multimodal activity may offer some advantages, such as better efficacy, superior treatment compliance (one instead of various pills at potentially different dosage intervals/frequencies), lowering the risk of drug–drug interactions, simpler pharmacokinetics, and less variability among patients, both in drug exposure and response to treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> With this view in mind, we decided to explore the preparation of dual ligands acting at the α2δ-1 subunit of voltage-gated calcium channels (Ca<sub>v</sub>α2δ-1) and at the norepinephrine (NE) transporter (NET, SLC6A2), two mechanisms with clear rationale in the treatment of pain.</div><div class="NLM_p">Voltage-gated calcium channels (VGCC)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> are required for many key functions in the body and are assembled through interactions of different subunits, namely, α<sub>1</sub> (Ca<sub>v</sub>α<sub>1</sub>), β (Ca<sub>v</sub>β), α<sub>2</sub>δ (Ca<sub>v</sub>α<sub>2</sub>δ), and γ (Ca<sub>v</sub>γ). The α<sub>1</sub> subunits are the key porous forming units of the channel complex, regulating Ca<sup>2+</sup> conduction and influx. The α<sub>2</sub>δ, β, and γ subunits are auxiliary but key for increasing the expression of the α<sub>1</sub> subunits in the plasma membrane and modulating their function. VGCC are subdivided into five different subtypes: low voltage-activated T-type (Ca<sub>v</sub>3.1, Ca<sub>v</sub>3.2, and Ca<sub>v</sub>3.3) and high voltage-activated L-type (Ca<sub>v</sub>1.1 through Ca<sub>v</sub>1.4), N-type (Ca<sub>v</sub>2.2), P/Q-type (Ca<sub>v</sub>2.1), and R-type (Ca<sub>v</sub>2.3). Both the Ca<sub>v</sub>1 and Ca<sub>v</sub>2 subfamilies contain an auxiliary α2δ subunit,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> which is also subdivided in four different subtypes: α2δ-1, initially cloned from skeletal muscle and showing a fairly ubiquitous distribution; α2δ-2 and α2δ-3 subunits, cloned from brain; and α2δ-4, recently cloned and largely non-neuronal.</div><div class="NLM_p">The Ca<sub>v</sub>α2δ-1 subunit (and the Ca<sub>v</sub>α<sub>2</sub>δ-2 but not Ca<sub>v</sub>α<sub>2</sub>δ-3 and Ca<sub>v</sub>α<sub>2</sub>δ-4 subunits) is the therapeutic target<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> of pregabalin (<b>1</b>) and gabapentin (<b>2</b>), two widely used drugs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) for treating neuropathic pain<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and fibromyalgia<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> as well as other nonpain indications, such as epilepsy<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> or restless leg syndrome.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The binding of these drugs to the Ca<sub>v</sub>α2δ-1 subunit results in a reduction in the calcium-dependent release of multiple neurotransmitters, and its upregulation in the spinal dorsal horn and dorsal root ganglia after nerve injury correlates with neuropathic pain development.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of described blockers of the Ca<sub>v</sub>α2δ-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An important effort has been devoted along the years to finding new Ca<sub>v</sub>α2δ-1 ligands for the treatment of pain.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Most of the described compounds have aminoacidic structures closely related to <b>1</b> and <b>2</b>, and mirogabalin (<b>3</b>)<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> has been the only newly approved compound in more than 15 years. A few nonaminoacidic structures have also been reported, but none of them have progressed into clinical development. Among others,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Merck reported several Ca<sub>v</sub>α2δ-1 ligands represented by compound <b>4</b>,<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> a structure that was later modified by GlaxoSmithKline<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> to afford compounds such as <b>5</b>, which showed good analgesic activity in the complete Freund’s adjuvant pharmacodynamic model of pain. Finally, Kyowa Hakko Kirin Co., filed two patent families,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> describing pyrimidodiazepinone tricyclic derivatives represented by compound <b>6</b>.</div><div class="NLM_p">On the other hand, NET is a monoamine transporter mostly expressed in the peripheral and central nervous systems, which recycles primarily NE (but also serotonin and dopamine) from synaptic spaces into presynaptic neurons. It is closely linked to the serotonin transporter (SERT), which exerts similar functions with serotonin. NET inhibition provides an increased availability of NE for binding to postsynaptic receptors that regulate adrenergic neurotransmission. Numerous studies have demonstrated that activation of spinal α2-adrenergic receptors exerts a strong antinociceptive effect<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and the tricyclic antidepressants (TCAs), represented by amitriptyline, have been used in the treatment of chronic pain for decades.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The TCAs are nonselective for NET and are the basis for the development of more specific inhibitors that modulate both the noradrenergic and the serotonergic systems with different degrees of selectivity, giving rise to selective serotonin reuptake inhibitors (SSRIs, represented by fluoxetine, <b>7</b>), selective NE reuptake inhibitors (NRIs, represented by reboxetine, <b>8</b>, and atomoxetine, <b>9</b>), and the dual inhibitors of SERT and NET (SNRIs, represented by duloxetine, <b>10</b>). This compound class is primarily used for the treatment of depression and other psychiatric disorders but has also relevant effects in the treatment of pain, mainly attributed to the NET.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In fact, the NRI reboxetine (<b>8</b>) has been shown to reverse allodynia in animal models<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and the SNRI duloxetine (<b>10</b>) produces a decrease in pain sensitivity, whereas the SSRI, fluoxetine (<b>7</b>), is ineffective. Duloxetine has been approved for the treatment of diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain by the Food and Drug Administration (FDA), reinforcing the involvement of monoamine transporters in pain etiology<named-content content-type="anchor" rid="fig2" type="simple"></named-content>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative SSRI (fluoxetine), NRI (reboxetine and atomoxetine), and SNRI (duloxetine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the search for dual ligands acting at the Ca<sub>v</sub>α2δ-1 and NET, we decided to focus on the nonaminoacidic Ca<sub>v</sub>α2δ-1 ligands since the SAR data published on the aminoacidic structures indicated that achieving relevant activity was restricted to a narrow structural framework. The pyrimidodiazepinone nucleus of compound <b>6</b> was selected for fusing or merging with the more homogeneous NET pharmacophore, common to compounds <b>7</b>–<b>10</b>. Although several approaches have been used for the design of dual compounds,<a onclick="showRef(event, 'ref6 ref30'); return false;" href="javascript:void(0);" class="ref ref6 ref30">(6,30)</a> such as mutual prodrugs<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> or bivalent ligands,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> the best scenario for achieving the desired drug-like properties is provided by “adding” the pharmacophores required for the individual activities or even better “merging” them by taking advantage of commonalities in their structures. This was not an obvious task since both target pharmacophores did not seem to have much in common, but as depicted in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, we hoped that this strategy would allow the identification of dual compounds that showed advantages over the individual therapies and their mere combination. We report here the structure–activity relationship (SAR) studies that led to the identification of a new series of bicyclic diazepinones<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> with dual affinity toward the Ca<sub>v</sub>α2δ-1 and NET.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Strategy for developing dual Ca<sub>v</sub>α2δ-1 and NET ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The synthesis of the compounds described herein (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) was accomplished, as depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><named-content content-type="anchor" rid="sch4" type="simple"></named-content><a class="ref internalNav" href="#sch5" aria-label="5">5</a>. The most simple oxadiazolyl derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) were prepared from methylthiopyrimidyl starting materials, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Pyrimidine intermediates <b>13</b> were obtained by SNAr amination of chloropyrimidine <b>11</b> with methyl or ethyl ethylenediamine (<b>12</b>) in the presence of a base, a reaction that proceeded with concomitant intramolecular cyclization. Copper-catalyzed coupling of <b>13</b> with iodoaryl <b>14</b> in the presence of <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine and K<sub>3</sub>PO<sub>4</sub> as bases provided the methylthio derivatives <b>15</b>, which were oxidized with <i>m</i>-CPBA and subsequently substituted with amines NHR<sub>1</sub>R<sub>2</sub>. The reduced derivative <b>23</b> was prepared in a seven-step sequence starting from aldehyde <b>18</b>. This involved reaction of <b>18</b> with <i>N</i><sup>1</sup>-methylethane-1,2-diamine (<b>12-1</b>), intramolecular reductive amination using NaBH(OAc)<sub>3</sub>, protection of the amino group with Boc, oxidation of the methylthio group to the sulfone, substitution with ethylamine, Boc deprotection, and final Pd-catalyzed N-arylation of <b>21</b> with the bromoaryl compound <b>22</b> using the catalytic system Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, and Cs<sub>2</sub>CO<sub>3</sub>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of compounds <b>15</b>, <b>16</b>, <b>17</b> and <b>23</b>.<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) for R = Me: KO<i><sup>t</sup></i>Bu, THF, rt, and 24 h; for R = Et: Et<sub>3</sub>N, ACN, 80 °C, and 48 h; (b) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100 °C, and 16 h; (c) <i>m</i>-CPBA, DCM, rt, and 1 h; (d) NHR<sub>1</sub>R<sub>2</sub>, THF, rt, and 16 h; (e) Et<sub>3</sub>N, ACN, 0 °C to rt, and 20 h; (f) NaBH(OAc)<sub>3</sub>, DCE, rt, and 1.5 h; (g) Boc<sub>2</sub>O, DCM, 0 °C to rt, and 20 h; (h) <i>m</i>-CPBA, DCM, rt, and 3.5 h; (i) EtNH<sub>2</sub>, H<sub>2</sub>O, rt, and 72 h; (j) HCl, dioxane, rt, and 16 h; and (k) Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 110 °C, and 24 h.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>31</b>–<b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, THF, rt, and 20 h; (b) methylamine, H<sub>2</sub>O, EtOH, 130 °C, and 1 h; (c) Boc<sub>2</sub>O, DCM, rt, and 2 h; (d) NaH, DMF, rt, and 3 h; (e) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 110 °C, and 16 h; (f) <i>m</i>-CPBA, DCM, rt, and 1 h; (g) ethylamine, THF, rt, and 16 h; (h) HCl, dioxane, rt, and 45 min; (i) paraformaldehyde, NaBH(OAc)<sub>3</sub>, DIPEA, AcOH, DCE, rt, and 70 h; and (j) methylamine, NaCN, EtOH, 100 °C, and 16 h.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMA, 90 °C, and 3 h; (b) R = Boc: Boc<sub>2</sub>O, DCM, rt, and 3 h; R = Teoc: 4-nitrophenyl-(2-(trimethylsilyl)ethyl)carbonate, DIPEA, DCM, rt, and 20 h; (c) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100 °C, and 20 h; (d) R = Boc: ZnBr<sub>2</sub>, DCM, rt, 24 h; (e) R = Teoc: CsF, DMF, 90 °C, and 90 min; (f) <i>m</i>-CPBA, DCM, rt, and 1 h; (g) NHR<sub>1</sub>R<sub>2</sub>, THF, rt, and 20 h or MW at 100 °C and 30 min; (h) Pd/C, Et<sub>3</sub>SiH, THF, 0 °C to rt, and 4 h; and (i) MeMgBr, THF, 0 °C, and 1 h.</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Pyridodiazepin-5(2<i>H</i>)-one Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>3</sub>N, THF, rt, and 2.5 h; (b) HCl, dioxane, rt, and 2 h; (c) CsF, Et<sub>3</sub>N, DMF, 75 °C, and 16 h; (d) EtNH<sub>2</sub>, H<sub>2</sub>O, 135 °C, MW, and 2 h; (e) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100–130 °C, and 20 h; (f) CsF, DMF, 90 °C, and 90 min or MW at 90 °C and 90 min; (g) Et<sub>3</sub>SiH, Pd/C, THF, rt, and 16 h; (h) MeB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, 130 °C, and 48 h; and (i) NaOMe, MeOH, 110 °C, MW, and 2 h.</p></p></figure><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Compounds <b>65</b>, <b>67</b>, <b>69</b>, and <b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100 °C, and 20 h; (b) CsF, DMF, 90 °C, and 90 min; and (c) paraformaldehyde, NaBH(OAc)<sub>3</sub>, DIPEA, AcOH, DCE, rt, 48 h.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Modifications of Compound <b>6</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0012.gif" alt="" id="gr11" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp</th><th class="colsep0 rowsep0" align="center">Ca<sub>v</sub>α2δ-1 (<i>K</i><sub>i</sub>, nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Ca<sub>v</sub>α2δ-2 (<i>K</i><sub>i</sub>, nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">NET (<i>K</i><sub>i</sub>, nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">NET (IC<sub>50</sub>, nM)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">19 ± 12</td><td class="colsep0 rowsep0" align="left">99 ± 2<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">11 ± 2</td><td class="colsep0 rowsep0" align="left">2148</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">39 ± 15</td><td class="colsep0 rowsep0" align="left">1.8 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15-1</b></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b></td><td class="colsep0 rowsep0" align="left">81 ± 15</td><td class="colsep0 rowsep0" align="left">2974</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16c</b></td><td class="colsep0 rowsep0" align="left">244 ± 97</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16d</b></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">178 ± 72</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">1026 ± 999</td><td class="colsep0 rowsep0" align="left">70 ± 8<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>, nM) in human α2δ-1-enriched membranes from hamster tumor CHO-K1 cells (human Cav2.2/β3/α2δ1 calcium channel cell line, ChanTest) using [<sup>3</sup>H]-gabapentin as the radioligand. Each value is the mean ± SD of two determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>, nM) in human α2δ-2-enriched membranes from human embryonic kidney HEK-293 cells using [<sup>3</sup>H]-gabapentin as the radioligand. Each value is the mean ± SD of at least two determinations.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>, nM) in human norepinephrine transporter (NET)-enriched membranes from human embryonic kidney HEK-293 cells using [<sup>3</sup>H]-nisoxetine as the radioligand. Each value is the mean ± SD of at least two determinations.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Functional activity (IC<sub>50</sub>, nM) in HEK-293 cells overexpressing human NET and using ASP<sup>+</sup> as the fluorescent substrate. Each value is the mean ± SD of two or three determinations.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Less than 50% inhibition at 10 μM.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">% Inhibition at 10 μM.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Not tested.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Initial Exploration of the MAP Moiety Attachment to the Ca<sub>v</sub>α2δ-1 Framework</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0013.gif" alt="" id="gr12" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp</th><th class="colsep0 rowsep0" align="center"><i>n</i>, position</th><th class="colsep0 rowsep0" align="center">Ca<sub>v</sub>α2δ-1 (<i>K</i><sub>i</sub>, nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">NET (<i>K</i><sub>i</sub>, nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">NET (IC<sub>50</sub>, nM)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31aR</b></td><td class="colsep0 rowsep0" align="left">0, meta</td><td class="colsep0 rowsep0" align="left">1417 ± 617</td><td class="colsep0 rowsep0" align="left">610 ± 242</td><td class="colsep0 rowsep0" align="left">203 ± 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31aS</b></td><td class="colsep0 rowsep0" align="left">0, meta</td><td class="colsep0 rowsep0" align="left">2238 ± 990</td><td class="colsep0 rowsep0" align="left">29 ± 17</td><td class="colsep0 rowsep0" align="left">54 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31b</b></td><td class="colsep0 rowsep0" align="left">0, para</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">995 ± 581</td><td class="colsep0 rowsep0" align="left">716 ± 86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31c</b></td><td class="colsep0 rowsep0" align="left">0, ortho</td><td class="colsep0 rowsep0" align="left">3493 ± 17</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31d</b></td><td class="colsep0 rowsep0" align="left">1, meta</td><td class="colsep0 rowsep0" align="left">706 ± 356</td><td class="colsep0 rowsep0" align="left">556 ± 85</td><td class="colsep0 rowsep0" align="left">184 ± 73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31e</b></td><td class="colsep0 rowsep0" align="left">1, para</td><td class="colsep0 rowsep0" align="left">6246 ± 2797</td><td class="colsep0 rowsep0" align="left">41 ± 7</td><td class="colsep0 rowsep0" align="left">7 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31f</b></td><td class="colsep0 rowsep0" align="left">1, ortho</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2450 ± 2166</td><td class="colsep0 rowsep0" align="left">>10,000<sup>e</sup></td><td class="colsep0 rowsep0" align="left">1862 ± 721</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33R</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">187 ± 0</td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33S</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">336 ± 131</td><td class="colsep0 rowsep0" align="left">842 ± 70</td><td class="colsep0 rowsep0" align="left">1533 ± 300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10,000<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>, nM) in human α2δ-1-enriched membranes from hamster tumor CHO-K1 cells (human Cav2.2/β3/α2δ1 calcium channel cell line, ChanTest) using [<sup>3</sup>H]-gabapentin as the radioligand. Each value is the mean ± SD of at least two determinations.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Binding affinity (<i>K</i><sub>i</sub>, nM) in human norepinephrine transporter (NET)-enriched membranes from human embryonic kidney HEK-293 cells using [<sup>3</sup>H]-nisoxetine as the radioligand. Each value is the mean ± SD of at least two determinations.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Functional activity (IC<sub>50</sub>, nM) in HEK-293 cells overexpressing human NET and using ASP<sup>+</sup> as the fluorescent substrate. Each value is the mean ± SD of two or three determinations.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Less than 50% inhibition at 10 μM.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activity Data of MAT Derivatives Depicted in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>, <a class="ref internalNav" href="#sch4" aria-label="4">4</a>, and <a class="ref internalNav" href="#sch5" aria-label="5">5</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0014.gif" alt="" id="gr13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See footnotes of <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">See footnotes of <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">See footnotes of <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Less than 50% inhibition at 1 μM.</p></div></div><div></div></div><div class="NLM_p">Compounds  <b>31</b>–<b>34</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) with a 3-methylamino-1-phenylpropoxy (MAP) moiety were prepared according to the sequence shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Key intermediates <b>27-1</b> (<i>n</i> = 0, X = I) were prepared by the Mitsunobu reaction of <b>24</b> with iodophenols <b>25</b> followed by the reaction with methylamine and Boc protection of the amino group. Intermediates <b>27-2</b> (<i>n</i> = 1, X = Br) were obtained by alkylation of <b>28</b><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> with bromobenzyl reagents <b>29</b> using NaH in DMF. Starting from compounds <b>27</b>, several final derivatives were obtained. Synthesis of compounds <b>31</b> involved copper-catalyzed N-arylation of <b>13-1</b> with <b>27</b>, oxidation of the thioether group to the sulfone, substitution with ethylamine, and final <i>N</i>-Boc deprotection, using the conditions described above. Compound <b>32</b>, with a dimethylamino substituent, was obtained in good yield by reductive amination of compound <b>31a</b> with paraformaldehyde. A similar methodology to that used for preparing compounds <b>31</b> was used for the synthesis of compound <b>33</b> using the tricyclic scaffold <b>35</b>, obtained as described in the literature.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In the case of <b>34</b>, the pyrimidine ethylamino substituent was already present in intermediate <b>37</b>, synthesized by an amidation reaction of <b>36</b> with methylamine. For the synthesis of pure enantiomers of compounds <b>31a</b> and <b>33</b>, commercial enantiopure intermediates <b>24</b> were used. No epimerization occurred in the Mitsunobu or alkylation reaction, and an enantiomeric excess of >96% was obtained. Throughout the manuscript, the suffix R or S after the number indicates that the compound is the corresponding pure enantiomer, while no suffix refers to a racemic derivative.</div><div class="NLM_p">The 3-methylamino-1-(thiophen-2-yl)propoxy (MAT) derivatives described in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> were prepared by a different methodology, outlined in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>, <a class="ref internalNav" href="#sch4" aria-label="4">4</a>, <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. The Mitsunobu-based route of <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> was not successful when working with enantiopure derivative <b>38</b> since epimerization was observed in the aryl ether product. A better alternative was the O-arylation of <b>38</b> with 3-fluorobromobenzene <b>39</b> using NaH as the base, which afforded intermediate <b>40</b> in good yield and no decrease in the enantiomeric excess in relation to the starting material used (typically, values of >96% ee were obtained in the final compounds). The copper-catalyzed N-arylation reaction required protection of the methylamino group, and initially, <i>N</i>-Boc-protected derivatives <b>41-1</b> were prepared. However, in some cases, ether cleavage in the final deprotection step under acidic conditions was observed. Although this could be solved in some instances by using ZnBr<sub>2</sub> in DCM instead of HCl, the trimethylsilylethoxycarbonyl (Teoc)-protecting group was alternatively used. <i>N</i>-Teoc-protected intermediates <b>41-2</b> were easily prepared by treating <b>40</b> with 4-nitrophenyl (2-(trimethylsilyl)ethyl)carbonate. The N-arylation with <b>41-2</b> of different bicyclic scaffolds was performed as described above, and the final deprotection step, using CsF in DMF at 90 °C or under MW irradiation conditions, provided the final compounds. In the case of enantiopure derivatives, good enantiomeric excess was always obtained.<named-content content-type="anchor" rid="tbl1" type="simple"></named-content><named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content></div><div class="NLM_p">In this way, the pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one derivatives (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) were obtained. Reactions of <b>41-1</b> and <b>41-2</b> with the methylthio-bicycle <b>13-1</b> provided compounds <b>42</b>. Compound <b>43</b> was prepared from <b>42-1</b> by deprotection of the Boc group using ZnBr<sub>2</sub> in DCM. Compound <b>42-1</b> was oxidized to the sulfone derivative <b>44-1</b>, which was reacted with ethylamine and deprotected with ZnBr<sub>2</sub> to provide compound <b>45a</b>, while the methyl derivative <b>47</b> resulted from methyl magnesium bromide attack to sulfone <b>44-1</b> and subsequent Boc deprotection. For the preparation of compounds <b>45b</b>, <b>45c</b>, <b>46</b>, and <b>48</b>, the Teoc-protecting group was preferred. The reaction of sulfone <b>44-2</b> with the corresponding amines, at rt or under MW irradiation at 100 °C, and deprotection with CsF in DMF provided derivatives <b>45b</b> and <b>45c</b>. The unsubstituted <b>46</b> was prepared by reduction of the thioether <b>42-2</b> with triethylsilane in the presence of Pd/C. The trifluoromethyl derivative <b>48</b> was prepared by the reaction of <b>41-2</b> with bicycle <b>49</b>, which in turn was obtained from ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate, using the conditions described above for the preparation of <b>13-1</b>.</div><div class="NLM_p">The pyridodiazepin-5(2<i>H</i>)-one derivatives were synthesized (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) from key intermediates <b>54</b> using in all cases the Teoc-protected derivative <b>41-2</b>. Compounds <b>54</b> were obtained from the two regioisomeric acid chlorides <b>50</b> by subsequent treatment with <i>N</i>-Boc-protected diamine <b>51</b> in the presence of Et<sub>3</sub>N, deprotection of the Boc group, and intramolecular cyclization in the presence of CsF and Et<sub>3</sub>N in DMF. Treatment of <b>54</b> with ethylamine under microwave irradiation gave the aminopyridyl scaffolds <b>55</b>, which were derivatized as described above to provide final compounds <b>56</b> and <b>57</b>. Halogenolysis of <b>54-2</b> to provide <b>58</b> was performed with triethylsilane and Pd/C in THF, and its final derivatization provided compound <b>59</b>. The Suzuki reaction of <b>54-2</b> with methylboronic acid provided scaffold <b>60</b>, which was further derivatized to compound <b>61</b>. The methoxy group was introduced with NaOMe in MeOH to give scaffold <b>62</b>, which was transformed to final compound <b>63</b>.</div><div class="NLM_p last">Final compounds <b>65</b>, <b>67</b>, <b>69</b>, and <b>71</b>, with alternative central scaffolds, were obtained (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) by the reaction of <b>41-2</b> with the corresponding bicyclic intermediates <b>64</b>, <b>66</b>, <b>68</b>, and <b>70</b>, respectively, using the conditions described above. The pyrido derivatives <b>64</b> and <b>66</b> were prepared, in a similar way to that described above for the preparation of <b>13-1</b>, from the corresponding fluoropyridinyl esters. Scaffold <b>70</b> was commercially available, and <b>68</b> was obtained by reductive amination of commercially available <b>72</b> with paraformaldehyde.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> SAR Studies</h3><div class="NLM_p">The biological activity of the compounds synthesized was evaluated in human α2δ-1- and α2δ-2-enriched membranes using [<sup>3</sup>H]-gabapentin as the radioligand. Both targets were evaluated since in principle we aimed at finding selective agents for the α2δ-1 subunit.<named-content content-type="anchor" rid="fig4" type="simple"></named-content> This was based on previous studies on the distribution and differential effects of the two subtypes,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> suggesting that the analgesic effects of compounds like pregabalin are due to the interaction with α2δ-1, while their major side effects such as sedation, dizziness, and ataxia may be caused by the interaction with α2δ-2. NET activity was evaluated by measuring the binding affinity to human ΝΕΤ-enriched membranes using [<sup>3</sup>H]-nisoxetine as the radioligand and the functional activity in cells overexpressing NET and using 4-(4-(dimethylamino)styryl)-<i>N</i>-methylpyridinium iodide (ASP<sup>+</sup>) as the fluorescent substrate. The results for the new compounds prepared are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, where the activities of reference compounds <b>1</b>, <b>6</b>, and <b>8</b> are also presented for comparison purposes.</div><div class="NLM_p">For the design of the dual Ca<sub>v</sub>α2δ-1 and NET ligands, we envisaged a merging approach from the scaffold represented by compound <b>6</b> and the NET pharmacophore common to compounds <b>7</b>–<b>10</b>. The SAR data around <b>6</b> were scarce since they were only described in a patent publication,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> so we first focused on exploring the key features for Ca<sub>v</sub>α2δ-1 binding and the most suitable positions, allowing substitution to attach the NET pharmacophore. The tricyclic scaffold of <b>6</b> was simplified by eliminating the fused pyrrolidine ring and keeping only a methyl group attached to the benzodiazepinone nitrogen (<b>I</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Maintaining an ethylamino group at the 2-position of the pyrimidine, we first explored the phenyl ring substitution. Several simple substituents were introduced in ortho-, meta-, and para-positions, and in general, they were poorly tolerated (results not shown), but a preferential trend for the meta-substitution was observed. The oxadiazolyl derivative in the meta-position was identified as the best substituent, and therefore, framework (<b>II</b>) was selected for further SAR studies (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modification sequence from <b>6</b> to <b>16a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This study showed that the ethylamino group in position 2 was important for the activity since <b>16a</b> was the most potent compound, while shortening to methylamino (<b>16c</b>) provided a drop in affinity and the methylthio (<b>15-1</b>) and methylethylamino (<b>16b</b>) derivatives were inactive. Elongating to methoxyethylamino (<b>16d</b>) and other substituents, including larger alkyl (butyl and pentyl), benzyl or phenyl groups provided a complete loss in affinity (Ca<sub>v</sub>α2δ1 <i>K</i><sub>i</sub> > 10,000 nM). In the same way, enlarging position 9 was detrimental since the ethyl derivative <b>17</b> showed reduced affinity in relation to <b>16a</b>. Finally, the benzodiazepinone oxygen atom was proven to be necessary since the reduced derivative <b>23</b> was substantially less potent than <b>16a</b>. The properties of compound <b>16a</b> were considered to be a good starting point since it exhibited a good ADME profile, with adequate <i>in vitro</i> metabolic stability in human and rodent liver microsomes (intrinsic clearance below 5 μL/min/mg protein),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> no potential for drug–drug interactions based on the low inhibition (<50% at 1 μM) of recombinant human cytochrome P450 isoforms (rhCYP 1A2, 2C9, 2C19, 2D6, and 3A4),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and IC<sub>50</sub> above 10 μM in the human ether-a-go-go-related gene (hERG)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> patch clamp assay, a well-known predictor of cardiac toxicity. Compound <b>16a</b> also exhibited selectivity for the Ca<sub>v</sub>α2δ-2, for which it showed a <i>K</i><sub>i</sub> = 2974 nM. All the remaining new compounds reported here showed <i>K</i><sub>i</sub> values above 10 μM for the Ca<sub>v</sub>α2δ-2, so these results are not reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</div><div class="NLM_p">The previous results indicated that substitution in positions 2 and 9 would not be tolerated, so we decided to explore the attachment of a NET pharmacophore onto the phenyl ring of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one scaffold. As the most representative NET framework, the 3-methylamino-1-phenylpropoxy (MAP) moiety was chosen, and the results of the initial exploration are provided in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Other shorter (3-methylamino-1-phenylethoxy) or longer (3-methylamino-1-phenylbutoxy) chains were also explored, but they provided weaker affinities (results not shown). We were pleased to see that the compound resulting from the MAP attachment in the meta-position, <b>31a</b>, provided dual activity, showing micromolar affinity for the Ca<sub>v</sub>α2δ-1 and, interestingly, higher affinity for the NET. The <i>S</i> enantiomer showed nanomolar potency for NET, both in the binding and functional tests, and was clearly superior to the <i>R</i> isomer, a result consistent with the usual behavior of NET inhibitors.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> On the contrary, pending the MAP moiety to the ortho- or para-position provided compounds <b>31b</b> and <b>31c</b>, with only residual affinities.</div><div class="NLM_p">Next, we explored the introduction of flexibility through a methylene linker between the MAP moiety and the phenyl ring. The meta-derivative <b>31d</b> exhibited dual affinity but reduced NET affinity in relation to <b>31a</b>. The para-derivative <b>31e</b> was highly potent on the NET but poorly active on the Ca<sub>v</sub>α2δ-1, and the ortho-derivative <b>31f</b> was again inactive. A dimethylamino group in place of the methylamino group on the MAP chain (compound <b>32</b>) proved to be clearly detrimental for NET inhibition. This result was consistent with previous findings in the monoamine transporter field, where dimethylation reduced NET affinity while maintaining or increasing SERT activity.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Attaching the MAP chain to the Ca<sub>v</sub>α2δ-1 scaffold of <b>6</b> provided derivative <b>33</b>, with both enantiomers showing two-digit nanomolar affinity for the Ca<sub>v</sub>α2δ-1 but poor activity at NET. Finally, the open derivative <b>34</b> was inactive for both targets. These results indicated that the proposed approach was indeed adequate to obtain dual derivatives, but that simultaneous improvement of activity in both targets would be challenging, as suggested by the comparison of <b>31aS</b> versus <b>33S</b>, where an increase in NET activity resulted in a decrease in Ca<sub>v</sub>α2δ-1 activity and vice versa.</div><div class="NLM_p">The phenyl group of the meta-MAP derivative <b>31a</b> was next changed to a 2-thiophenyl group to provide compound <b>45a</b>, where the <i>S</i> enantiomer was again the eutomer for NET activity, while both enantiomers kept similar Ca<sub>v</sub>α2δ-1 affinities. The 3-methylamino-1-(thiophen-2-yl)propoxy (MAT) chain of <b>45aS</b> seemed to provide superior Ca<sub>v</sub>α2δ-1 affinity versus its MAP counterpart, <b>31aS</b>, and was the framework selected to study the variation of the bicyclic core (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It should be noted that in many cases, the racemic compounds were first prepared and for the most active derivatives, the <i>S</i> enantiomers (which were consistently the eutomers for NET, following the trends of <b>31aR/S</b> and <b>45aR/S</b>) were then synthesized. For the sake of the length of the paper, we report only the <i>S</i> enantiomers when available.</div><div class="NLM_p">Surprisingly, intermediate <b>43S</b> showed a very high NET activity both in the binding and functional assay as well as submicromolar Ca<sub>v</sub>α2δ-1 activity, a result unexpected in view of the low Ca<sub>v</sub>α2δ-1 affinity of <b>15-1</b>. This result indicated that the 2-position, where the ethylamino group was identified as key for Ca<sub>v</sub>α2δ-1 activity in the first study (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), could be further explored. The dimethylamino derivative <b>45b</b> showed a worsening in all activities, and the amino <b>45cS</b> and unsubstituted <b>46S</b> were again fairly potent in both targets. The methyl (<b>47S</b>) and trifluoromethyl (<b>48</b>) derivatives showed an impairment at Ca<sub>v</sub>α2δ-1.</div><div class="NLM_p">Deletion of one nitrogen atom of the pyrimido bicycle provided the pyrido derivatives <b>56S</b> and <b>57S</b>, with dual affinities comparable to those of <b>45aS</b>. Many analogues of both pyridine isomers were prepared, and only a handful of the most active compounds (<b>59S</b>, <b>61S</b>, and <b>63S</b>) are reported in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The other two pyrido isomers <b>65</b> and <b>67</b> showed a decreased affinity at NET, similar to the benzo derivative <b>69</b>. The monocyclic diazepinone <b>71</b> showed a substantial decrease in affinity, with NET activity retained in the <i>S</i> enantiomer and Ca<sub>v</sub>α2δ-1 activity mainly in the <i>R</i> enantiomer.</div><div class="NLM_p">Several of the compounds reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> show quite a balanced dual profile, but in general, the compounds are more potent in NET than in the Ca<sub>v</sub>α2δ-1, with several compounds, such as <b>31aS</b> and <b>43S</b>, with outstanding NET results. These findings were surprising since we were expecting the opposite as many of the NET inhibitors described in the literature correspond to small ligands circumscribed to structures related to those depicted in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. When analyzing the NET structural information published by the group of Gouaux, first for LeuT, bacterial homolog of biogenic amine transporters (BATs), engineered to achieve human BAT-like pharmacology,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and later on for the human SERT,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> we guessed that a cavity located near the primary binding site, corresponding to a low affinity or allosteric site in the homologous proteins, might allow the accommodation of larger derivatives, such as <b>31aS</b> and <b>43S</b>.</div><div class="NLM_p">To check this hypothesis and get more knowledge about the key ligand–receptor interactions, which might help in a later optimization program, we built a NET homology model using as a template the six crystallized SERT structures (details given in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) and docked into it compound <b>31aS</b>. We observed that the MAP moiety was positioned in the expected primary binding site, orienting the bicyclic diazepinone framework in a contiguous site in the extracellular vestibule. We embedded the resulting docked structure in an explicit lipid bilayer, solvated it, and ran a 1 ms MD simulation. The main interactions observed in the resulting trajectory are schematically drawn in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. The MAP amine group interacts with the carboxylate of the conserved Asp75 and with Phe72, with which it establishes cation−π interactions. Ser318 and Ser419 on each side of the ligand basic amine interact with it directly (Ser318) or through water bridges (Ser419), defining together with Asp75 and Phe72 what has been previously defined<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> as subsite A. Subsite B is occupied by the phenyl group of the MAP moiety engaging in π–π stacking interactions with Phe323, mostly edge to face, and in hydrophobic interactions with Val148, Val325, and Tyr152. These residues together with Phe323 start defining subsite C by π stacking with the phenyl that constitutes the intersection of the original Ca<sub>v</sub>α2δ-1 scaffold with the NET pharmacophore. This phenyl ring additionally establishes hydrophobic interactions with Ala477 and Val148 and forms an edge-to-face aromatic interaction with Tyr151. Subsite C connects the primary binding site with a site in the extracellular vestibule, which is able to harbor the Ca<sub>v</sub>α2δ-1 pharmacophore. It is lined by transmembrane helices 1, 6, and 10 and located halfway between the sites found in LeuT and SERT. The pyrimidodiazepinone ring system is stabilized by hydrophobic interactions with Ala77, Phe317, and Ala477 and by ionic interactions of Arg81 with the nitrogen atoms in positions 1 and 3 and of the 2-ethylamino group. Additional hydrogen bonding is established with Gln314 and one or both the 2-ethylamino group and the nitrogen in position 3 of the pyrimidine ring. This H bond interaction between the ligand and the amide of Gln314 may explain the worsening in NET affinity of the dimethylamino derivative <b>45b</b>, and altogether, the mentioned polar interactions in this subsite explain the convenience of polar substitution in the bicycle and the complete loss of NET affinity of the benzodiazepinone <b>69</b>. Further insight into the intriguing binding of this compound series in the NET will be reported in due course.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking of compound <b>31aS</b> in the NET homology model generated from the SERT structures l5I6X, 5I6Z, 5I71, 5I73, 5I74, and 5I75. (A) RMSD of the protein and the docked ligand in the 1 μs molecular dynamics simulations. (B) 2D representation of the interactions of <b>31aS</b> in the active site of NET. (C) Image of NET embedded in the lipid bilayer and solvated. (D) Compound <b>31aS</b> in the NET binding site; the aminoacids belonging to the different subsites have been colored in orange for subsite A, purple for B, cyan for C, and yellow for the residues belonging to the allosteric site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Besides exhibiting promising dual affinities, several compounds among those reported in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> showed a good ADMET profile. For example, compounds <b>45cS</b> and <b>59S</b> showed a balanced dual profile accompanied by a good physicochemical profile (MW: 438.5 and 422.5, respectively; cLogP: 2.4 and 3.2, respectively; and kinetic solubility above 10 μM in both cases), an adequate metabolic stability in human, mouse, and rat liver microsomes (intrinsic clearance below 5 μL/min/mg protein), no potential for drug–drug interactions based on the low inhibition (<50% at 1 μM) of recombinant human cytochrome P450 isoforms (rhCYP 1A2, 2C9, 2C19, 2D6, and 3A4), and IC<sub>50</sub> above 10 μM in the human ether-a-go-go-related gene (hERG) patch clamp assay. These results prompted the initiation of a lead optimization program toward the finding of a preclinical candidate dual compound for the treatment of pain, which identification will be reported soon.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, the synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the Ca<sub>v</sub>α2δ-1 and the NET have been studied. A nonaminoacidic Ca<sub>v</sub>α2δ-1 scaffold described in the literature was simplified, and its different positions were explored in order to identify Ca<sub>v</sub>α2δ-1 key binding features and the best positions for the attachment of NET pharmacophores. Among the patterns explored, substitution with the 3-methylamino-1-phenylpropoxy (MAP) and 3-methylamino-1-thiophenylpropoxy (MAT) moieties in the meta-position of the phenyl ring of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one scaffold was the most interesting. The dual compounds showed excellent NET functionality despite being substantially larger than prototypic NET inhibitors described in the literature. The existence of a cavity located near the NET primary binding site, which might allow the accommodation of larger derivatives, can explain this fact.</div><div class="NLM_p last">Changing the central scaffold by other bicycles provided balanced dual compounds that also exhibited good ADMET properties and were the basis for a lead optimization program, which allowed the identification of a suitable preclinical candidate for the treatment of pain that will be published soon.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Reference compounds were obtained as follows: pregabalin (<b>1</b>)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and compound <b>6</b><sup>23</sup> were prepared following the routes described in the literature, and reboxetine (<b>8</b>) was acquired from Waterstonetech (WS50505). Flash chromatography was performed on a Teledyne Isco CombiFlash RF system with disposable columns. NMR spectra were recorded on a Bruker Fourier 300, Bruker Avance I 400, or Bruker Avance I 500, operating at frequencies of 300, 400, and 500 MHz for <sup>1</sup>H and 75, 100, and 125 MHz for <sup>13</sup>C, respectively. Chemical shifts (δ) are in parts per million. Accurate mass measurements were carried out using a 6540 UHD high-resolution mass spectrometer QTOF system and obtained by electron spray ionization (ESI) in positive mode. Data were acquired and processed using MassHunter software. Commercially available reagents and solvents (HPLC grade) were used without further purification for all the analytical tests. Analytical HPLC purity data for all final compounds were obtained on an Agilent HP 1200-MS 6120 system using method 1: Agilent Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm), gradient 5–95% B (A = H<sub>2</sub>O (0.05% TFA), B = acetonitrile) over 7 min, then isocratic 95% B for 5 min, injection volume: 1 μL, and flow: 1 mL/min. UV spectra were recorded at 254 nm using an Agilent HP 1200 VWD detector. Data were integrated and reported using Agilent ChemStation software. All compounds showed purity higher than 95% as determined by this method. Chiral SFC analysis of intermediates for ee determination was performed on a Waters ACQUITY UPC<sup>2</sup> system using method 2: CHIRALPAK IB column (4.6 × 100 mm, 3 μM), IPA/CO<sub>2</sub> 5:95, and 230 nm. Chiral analytical HPLC of final compounds for ee determination was performed in an Agilent 1260 system. The coated or immobilized polysaccharide columns were acquired from Chiral Technologies Europe. Three methods were used: method 3: CHIRALCEL AS-H column (4.6 × 250 mm, 5 μm), isocratic <i>n</i>-heptane/ethanol + 0.33% DEA 80:20, injection volume: 5 μL, and flow: 0.8 mL/min; method 4: CHIRALCEL AS-H column (4.6 × 250 mm, 5 μm), isocratic <i>n</i>-heptane/ethanol + 0.33% DEA 70:30, injection volume: 5 μL, and flow: 0.8 mL/min; and method 5: CHIRALPAK AD-H column (4.6 × 250 mm, 5 μm), isocratic <i>n</i>-heptane/<i>iso</i>-propanol + 0.33% DEA 70:30, injection volume: 5 μL, and flow: 0.8 mL/min. All compounds active in biological assays were electronically filtered for structural attributes common to pan-assay interference compounds (PAINS) and were found to be negative.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Determination of Physicochemical Properties</h3><div class="NLM_p last">p<i>K</i><sub>a</sub> was calculated using ACDLabs 9.0.3 and cLog<i>P</i> using ChemDraw Ultra 10.0.3. Kinetic solubility was measured by HPLC after centrifugation of a sample obtained by adding phosphate buffer at pH = 7.4 (1 mL) to 10 μL of a 10 mM solution of the test compound in DMSO and stirring for 4 h.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedures for the preparation of compound</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> s9-Methyl-2-(methylthio)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>13-1</b>)</h4><div class="NLM_p last">A solution of potassium <i>tert</i>-butoxide (1.0 g, 8.42 mmol) in THF (0.2% water content, 25 mL) was stirred under air at rt for 10 min. Then, a solution of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (<b>11</b>, 1.0 g, 4.21 mmol) and <i>N</i><sup>1</sup>-methylethane-1,2-diamine (<b>12-1</b>, 329 mg, 4.21 mmol) in THF (0.2% water content, 18 mL) was added dropwise and the mixture was stirred at rt for 20 h. Additional amounts of potassium <i>tert</i>-butoxide were added after 4 h (4.21 mmol) and 16 h (6.31 mmol) to complete the reaction. The reaction mixture was concentrated under vacuum, DCM was added, and the solution was washed successively with water, NH<sub>4</sub>Cl saturated solution, and brine. The organic phase was concentrated under vacuum to afford <b>13-1</b> (388 mg, 41% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.65 (s, 1H), 4.86 (s, 3H), 3.73 (m, 2H), 3.51 (m, 2H), 2.55 (s, 3H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 9-Methyl-6-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-2-(methylthio)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>15-1</b>)</h4><div class="NLM_p last">To a solution of compound <b>13-1</b> (71 mg, 0.31 mmol) and 2-(3-iodophenyl)-5-methyl-1,3,4-oxadiazole (<b>14</b>)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (145 mg, 0.50 mmol) in dioxane (3 mL), CuI (30 mg, 0.15 mmol), K<sub>3</sub>PO<sub>4</sub> (134 mg, 0.63 mmol), and <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine (17 μL, 0.15 mmol) were added, and the mixture was heated at 100 °C under an Ar atmosphere for 16 h. The reaction mixture was cooled to rt and filtered through a pad of Celite, and the solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient hexane to 100% acetone, afforded <b>15-1</b> (15 mg, 13% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.82 (bs, 1H), 7.97 (t, <i>J</i> = 1.5 Hz, 1H), 7.92 (dt, <i>J</i> = 1.5, 7.7 Hz, 1H), 7.58 (t, <i>J</i> = 7.7 Hz, 1H), 7.53–7.51 (m, 1H), 4.09–4.07 (m, 2H), 3.87–3.85 (m, 2H), 3.35 (s, 3H), 2.64 (s, 3H), 2.59 (s, 3H). HPLC, method 1: RT, 5.03 min; purity, 98.0%. HRMS calcd for C<sub>18</sub>H<sub>19</sub>N<sub>6</sub>O<sub>2</sub>S, 383.1285 [M + H]<sup>+</sup>; found, 383.1275 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-(Ethylamino)-9-methyl-6-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>16a</b>)</h4><div class="NLM_p last">To a solution of <b>15-1</b> (66 mg, 0.17 mmol) in DCM (1.5 mL), <i>m</i>-CPBA (55 mg, 0.22 mmol) was added, and the mixture was stirred at rt for 1 h. NaHCO<sub>3</sub> saturated solution was added, and the mixture was extracted with DCM. The organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. The crude product was dissolved in THF (1 mL), ethylamine (0.43 mL of a 2 M solution in THF, 0.86 mmol) was added, and the mixture was stirred at rt for 16 h. The crude residue was concentrated under vacuum and purified by flash chromatography, silica gel, gradient hexane to 100% acetone, to afford compound <b>16a</b> (40 mg, 61% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.72 (bs, 1H), 7.95 (t, <i>J</i> = 1.5 Hz, 1H), 7.90 (dt, <i>J</i> = 1.7, 7.0 Hz, 1H), 7.47–7.54 (m, 2H), 5.78 (bs, 1H), 4.04–4.02 (m, 2H), 3.78–3.75 (m, 2H), 3.47 (m, 2H), 3.23 (s, 3H), 2.60 (s, 3H), 1.24 (t, <i>J</i> = 7.2 Hz, 3H). HPLC, method 1: RT, 4.88 min; purity, 98.4%. HRMS calcd for C<sub>19</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>, 380.1829 [M + H]<sup>+</sup>; found, 380.1831[M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-((2-Aminoethyl)(methyl)amino)-2-(methylthio)pyrimidine-5-carbaldehyde (<b>19</b>)</h4><div class="NLM_p last">To a solution of 4-chloro-2-(methylthio)pyrimidine-5-carbaldehyde (<b>18</b>, 712 mg, 3.77 mmol) in acetonitrile (40 mL) at 0 °C, Et<sub>3</sub>N (2.47 mL, 17.74 mmol) and <i>N</i><sup>1</sup>-methylethane-1,2-diamine (<b>12-1</b>, 0.42 mL, 4.91 mmol) were added, and the mixture was stirred at rt for 20 h. NaHCO<sub>3</sub> saturated solution was added and extracted with EtOAc. The organic phase was concentrated under vacuum, and the residue was purified by flash chromatography, silica gel, gradient DCM to 30% MeOH, to afford compound <b>19</b> (627 mg, 73% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.56 (s, 3H), 3.34 (s, 3H), 3.51 (m, 2H), 4.04 (m, 2H), 8.06 (m, 1H), 8.16 (s, 1H).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl 9-Methyl-2-(methylthio)-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepine-6-carboxylate (<b>20</b>)</h4><div class="NLM_p">To a solution of compound <b>19</b> (210 mg, 0.92 mmol) in DCE (38 mL), NaBH(OAc)<sub>3</sub> (393 mg, 1.85 mmol) was added, and the reaction mixture was stirred at rt for 1.5 h. NaHCO<sub>3</sub> saturated solution was added and extracted with DCM. The organic phase was concentrated under vacuum, and the residue was purified by flash chromatography, silica gel, gradient DCM to 20% MeOH, to afford 9-methyl-2-(methylthio)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepine (152 mg, 78% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.11 (s, 1H), 4.03 (m, 2H), 3.52 (m, 2H), 3.34 (s, 3H), 2.55 (s, 3H).</div><div class="NLM_p last">To a solution of the previous compound (145 mg, 0.69 mmol) in DCM (6.5 mL) at 0 °C, di-<i>tert</i>-butyldicarbonate (150 mg, 0.69 mmol) was added, and the mixture was stirred at rt for 20 h. NaHCO<sub>3</sub> saturated solution was added, extracted with DCM, and concentrated under vacuum to afford compound <b>20</b> that was used in the next step without further purification (214 mg, quant yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ rotamers 7.75 and 7.69 (s, 1H), 4.51 and 4.45 (s, 2H), 3.79 (m, 4H), 3.20 (s, 3H), 2.49 (s, 3H), 1.45 and 1.38 (s, 9H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-Ethyl-9-methyl-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-2-amine (<b>21</b>)</h4><div class="NLM_p">To a solution of compound <b>20</b> (227 mg, 0.73 mmol) in DCM (4 mL), <i>m</i>-CPBA (252 mg, 1.46 mmol) was added, and the mixture was stirred at rt for 3.5 h. NaHCO<sub>3</sub> saturated solution was added, and the mixture was extracted with DCM. The organic layer was dried with MgSO<sub>4</sub>, and the solvent was removed under vacuum. The crude residue was treated with ethylamine (70% solution in water, 2.1 mL, 26.10 mmol), and the mixture was stirred at rt for 72 h. The reaction mixture was concentrated under vacuum and purified by flash chromatography, silica gel, gradient DCM to 20% MeOH, to afford <i>tert</i>-butyl 2-(ethylamino)-9-methyl-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepine-6-carboxylate (94 mg, 47% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.20 (t, <i>J</i> = 7.2 Hz, 3H), 1.43 (s, 9H), 3.10 (s, 3H), 3.40 (m, 2H), 3.57 (m, 2H), 3.73 (m, 2H), 4.29 and 4.41 (s, 2H), 5.06 (bs, 1H), 7.59 and 7.69 (s, 1H).</div><div class="NLM_p last">To a solution of the previous compound (94 mg, 0.30 mmol) in dioxane (0.3 mL), HCl (4 M solution in dioxane, 1.0 mL, 4.28 mmol) was added, and the mixture was stirred at rt for 16 h. The reaction mixture was concentrated under vacuum, 10% Na<sub>2</sub>CO<sub>3</sub> aqueous solution was added and extracted with DCM, and the organic phase was concentrated to dryness to afford compound <b>21</b> (61 mg, 96% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 7.57 (s, 1H), 3.70 (s, 2H), 3.47 (m, 2H), 3.34 (q, <i>J</i> = 7 Hz, 2H), 3.11 (m, 2H), 3.08 (s, 3H), 1.18 (t, <i>J</i> = 7 Hz, 3H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-Ethyl-9-methyl-6-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5<i>-e</i>][1,4]diazepin-2-amine (<b>23</b>)</h4><div class="NLM_p last">A mixture of Pd<sub>2</sub>(dba)<sub>3</sub> (5 mg, 0.0053 mmol), Xantphos (5 mg, 0.012 mmol), compound <b>21</b> (30 mg, 0.14 mmol), 2-(3-bromophenyl)-5-methyl-1,3,4-oxadiazole (<b>22</b>, 25 mg, 0.10 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (48 mg, 0.14 mmol) in dry dioxane (0.5 mL) under argon was heated at 110 °C in a sealed tube for 24 h. The reaction mixture was cooled to rt and filtered through a pad of Celite, and the filtrate was concentrated under vacuum. Purification by flash chromatography, silica gel, gradient hexane to 100% acetone, afforded compound <b>23</b> (6 mg, 15% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.78 (bs, 1H), 7.39 (m, 1H), 7.34–7.29 (m, 2H), 6.88–6.85 (m, 1H), 5.14 (bs, 1H), 4.48 (s, 2H), 3.80–3.76 (m, 4H), 3.42–3.35 (m, 2H), 3.12 (s, 3H), 2.62 (s, 3H), 1.20 (t, <i>J</i> = 7.2 Hz, 3H). HPLC, method 1: RT, 5.51 min; purity, 95.1%. HRMS calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>O, 366.2037 [M + H]<sup>+</sup>; found, 366.2031 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-1-(3-Chloro-1-phenylpropoxy)-3-iodobenzene (<b>26R-meta</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-3-chloro-1-phenylpropan-1-ol (<b>24S</b>, 400 mg, 2.34 mmol) in THF (11 mL), 3-iodophenol (774 mg, 3.52 mmol) and PPh<sub>3</sub> (922 mg, 3.52 mmol) were added. The solution was cooled at 0 °C, DIAD (0.692 mL, 3.52 mmol) was added dropwise with rapid stirring, and the reaction mixture was stirred at rt for 20 h. The solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient hexane to 100% ethyl acetate, afforded compound <b>26R-meta</b> (779 mg, 89% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.41–7.36 (m, 4H), 7.32 (m, 1H), 7.29 (m, 1H), 7.25 (m, 1H), 6.91 (t, <i>J</i> = 8.5 Hz, 1H), 6.82 (m, 1H), 5.37 (m, 1H), 3.84–3.77 (m, 1H), 3.65–3.58 (m, 1H), 2.53–2.43 (m, 1H), 2.28–2.18 (m, 1H).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl (<i>R</i>)-(3-(3-Iodophenoxy)-3-phenylpropyl)(methyl)carbamate (<b>27-1R-meta</b>)</h4><div class="NLM_p last">To a solution of <b>26R-meta</b> (779 mg, 2.09 mmol) in EtOH (2.3 mL), methylamine (40% solution in water, 5.4 mL, 62.7 mmol) was added, and the mixture was heated at 130 °C in a sealed tube for 1 h. The reaction mixture was cooled at rt, water was added, the mixture was extracted with DCM, and the organic phases were concentrated under vacuum. The crude product was dissolved in DCM (17 mL), di-<i>tert</i>-butyldicarbonate (502 mg, 2.30 mmol) was added at 0 °C, and the reaction mixture was stirred at rt for 2 h. Water was added, and the mixture was extracted with DCM and washed with NaHCO<sub>3</sub> saturated solution and brine. The solvent was removed under vacuum, and the residue was purified by flash chromatography, silica gel, gradient cyclohexane to 100% EtOAc, to afford compound <b>27-1R-meta</b> (838 mg, 86% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.41–7.26 (m, 5H), 7.25 (m, 1H), 7.21 (m, 1H), 6.88 (t, <i>J</i> = 8.5 Hz, 1H), 6.77 (m, 1H), 5.10 (m, 1H), 3.56–3.26 (m, 2H), 2.87 (s, 3H), 2.28–2.01 (m, 2H), 1.52–1.33 (bs, 9H). Chiral SFC analysis, method 2: RT, 2.63 min; 96% ee.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>tert</i>-Butyl (3-((3-Bromobenzyl)oxy)-3-phenylpropyl)(methyl)carbamate (<b>27-2-meta</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl (3-hydroxy-3-phenylpropyl)(methyl)carbamate (<b>28</b>, 115 mg, 0.43 mmol) in DMF (6 mL) cooled at 0 °C, NaH (35 mg, 60% in mineral oil, 0.86 mmol) was added, and the solution was stirred at rt for 30 min. Then, a solution of 1-bromo-3-(bromomethyl)benzene (162 mg, 0.65 mmol) in DMF (2 mL) was added at 0 °C and the mixture was stirred at rt for 3 h. Water was added, and the mixture was extracted with ethyl acetate. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded compound <b>27-2-meta</b> (159 mg, 80% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.48 (s, 1H), 7.44–7.37 (m, 3H), 7.37–7.30 (m, 3H), 7.26–7.19 (m, 2H), 4.40 (d, <i>J</i> = 12.1 Hz, 1H), 4.34 (m, 1H), 4.25 (d, <i>J</i> = 12.1 Hz, 1H), 3.41–3.22 (m, 2H), 2.85 (s, 3H), 2.07 (m, 1H), 1.94 (m, 1H), 1.45 (s, 9H).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl (<i>R</i>)-Methyl(3-(3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)carbamate (<b>30aR</b>)</h4><div class="NLM_p last">To a solution of <b>13-1</b> (150 mg, 0.67 mmol) and <b>27-1R-meta</b> (313 mg, 0.67 mmol) in dioxane (10 mL), CuI (38 mg, 0.20 mmol), K<sub>3</sub>PO<sub>4</sub> (284 mg, 1.33 mmol), and <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine (17 mg, 0.20 mmol) were added, and the mixture was heated at 110 °C under an Ar atmosphere for 16 h. The reaction mixture was cooled to rt, and the solvent was removed under vacuum to give a crude product that was purified by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, to afford compound <b>30aR</b> (267 mg, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.78 (s, 1H), 7.35 (m, 4H), 7.28 (m, 1H), 7.20 (m, 1H), 6.82 (m, 2H), 6.72 (m, 1H), 5.13 (m, 1H), 3.90 (m, 2H), 3.71 (m, 2H), 3.41 (m, 2H), 3.28 (s, 3H), 2.86 (s, 3H), 2.57 (s, 3H), 2.14 (m,2 H), 1.42 (s, 9H).</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>R</i>)-2-(Ethylamino)-9-methyl-6-(3-(3-(methylamino)-1-phenylpropoxy)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>31aR</b>)</h4><div class="NLM_p">To a solution of <b>30aR</b> (187 mg, 0.33 mmol) in DCM (6 mL), <i>m</i>-CPBA (123 mg, 0.49 mmol) was added, and the mixture was stirred at rt for 1 h. NaHCO<sub>3</sub> saturated solution was added, and the mixture was extracted with DCM. The organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. The crude product was dissolved in THF (6 mL), ethylamine (1.66 mL of a 2 M solution in THF, 3.32 mmol) was added, and the mixture was stirred at rt for 16 h. The crude residue was concentrated under vacuum and purified by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, to afford <i>tert</i>-butyl (<i>R</i>)-(3-(3-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)(methyl)carbamate (175 mg, 94% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.71 (s, 1H), 7.35 (m, 4H), 7.26 (m, 1H), 7.17 (m, 1H), 6.83 (m, 2H), 6.68 (m, 1H), 5.11 (m, 1H), 3.87 (m, 2H), 3.63 (m, 2H), 3.48 (m, 2H), 3.40 (m, 2H), 3.20 (s, 3H), 2.85 (s, 3H), 2.16 (m, 1H), 2.09 (m, 1H), 1.42 (s, 9H), 1.25 (t, <i>J</i> = 7 Hz, 3H).</div><div class="NLM_p last">To a solution of the previous compound (128 mg, 0.22 mmol) in dioxane (0.4 mL), HCl (4 M in dioxane, 0.800 mL, 3.20 mmol) was added, and the mixture was stirred at rt for 45 min. The reaction mixture was concentrated to dryness under vacuum. To obtain the free base, DCM was added and washed with Na<sub>2</sub>CO<sub>3</sub> (10% aqueous solution), and the aqueous phase was extracted with DCM. The combined organic layers were concentrated under vacuum to afford <b>31aR</b> (101 mg, 89% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.58 (bs, 1H), 7.48–7.46 (m, 2H), 7.42–7.38 (m, 2H), 7.34–7.26 (m, 2H), 6.92–6.91 (m, 1H), 6.89–6.85 (m, 2H), 5.42 (dd, <i>J</i> = 4.8, 8.0 Hz, 1H), 3.94–3.92 (m, 2H), 3.77–3.76 (m, 2H), 3.52–3.47 (m, 2H), 3.29 (s, 3H), 2.85–2.73 (m, 2H), 2.44 (s, 3H), 2.31–2.20 (m, 1H), 2.14–2.06 (m, 1H), 1.29 (t, <i>J</i> = 7.2 Hz, 3H). HPLC, method 1: RT, 4.95 min; purity, 97.2%. HRMS calcd for C<sub>26</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>, 461.266 [M + H]<sup>+</sup>; found, 461.267 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-(3-(3-(Dimethylamino)-1-phenylpropoxy)phenyl)-2-(ethylamino)-9-methyl-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>32</b>)</h4><div class="NLM_p last">To a solution of <b>31a</b> (57 mg, 0.124 mmol) in DCE (3 mL), paraformaldehyde (16 mg, 0.495 mmol), DIPEA (0.108 mL, 0.62 mmol), NaBH(OAc)<sub>3</sub> (105 mg, 0.49 mmol), and AcOH (7 μL, 0.12 mmol) were added, and the reaction mixture was stirred at rt for 70 h. NaHCO<sub>3</sub> aqueous saturated solution was added, extracted with DCM, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 20% MeOH, afforded <b>32</b> (63 mg, quant yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.50 (bs, 1H), 7.40–7.38 (m, 2H), 7.34–7.30 (m, 2H), 7.26–7.18 (m, 2H), 6.84–6.83 (m, 1H), 6.81–6.76 (m, 2H), 5.31 (dd, <i>J</i> = 4.7, 7.9 Hz, 1H), 3.85–3.84 (m, 2H), 3.69–3.67 (m, 2H), 3.42 (q, <i>J</i> = 7.1, 16.0 Hz, 2H), 3.21 (s, 3H), 2.59–2.41 (m, 2H), 2.24 (s, 6H), 2.21–2.13 (m, 1H), 2.05–1.96 (m, 1H), 1.21 (t, <i>J</i> = 7.1 Hz, 3H). HPLC, method 1: RT, 4.97 min; purity, 96.1%. HRMS calcd for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>2</sub>, 475.2816 [M + H]<sup>+</sup>; found, 475.2817 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(Ethylamino)-<i>N</i>-methyl-<i>N</i>-(3-(3-(methylamino)-1-phenylpropoxy)phenyl)pyrimidine-5-carboxamide (<b>34</b>)</h4><div class="NLM_p">To a solution of <b>37</b> (50 mg, 0.27 mmol) and <b>27-1-meta</b> (213 mg, 0.41 mmol) in dioxane (3 mL), CuI (16 mg, 0.08 mmol), K<sub>3</sub>PO<sub>4</sub> (118 mg, 0.55 mmol), and <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine (9 μL, 0.08 mmol) were added, and the mixture was heated at 110 °C under an Ar atmosphere for 16 h. The reaction mixture was cooled to rt, and the solvent was removed under vacuum to give a crude product that was purified by flash chromatography, silica gel, gradient DCM to 25% MeOH, to afford <i>tert</i>-butyl (3-(3-(2-(ethylamino)-<i>N</i>-methylpyrimidine-5-carboxamido)phenoxy)-3-phenylpropyl)(methyl)carbamate (51 mg, 35% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.65 (s, 2H), 7.34–7.19 (m, 5H), 6.81–6.74 (m, 2 H), 6.72 (m, 1H), 6.13 (m, 1H), 5.10 (dd, <i>J</i> = 4.2, 8.1 Hz, 1H), 3.97–3.83 (m, 2H), 3.47–3.35 (m, 2H), 2.97 (d, <i>J</i> = 4.8 Hz, 3H), 2.84 (s, 3H), 2.23–2.02 (m, 2H), 1.40 (s, 9H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p last">To a solution of the previous compound (40 mg, 0.07 mmol) in dioxane (0.2 mL), HCl (4 M in dioxane, 0.27 mL, 1.07 mmol) was added, and the mixture was stirred at rt for 30 min. The reaction mixture was concentrated to dryness under vacuum. To obtain the free base, DCM was added and washed with Na<sub>2</sub>CO<sub>3</sub> (10% aqueous solution), and the aqueous phase was extracted with DCM. The combined organic layers were concentrated under vacuum to afford <b>34</b> (30 mg, quant yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.65 (s, 2H), 7.38–7.36 (m, 2H), 7.33–7.30 (m, 2H), 7.25–7.22 (m, 2H), 6.86–6.84 (m, 1H), 6.75–6.74 (m, 2H), 5.31 (dd, <i>J</i> = 4.7, 8.0 Hz, 1H), 3.99–3.88 (m, 2H), 2.88 (s, 3H), 2.75–2.66 (m, 2H), 2.36 (s, 3H), 2.22–2.15 (m, 1H), 2.06–1.99 (m, 1H), 1.08 (t, <i>J</i> = 7.2 Hz, 3H). HPLC, method 1: RT, 5.48 min; purity, 97.5%. HRMS calcd for C<sub>24</sub>H<sub>30</sub>N<sub>5</sub>O<sub>2</sub>, 420.2394 [M + H]<sup>+</sup>; found, 420.2380 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-(Ethylamino)-<i>N</i>-methylpyrimidine-5-carboxamide (<b>37</b>)</h4><div class="NLM_p last">To a solution of ethyl 2-(methylthio)pyrimidine-5-carboxylate (<b>36</b>, 110 mg, 0.55 mmol) in DCM (4 mL), <i>m</i>-CPBA (166 mg, 0.72 mmol) was added, and the mixture was stirred at rt for 1 h. A NaHCO<sub>3</sub> aqueous saturated solution was added, and the mixture was extracted with DCM. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the solvent was removed under vacuum. The residue was dissolved in THF (4 mL), ethylamine (2 M solution in THF, 1.38 mL, 2.77 mmol) was added, and the mixture was stirred at rt for 3 h. The solvent was removed under vacuum. The residue was treated with methylamine (3 mL of a 33% solution in EtOH, 24.19 mmol) and NaCN (3 mg, 0.061 mmol), and the mixture was heated at 100 °C for 16 h. The solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 20% MeOH, afforded <b>37</b> (90 mg, 90% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.68 (s, 2H), 3.44 (q, <i>J</i> = 7.2 Hz, 2H), 2.89 (s, 3H), 1.22 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-3-(3-Bromophenoxy)-<i>N</i>-methyl-3-(thiophen-2-yl)propan-1-amine (<b>40S</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-3-(methylamino)-1-(thiophen-2-yl)propan-1-ol (<b>38S</b>, 1.2 g, 7.01 mmol) in dimethylacetamide (20 mL), NaH (420 mg, 60% in mineral oil, 10.51 mmol) was added, and the mixture was stirred at rt for 30 min. 1-Bromo-3-fluorobenzene (<b>39</b>, 2.45 g, 14.01 mmol) was added, and the mixture was heated at 90 °C for 3 h. Water was added, and the mixture was extracted with ethyl acetate. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford compound <b>40S</b> that was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.25 (dd, <i>J</i> = 1.2, 5.1 Hz, 1H), 7.13 (m, 1H), 7.10–7.06 (m, 2H), 7.03 (m, 1H), 6.96 (dd, <i>J</i> = 3.4, 5.0 Hz, 1H), 6.87 (dt, <i>J</i> = 2.2, 7.2 Hz, 1H), 5.57 (dd, <i>J</i> = 5.2, 7.5 Hz, 1H), 2.78 (m, 2H), 2.47 (s, 3H), 2.32 (m, 1H), 2.24 (bs, 1H), 2.13 (m, 1H).</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>tert</i>-Butyl (<i>S</i>)-(3-(3-Bromophenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate (<b>41-1S</b>)</h4><div class="NLM_p last">To a solution of <b>40S</b> (1.42 g, 4.38 mmol) in DCM (25 mL) at 0 °C, di-<i>tert</i>-butyldicarbonate (1.25 g, 5.73 mmol) was added, and the mixture was stirred at rt for 3 h. Water was added, and the mixture was extracted with DCM, washed with NaHCO<sub>3</sub> aqueous saturated solution and brine, and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded <b>41-1S</b> (1.3 g, 70% yield global two steps). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.25 (d, <i>J</i> = 5 Hz, 1H), 7.10 (m, 1H), 7.06 (m, 2H), 7.02 (m, 1H), 6,96 (m, 1H), 6.85 (td, <i>J</i> = 7, 2.5 Hz, 1H), 5.41 (m, 1H), 3.43 (m, 2H), 2.87 (s, 3H), 2.31 (m, 1H), 2.18 (m, 1H), 1.42 (s, 9H). Chiral SFC analysis, method 2: RT, 1.94 min; 98% ee.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(Trimethylsilyl)ethyl (<i>S</i>)-(3-(3-Bromophenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate (<b>41-2S</b>)</h4><div class="NLM_p last">To a solution of <b>40S</b> (2 g, 6.13 mmol) in DCM (14 mL), DIPEA (1.07 mL, 6.13 mmol) and a solution of 4-nitrophenyl (2-(trimethylsilyl)ethyl) carbonate (1.73 g, 6.13 mmol) in DCM (6 mL) were added, and the mixture was stirred at rt for 20 h. The reaction mixture was washed with NaHCO<sub>3</sub> aqueous saturated solution and 2 M NaOH until the bright yellow color almost disappeared. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded <b>41-2S</b> (2.05 g, 62% yield global two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.21 (m, 1H), 7.11–7.05 (m, 3H), 7.03–6.98 (m, 1H), 6.92 (m, 1H), 6.83 (m, 1H), 5.42 (m, 1H), 4.19–3.93 (m, 2H), 3.57 (m, 1H), 3.37 (m, 1H), 2.89 (m, 3H), 2.29 (m, 1H), 2.16 (m, 1H), 0.99 (m, 1H), 0.81 (m, 1H), 0.03 (s, 9H).</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>tert</i>-Butyl (<i>S</i>)-Methyl(3-(3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate (<b>42-1S</b>)</h4><div class="NLM_p last">To a solution of <b>13-1</b> (150 mg, 0.67 mmol) and <b>41-1S</b> (371 mg, 0.87 mmol) in dioxane (10 mL), CuI (38 mg, 0.20 mmol), K<sub>3</sub>PO<sub>4</sub> (284 mg, 1.34 mmol), and <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine (22 μL, 0.20 mmol) were added, and the mixture was heated at 100 °C in a sealed tube for 20 h. The reaction mixture was cooled to rt and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded <b>42-1S</b> (320 mg, 84% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.78 (s,1H), 7.25 (m, 2H), 7.03 (m, 1H), 6.95 (m, 1H), 6.87 (m, 2H), 6.82 (m, 1H), 5.43 (m, 1H), 3.93 (m, 2H), 3.75 (m, 2H), 3.39 (m, 2H), 3.29 (s, 3H), 2.86 (s, 3H), 2.56 (s, 3H), 2.25 (m, 2H), 1.42 (s, 9H).</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(Trimethylsilyl)ethyl (<i>S</i>)-Methyl(3-(3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate (<b>42-2S</b>)</h4><div class="NLM_p last">To a solution of <b>13-1</b> (350 mg, 1.56 mmol) and <b>41-2S</b> (1.1 g, 2.34 mmol) in dioxane (15 mL), CuI (89 mg, 0.47 mmol), K<sub>3</sub>PO<sub>4</sub> (662 mg, 3.12 mmol), and <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine (50 μL, 0.47 mmol) were added, and the mixture was heated at 100 °C in a sealed tube for 20 h. The reaction mixture was cooled to rt and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded <b>42-2S</b> (815 mg, 85% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.78 (s, 1H), 7.26 (m, 2H), 7.04 (m, 1H), 6.96 (m, 1H), 6.88 (m, 2H), 6.84 (m, 1H), 5.45 (m, 1H), 4.15 (m, 2H), 3.95 (m, 2H), 3.76 (m, 2H), 3.45 (m, 2H), 3.30 (s, 3H), 2.91 (s, 3H), 2.57 (s, 3H), 2–33 (m, 1H), 2–19 (m, 1H), 1.00 (m, 1H), 0.93 (m, 1H), 0.05 (s, 9H).</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-2-(Ethylamino)-9-methyl-6-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>45aS</b>)</h4><div class="NLM_p">To a solution of <b>42-1S</b> (970 mg, 1.70 mmol) in DCM (20 mL), <i>m</i>-CPBA (588 mg, 2.55 mmol) was added, and the mixture was stirred at rt for 1 h. NaHCO<sub>3</sub> aqueous saturated solution was added, and the mixture was extracted with DCM. The organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. The crude product was dissolved in THF (15 mL), and ethylamine (2 M solution in THF, 4.26 mL, 8.51 mmol) was added. The mixture was stirred at rt for 20 h. The solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded <i>tert</i>-butyl (<i>S</i>)-(3-(3-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate (817 mg, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (s, 1H), 7.23–7.19 (m, 2H), 7.01 (d, <i>J</i> = 3.0 Hz, 1H), 6.93 (dd, <i>J</i> = 3.6, 5.0 Hz, 1H), 6.87–6.85 (m, 2H), 6.78 (ddd, <i>J</i> = 0.8, 2.2, 8.2 Hz, 1H), 5.41 (dd, <i>J</i> = 5.2, 7.8, 1H), 5.16 (bs, 1H), 3.90–3.88 (m, 2H), 3.67–3.65 (m, 2H), 3.50–3.43 (m, 2H), 3.41–3.33 (m, 2H), 3.20 (s, 3H), 2.84 (s, 3H), 2.32–2.26 (m, 1H), 2.20–2.11 (m, 1H), 1.41 (s, 9H), 1.23 (t, <i>J</i> = 7.3 Hz, 3H).</div><div class="NLM_p last">A solution of the previous compound (800 mg, 1.41 mmol) in DCM (15 mL) was added to ZnBr<sub>2</sub> (1.9 g, 8.47 mmol, dried under vacuum at 250 °C for 2 h) under an atmosphere of Ar, and the reaction mixture was stirred at rt for 48 h. Water was added and stirred until complete solution with the help of ultrasound irradiation. The layers were separated, and the aqueous phase was extracted with DCM. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 40% MeOH, afforded a salt that was treated with NaHCO<sub>3</sub> aqueous saturated solution and extracted with DCM. The solvent was removed under vacuum to afford <b>45aS</b> (345 mg, 52% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.52 (s, 1H), 7.32 (dd, <i>J</i> = 1.1, 5.2 Hz, 1H), 7.24 (t, <i>J</i> = 8.2 Hz, 1H), 7.10 (dd, <i>J</i> = 0.7, 3.5 Hz, 1H), 6.95 (dd, <i>J</i> = 3.5, 5.1 Hz, 1H), 6.92–6.88 (m, 2H), 6.83 (ddd, <i>J</i> = 0.7, 1.7, 8.2 Hz, 1H), 5.67 (dd, <i>J</i> = 5.7, 7.5 Hz, 1H), 3.89–3.87 (m, 2H), 3.73–3.71 (m, 2H), 3.45–3.40 (m, 2H), 3.22 (s, 3H), 2.72–2.66 (m, 2H), 2.36 (s, 3H), 2.36–2.25 (m, 1H), 2.14–2.06 (m, 1H), 1.22 (t, <i>J</i> = 7.2 Hz, 3H). HPLC, method 1: RT, 4.82 min; purity, 99.3%. HRMS calcd for C<sub>24</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>S, 467.2224 [M + H]<sup>+</sup>; found, 467.2233 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(Dimethylamino)-9-methyl-6-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>45b</b>)</h4><div class="NLM_p">To a solution of <b>42-2</b> (105 mg, 0.17 mmol) in DCM (5 mL), <i>m</i>-CPBA (59 mg, 0.26 mmol) was added, and the mixture was stirred at rt for 1 h. NaHCO<sub>3</sub> aqueous saturated solution was added, and the mixture was extracted with DCM. The organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. The crude product was dissolved in THF (1 mL), and dimethylamine (40% solution in water, 0.43 mL) was added. The mixture was stirred at rt for 20 h. The solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 25% MeOH, afforded 2-(trimethylsilyl)ethyl (3-(3-(2-(dimethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate (90 mg, 86% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.75 (s, 1H), 7.21–7.17 (m, 2H), 7.03–6.68 (m, 1H), 6.93–6.91 (m, 1H), 6.86–6.84 (m, 2H), 6.78–6.74 (m, 1H), 5.44–5.39 (m, 1H), 4.17–4.03 (m, 2H), 3.88–3.86 (m, 2H), 3.65–3.63 (m, 2H), 3.50–3.34 (m, 2H), 3.19 (s, 6H), 3.18 (s, 3H), 2.87 (s, 3H), 2.34–2.24 (m, 1H), 2.21–2.11 (m, 1H), 1.00–0.87 (m, 2H), 0.01 (s, 9H).</div><div class="NLM_p last">To a solution of the previous compound (90 mg, 0.14 mmol) in DMF (4 mL), CsF (112 mg, 0.73 mmol) was added, and the mixture was heated at 90 °C for 90 min. The solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 40% MeOH, afforded <b>45b</b> (55 mg, 85% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.58 (s, 1H), 7.32 (dd, <i>J</i> = 1.2 5.1 Hz, 1H), 7.24 (t, 1H), 7.10 (dd, <i>J</i> = 1.1, 3.3 Hz, 1H), 6.95 (dd, <i>J</i> = 3.6, 5.1 Hz, 1H), 6.92–6.88 (m, 2H), 6.83 (ddd, <i>J</i> = 0.7, 1.9, 8.0 Hz, 1H), 5.68 (dd, <i>J</i> = 5.4, 7.5, 1H), 3.88–3.86 (m, 2H), 3.72–3.70 (m, 2H), 3.21 (s, 3H), 3.18 (s, 6H), 2.85–2.72 (m, 2H), 2.41 (s, 3H), 2.35–2.27 (m, 1H), 2.17–2.10 (m, 1H). HPLC, method 1: RT, 4.73 min; purity, 100%. HRMS calcd for C<sub>24</sub>H<sub>31</sub>N<sub>6</sub>O<sub>2</sub>S, 467.2224 [M + H]<sup>+</sup>; found, 467.2230 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-2-Amino-9-methyl-6-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>45cS</b>)</h4><div class="NLM_p last">A similar procedure to that used for the preparation of <b>45b</b> was used for the preparation of <b>45cS</b>, using, in step 1, ammonia 30% solution in water under MW irradiation at 100 °C for 30 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.52 (s, 1H), 7.30 (d, <i>J</i> = 4.9 Hz, 1H), 7.23 (t, 1H), 7.09 (d, <i>J</i> = 3.6 Hz, 1H), 6.94–6.87 (m, 3H), 6.81 (d, <i>J</i> = 7.9 Hz, 1H), 5.66 (dd, <i>J</i> = 5.8, 7.7, 1H), 3.85–3.83 (m, 2H), 3.68–3.66 (m, 2H), 3.17 (s, 3H), 2.75–2.62 (m, 2H), 2.35 (s, 3H), 2.33–2.24 (m, 1H), 2.14–2.06 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 168.08, 163.19, 162.62, 158.73, 158.41, 144.71, 144.59, 129.64, 126.31, 125.38, 124.98, 118.88, 114.54, 114.50, 103.44, 74.57, 54.53, 49.64, 47.55, 37.84, 37.62, 34.78. HRMS calcd for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub>S, 439.1900 [M + H]<sup>+</sup>; found, 439.1902 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>S</i>)-9-Methyl-6-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>46S</b>)</h4><div class="NLM_p">A mixture of <b>42-2S</b> (1 g, 1.63 mmol) and 5% Pd/C (139 mg, 0.065 mmol) in THF (15 mL) was cooled at 0 °C, and triethylsilane (1.3 mL, 8.15 mmol) was added. The reaction mixture was stirred at 0 °C in a sealed tube for 5 min and then at rt for 4 h. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated under vacuum. Purification by flash chromatography, silica gel, gradient hexane to 100% acetone, afforded 2-(trimethylsilyl)ethyl (<i>S</i>)-methyl(3-(3-(9-methyl-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate (750 mg, 81% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.91 (s, 1H), 8.69 (s, 1H), 7.27–7.23 (m, 2H), 7.04 (m, 1H), 6.95 (m, 1H), 6.88 (m, 2H), 6.84 (m, 1H), 5.45 (m, 1H), 4.20–4.05 (m, 2H), 3.94 (m, 2H), 3.77 (m, 2H), 3.51–3.39 (m, 2H), 3.28 (s, 3H), 2.90 (s, 3H), 2.32 (m, 1H), 2.19 (m, 1H), 0.99 (m, 1H), 0.92 (m, 1H), 0.04 (s, 9H).</div><div class="NLM_p last">To a solution of the previous compound (720 mg, 1.27 mmol) in DMF (12 mL), CsF (963 mg, 6.34 mmol) was added, and the mixture was heated at 90 °C for 90 min. Water was added and stirred until complete solution with the help of ultrasound irradiation. DCM was added, and the mixture was filtered through a pad of Celite and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 35% MeOH/NH<sub>3</sub> aq (1:0.01), afforded <b>46S</b> (510 mg, 87% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.72 (s, 1H), 8.56 (s, 1H), 7.32 (dd, <i>J</i> = 0.9, 4.9 Hz, 1H), 7.27 (t, 1H), 7.10 (d, <i>J</i> = 3.3 Hz, 1H), 6.96–6.91 (m, 3H), 6.87 (d, <i>J</i> = 8.0 Hz, 1H), 5.68 (dd, <i>J</i> = 5.7, 7.7, 1H), 3.95–3.93 (m, 2H), 3.84–3.82 (m, 2H), 3.28 (s, 3H), 2.76–2.63 (m, 2H), 2.36 (s, 3H), 2.34–2.24 (m, 1H), 2.15–2.06 (m, 1H). HPLC, method 1: RT, 4.38 min; purity, 99.2%. HRMS calcd for C<sub>22</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>S, 424.1802 [M + H]<sup>+</sup>; found, 424.1808 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-2,9-Dimethyl-6-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-6,7,8,9-tetrahydro-5<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one (<b>47S</b>)</h4><div class="NLM_p">To a solution of <b>42-1S</b> (250 mg, 0.44 mmol) in DCM (7 mL), <i>m</i>-CPBA (151 mg, 0.66 mmol) was added, and the mixture was stirred at rt for 1 h. NaHCO<sub>3</sub> aqueous saturated solution was added, and the mixture was extracted with DCM. The organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. The crude product was dissolved in THF (7 mL) and cooled at 0 °C, and MeMgBr (3 M solution in Et<sub>2</sub>O, 0.176 mL, 0.52 mmol) was added. The mixture was stirred at 0 °C for 1 h. Some drops of water were added, and the solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 80% acetone, afforded <i>tert</i>-butyl (<i>S</i>)-(3-(3-(2,9-dimethyl-5-oxo-5,7,8,9-tetrahydro-6<i>H</i>-pyrimido[4,5-<i>e</i>][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate (160 mg, 68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.87 (s,1H), 7.23 (m, 2H), 7.03 (m, 1H), 6.94 (m, 1H), 6.87 (m, 2H), 6.82 (m, 1H), 5.43 (m, 1H), 3.91 (m, 2H), 3.73 (m, 2H), 3.38 (m, 2H), 3.27 (s, 3H), 2.85 (s, 3H), 2.57 (s, 3H), 2.30 (m, 1H), 2.18 (m, 1H), 1.42 (s, 9H).</div><div class="NLM_p last">A solution of the previous compound (160 mg, 0.30 mmol) in DCM (5 mL) was added to ZnBr<sub>2</sub> (402 mg, 1.78 mmol, dried under vacuum at 250 °C for 2 h) under an atmosphere of Ar, and the reaction mixture was stirred at rt for 24 h. Water was added, and the mixture was stirred until the solids completely dissolved with the help of ultrasound irradiation. The layers were separated, and the aqueous phase was extracted with DCM. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 35% MeOH, afforded a salt that was treated with NaHCO<sub>3</sub> aqueous saturated solution and extracted with DCM. The solvent was removed under vacuum to afford <b>47S</b> (44 mg, 31% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.74 (s, 1H), 7.40 (dd, <i>J</i> = 1.2, 5.0 Hz, 1H), 7.34 (t, 1H), 7.18 (dd, <i>J</i> = 1.1, 3.5 Hz, 1H), 7.04–6.98 (m, 3H), 6.94 (ddd, <i>J</i> = 0.8, 1.9, 7.9 Hz, 1H), 5.76 (dd, <i>J</i> = 5.7, 7.5 Hz, 1H), 4.01–3.99 (m, 2H), 3.90–3.88 (m, 2H), 3.36 (s, 3H), 2.84–2.71 (m, 2H), 2.58 (s, 3H), 2.44 (s, 3H), 2.42–2.31 (m, 1H), 2.21–2.14 (m, 1H). HPLC, method 1: RT, 4.50 min; purity, 96.1%. HRMS calcd for C<sub>23</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>S, 438.1957 [M + H]<sup>+</sup>; found, 438.1959 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>tert</i>-Butyl (2-(2,6-Dichloronicotinamido)ethyl)(methyl)carbamate (<b>52-2</b>)</h4><div class="NLM_p last">To a solution of 2,6-dichloronicotinoyl chloride (<b>50-2</b>, 2.45 g, 11.67 mmol) in THF (18 mL) at 0 °C, a solution of <i>tert</i>-butyl (2-aminoethyl)(methyl)carbamate (<b>51</b>, 1.90 g, 10.90 mmol) in THF (27 mL) and Et<sub>3</sub>N (5.64 mL, 40.50 mmol) were added. The mixture was stirred at 0 °C for 10 min and then at rt for 2.5 h. Water was added, the mixture was extracted with DCM, the DCM extract was isolated and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient cyclohexane to 100% ethyl acetate, afforded <b>52-2</b> (2.9 g, 76% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.01 (d, <i>J</i> = 7.83 Hz, 1H), 7.34 (d, <i>J</i> = 7.83 Hz, 1H), 3.60–3.64 (m, 2H), 3.50–3.54 (m, 2H), 2.93 (s, 3H), 1.43 (s, 9H).</div></div><div id="sec4_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2,6-Dichloro-<i>N</i>-(2-(methylamino)ethyl)nicotinamide Hydrochloride (<b>53-2</b>)</h4><div class="NLM_p last">To a solution of <b>52-2</b> (2.9 g, 8.33 mmol) in dioxane (15 mL), HCl (4 M solution in dioxane, 31.2 mL, 125 mmol) was added, and the mixture was stirred at rt for 2 h. The reaction mixture was concentrated to dryness under vacuum to afford <b>53-2</b> (2.3 g, quant yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.08 (d, <i>J</i> = 8.01 Hz, 1H), 7.56 (d, <i>J</i> = 8.01 Hz, 1H), 3.72 (t, <i>J</i> = 6.02 Hz, 2H), 3.28 (t, <i>J</i> = 6.02 Hz, 2H), 2.79 (s, 3H).</div></div><div id="sec4_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 8-Chloro-1-methyl-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-5-one (<b>54-2</b>)</h4><div class="NLM_p last">To a mixture of <b>53-2</b> (1.2 g, 3.74 mmol) and CsF (2.84 g, 18.69 mmol) in DMF (125 mL) under an Ar atmosphere, Et<sub>3</sub>N (1.25 mL, 8.97 mmol) was added, and the mixture was heated at 75 °C for 16 h. The reaction mixture was cooled to rt, and the solvent was removed under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 40% MeOH, afforded <b>54-2</b> (729 mg, 92% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.26 (bs, 1H), 6.69 (d, <i>J</i> = 8.0 Hz, 1H), 3.65 (m, 2 H), 3.54 (m, 2H), 3.19 (s, 3H).</div></div><div id="sec4_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 8-(Ethylamino)-1-methyl-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-5-one (<b>55-2</b>)</h4><div class="NLM_p">A mixture of <b>54-2</b> (95 mg, 0.45 mmol) and ethylamine (70% solution in water, 2.75 mL, 34.1 mmol) was irradiated with microwaves at 130 °C for 2 h. The solvent was removed under vacuum, and the residue was purified by flash chromatography, silica gel, gradient DCM to 40% MeOH, to afford <b>55-2</b> (84 mg, 85% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.15 (d, <i>J</i> = 8.5 Hz, 1H), 6.19 (bs, 1H), 5.85 (d, <i>J</i> = 8.5 Hz, 1H), 4.58 (bs, 1H), 3.58 (m, 2 H), 3.49 (m, 2H), 3.38 (m, 2H), 3.17 (s, 3H), 1.26 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p last">A similar procedure was used for the preparation of <b>55-1</b> starting from <b>50-1</b>.</div></div><div id="sec4_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-8-(Ethylamino)-1-methyl-4-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-5-one (<b>57S</b>)</h4><div class="NLM_p">A mixture of CuI (18 mg, 0.09 mmol) and <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine (10 μL, 0.09 mmol) in dioxane (0.25 mL) was stirred at rt for 20 min. To this mixture, a solution of <b>55-2</b> (41 mg, 0.19 mmol) and <b>41-2S</b> (96 mg, 0.19 mmol) in a mixture of dioxane (1.25 mL) and DMSO (0.2 mL) and K<sub>3</sub>PO<sub>4</sub> (119 mg, 0.56 mmol) were added. The reaction mixture was heated at 130 °C in a sealed tube for 20 h. The reaction mixture was cooled at rt and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient hexane to 100% ethyl acetate, afforded 2-(trimethylsilyl)ethyl (<i>S</i>)-(3-(3-(8-(ethylamino)-1-methyl-5-oxo-1,2,3,5-tetrahydro-4<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate (51 mg, 45% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.95 (d, <i>J</i> = 8.5 Hz, 1H), 7.27–7.19 (m, 2H), 7.03 (br, 1H), 6.95–6.90 (m, 3H), 6.78 (d, <i>J</i> = 8.0 Hz, 1H), 5.87 (d, <i>J</i> = 8.4 Hz, 1H), 5.46–5.42 (m, 1H), 4.63–4.59 (m, 1H), 4.17–4.10 (m, 2H), 3.91–3.88 (m, 2H), 3.60–3.57 (m, 2H), 3.45–3.31 (m, 4H), 3.09 (s, 3H), 2.90 (s, 3H), 2.35–2.28 (m, 1H), 2.22–2.12 (m, 1H), 1.26 (t, <i>J</i> = 7.2 Hz, 3H), 0.97 (bs, 2H), 0.04 (s, 9H).</div><div class="NLM_p">To a solution of the previous compound (51 mg, 0.08 mmol) in DMF (0.6 mL), CsF (64 mg, 0.42 mmol) was added, and the mixture was irradiated with MW at 90 °C for 90 min. The reaction mixture was cooled at rt, filtered through a pad of Celite, and concentrated under vacuum to afford <b>57S</b> (38 mg, 98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94 (d, <i>J</i> = 8.5 Hz, 1H), 7.22–7.18 (m, 2H), 7.01 (d, <i>J</i> = 3.4 Hz, 1H), 6.94–6.87 (m, 3H), 6.79 (dd, <i>J</i> = 2.3, 8.4 Hz, 1H), 5.86 (d, <i>J</i> = 8.5 Hz, 1H), 5.55 (dd, <i>J</i> = 5.6, 7.6 Hz, 1H), 4.59 (br, 1H), 3.89–3.87 (m, 2H), 3.58–3.56 (m, 2H), 3.39–3.32 (m, 2H), 3.07 (s, 3H), 2.77–2.67 (m, 2H), 2.41 (s, 3H), 2.32–2.21 (m, 1H), 2.12–2.04 (m, 1H), 1.24 (t, 3H). HPLC, method 1: RT, 4.84 min; purity, 96.0%. HRMS calcd for C<sub>25</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub>S, 466.2271 [M + H]<sup>+</sup>; found, 466.2276 [M + H]<sup>+</sup>.</div><div class="NLM_p last">A similar procedure was used for the preparation of <b>56S</b>, <b>59S</b>, <b>61S</b>, <b>63S</b>, <b>65</b>, <b>67</b>, <b>69</b>, <b>71R</b>, and <b>71S</b> from the corresponding starting materials. In some examples, purification by flash chromatography was needed (silica gel, gradient DCM to 40% MeOH).</div></div><div id="sec4_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-1-Methyl-4-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-3,4-dihydro-1<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-5(2<i>H</i>)-one (<b>59S</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.33 (dd, <i>J</i> = 2.1, 4.8 Hz, 1H), 8.04 (dd, <i>J</i> = 2.1, 7.6 Hz, 1H), 7.27–7.22 (m, 2H), 7.02 (d, <i>J</i> = 3.1 Hz, 1 H), 6.96–6.91 (m, 3H), 6.85 (dd, <i>J</i> = 2.3, 8.2 Hz, 1H), 6.80 (dd, <i>J</i> = 4.8, 7.8 Hz, 1H), 5.57 (dd, <i>J</i> = 5.4, 7.7 Hz, 1H), 3.90–3.87 (m, 2H), 3.61–3.58 (m, 2H), 3.08 (s, 3H), 2.77–2.67 (m, 2H), 2.42 (s, 3H), 2.35–2.20 (m, 1H), 2.14–2.03 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.78, 158.63, 155.56, 151.22, 144.97, 143.72, 140.87, 129.85, 126.59, 124.89, 124.83, 119.64, 118.90, 114.68, 114.51, 114.34, 74.99, 56.81, 49.17, 48.17, 38.76, 38.75, 36.53. HRMS calcd for C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>S, 423.1853 [M + H]<sup>+</sup>; found, 423.1849 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-Methyl-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-5-one (<b>58</b>)</h4><div class="NLM_p last">To a solution of <b>54-2</b> (550 mg, 2.60 mmol) in THF (12 mL), Pd/C (5% wt, 221 mg, 0.10 mmol) was added, and the mixture was cooled at 0 °C in a sealed tube. Triethylsilane (1.51 g, 13.0 mmol) was added, and the reaction mixture was stirred at 0 °C for 5 min and then at rt for 16 h. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 30% MeOH, afforded <b>58</b> (378 mg, 82% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.32 (dd, <i>J</i> = 2.0, 4.6 Hz, 1H), 8.21 (dd, <i>J</i> = 2.0, 7.6 Hz, 1H), 7.01 (bs, 1H), 6.75 (dd, <i>J</i> = 4.6, 7.6 Hz, 1H), 3.62 (m, 2 H), 3.54 (m, 2H), 3.16 (s, 3H).</div></div><div id="sec4_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1,8-Dimethyl-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[2,3<i>-e</i>][1,4]diazepin-5-one (<b>60</b>)</h4><div class="NLM_p last">To a mixture of <b>54-2</b> (50 mg, 0.23 mmol), methylboronic acid (16 mg, 0.27 mmol), Pd(Ph<sub>3</sub>)<sub>4</sub> (27 mg, 0.024 mmol), and K<sub>2</sub>CO<sub>3</sub> (98 mg, 0.71 mmol) under Ar, degassed dioxane (1.2 mL) was added, and the mixture was heated at 130 °C in a sealed tube for 48 h. The reaction mixture was cooled to rt and filtered through a pad of Celite. The filtrate was concentrated under vacuum, and the residue was purified by flash chromatography, silica gel, gradient hexane to 100% acetone, to afford <b>60</b> (45 mg, 77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.15 (d, <i>J</i> = 7.8 Hz, 1H), 6.61 (d, <i>J</i> = 7.8 Hz, 1H), 6.56 (bs, 1H), 3.61 (m, 2 H), 3.53 (m, 2H), 3.19 (s, 3H), 2.45 (s, 3H).</div></div><div id="sec4_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 8-Methoxy-1-methyl-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[2,3-<i>e</i>][1,4]diazepin-5-one (<b>62</b>)</h4><div class="NLM_p last">To a solution of <b>54-2</b> (500 mg, 2.36 mmol) in MeOH (17 mL), NaOMe (766 mg, 14.17 mmol) was added, and the mixture was irradiated with MW at 110 °C for 2 h. The solvent was removed under vacuum, and the residue was purified by flash chromatography, silica gel, gradient DCM to 30% MeOH, to afford <b>62</b> (440 mg, 90% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 6.10 (d, <i>J</i> = 8.5 Hz, 1H), 3.91 (s, 3H), 3.63 (m, 2 H), 3.47 (m, 2H), 3.22 (s, 3H).</div></div><div id="sec4_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-Methyl-1,2,3,4-tetrahydro-5<i>H</i>-pyrido[3,2-<i>e</i>][1,4]diazepin-5-one (<b>64</b>)</h4><div class="NLM_p">To a solution of ethyl 3-fluoropicolinate (190 mg, 1.12 mmol) in dimethylacetamide (2.2 mL), K<sub>2</sub>CO<sub>3</sub> (310 mg, 2.24 mmol) and <i>N</i><sup>1</sup>-methylethane-1,2-diamine (83 mg, 1.12 mmol) were added, and the mixture was heated at 150 °C in a sealed tube for 64 h. The reaction mixture was cooled at rt and concentrated under vacuum. Purification by flash chromatography, silica gel, gradient DCM to 20% MeOH, afforded compound <b>64</b> (56 g, 28% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.33 (m, 1H), 7.98 (bs, 1H), 7.32 (m, 1H), 7.27 (m, 1H), 3.45 (m, 2H), 3.37 (m, 2H), 2.89 (s, 3H).</div><div class="NLM_p last">A similar procedure was used for the preparation of <b>66</b> from methyl 3-fluoroisonicotinate.</div></div><div id="sec4_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-Methyl-1,2,3,4-tetrahydro-5<i>H</i>-benzo[<i>e</i>][1,4]diazepin-5-one (<b>68</b>)</h4><div class="NLM_p last">To a suspension of 1,2,3,4-tetrahydro-5<i>H</i>-benzo[<i>e</i>][1,4]diazepin-5-one (<b>72</b>, 410 mg, 2.53 mmol) in DCE (20 mL), DIPEA (653 mg, 5.06 mmol), paraformaldehyde (296 mg, 9.35 mmol), NaBH(OAc)<sub>3</sub> (1.98 g, 9.35 mmol), and acetic acid (152 mg, 2.53 mmol) were added, and the reaction mixture was stirred at rt for 48 h. NaHCO<sub>3</sub> aqueous saturated solution was added, and the mixture was extracted with DCM. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was removed under vacuum. The residue was treated with diethyl ether, and the solid obtained was filtered and washed with diethyl ether to afford <b>68</b> (410 mg, 92% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.37 (bs, 1H), 7.67 (m, 1H), 7.38 (m, 1H), 6.98 (m, 1H), 6.89 (m, 1H), 3.36 (m, 2H), 3.30 (m, 2H), 2.84 (s, 3H).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> NET Modeling</h3><div class="NLM_p last">The human sequence of the sodium-dependent noradrenaline transporter (spP23975) was aligned to the SERT sequences of the crystallized structures 5I6X, 5I6Z, 5I71, 5I73, 5I74, and 5I75,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and 100 homology models were generated using the MODELLER<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> program within Discovery Studio.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The model with the lower PDF total energy was selected, and its loops were optimized with MODELLER using the DOPE method. The best homology model obtained was typed with CHARMM, residue p<i>K</i>’s were calculated, the protein was ionized at pH 7, and compound <b>31aS</b> was docked with LibDock,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> defining the binding site as an 8 Å sphere centered on the paroxetine structure of the aligned 5I6X crystal structure. The obtained complex was inserted into an SPC–POPC orthorhombic box, using the Maestro’s system builder,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> with a 10 Å buffer between the system and the edge of the box, and sodium and chloride ions were added to neutralize and reach a final concentration of 0.15 M. Both systems were typed with the OPLS force field and equilibrated by a standard eight-step protocol for transmembrane proteins, and finally, a 1 μs production simulation in the NPgT ensemble was run and analyzed with Desmond.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Human α2δ-1 Subunit of Cav2.2 Calcium Channel Assay</h3><div class="NLM_p last">Human α2δ-1-enriched membranes (3 μg) from hamster tumor CHO-K1 cells (human Cav2.2/β3/α2δ calcium channel cell line, catalog #CT6159, ChanTest) were incubated with 15 nM radiolabeled [<sup>3</sup>H]-gabapentin in assay buffer containing HEPES/KOH 10 mM (pH 7.4). Nonspecific binding (NSB) was measured by adding 10 μM pregabalin. The final volume was 100 μL. The binding of the tested compounds was measured at five different concentrations per duplicate, to determine affinity values (<i>K</i><sub>i</sub>). After 60 min of incubation at 27 °C, the binding reaction was terminated by filtering through MultiScreen GF/C (Millipore) presoaked in 0.5% polyethyleneimine in a vacuum manifold station followed by three washes with ice-cold filtration buffer containing 50 mM Tris–HCl (pH 7.4). Filter plates were dried at 60 °C for 2 h, and 30 μL of scintillation cocktail was added to each well before radioactivity reading. Readings were performed in a TriLux 1450 MicroBeta radioactive counter (PerkinElmer).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Human α2δ-2 Subunit of Cav2.2 Calcium Channel Assay</h3><div class="NLM_p last">Human α2δ-2-enriched membranes (6 μg) from human embryonic kidney HEK-293 cells were incubated with 15 nM radiolabeled [<sup>3</sup>H]-gabapentin in assay buffer containing HEPES/KOH 10 mM (pH 7.4). Nonspecific binding (NSB) was measured by adding 10 μM pregabalin. The final volume was 100 μL. The binding of the tested compounds was measured at five different concentrations, duplicate, to determine affinity values (<i>K</i><sub>i</sub>). After 60 min of incubation at 27 °C, the binding reaction was terminated by filtering through MultiScreen GF/C (Millipore) presoaked in 0.5% polyethyleneimine in a vacuum manifold station followed by three washes with ice-cold filtration buffer containing 50 mM Tris–HCl (pH 7.4). Filter plates were dried at 60 °C for 2 h, and 30 μL of scintillation cocktail was added to each well before radioactivity reading. Readings were performed in a TriLux 1450 MicroBeta radioactive counter (PerkinElmer).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> NET Binding Assay</h3><div class="NLM_p last">NET-enriched membranes (5 μg) were incubated with 5 nM radiolabeled [<sup>3</sup>H]-nisoxetine in assay buffer containing 50 mM Tris–HCl, 120 mM NaCl, and 5 mM KCl (pH 7.4). NSB (nonspecific binding) was measured by adding 10 μM desipramine. The binding of the test compound was measured at either one concentration (% inhibition at 1 or 10 μM) or five different concentrations to determine affinity values (<i>K</i><sub>i</sub>). After 60 min of incubation at 4 °C, the binding reaction was terminated by filtering through MultiScreen GF/C (Millipore) presoaked in 0.5% polyethyleneimine in a vacuum manifold station followed by three washes with ice-cold filtration buffer containing 50 mM Tris–HCl and 0.9% NaCl (pH 7.4). Filter plates were dried at 60 °C for 1 h, and 30 μL of scintillation cocktail was added to each well before radioactivity reading. Readings were performed in a TriLux 1450 MicroBeta radioactive counter (PerkinElmer).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> NET Functional Assay</h3><div class="NLM_p last">The day before the experiment, 5000 cells/well were seeded in 384 poly-<span class="smallcaps smallerCapital">d</span>-lysine-treated well plates (Corning) in a complete medium and maintained at 37 °C at 5% CO<sub>2</sub>. On the experiment day, the cell culture medium was removed and trypan blue (20 μL) was added (600 μM final concentration). This was immediately followed by the application of the test compounds (10 μL/well) at different final concentrations (from 10<sup>–4</sup> to 10<sup>–11</sup> M). Then, the plates were left at 37 °C for 20 min. After this time, ASP<sup>+</sup> (4-(4-(dimethylamino) styryl)-<i>N</i>-methylpyridinium iodide, 20 μL) was added (10 mM final well concentration). The reaction was incubated for 90 min at 37 °C. Finally, the fluorescence was read with the fluorescent reader EnVision (PerkinElmer).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01867" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01867?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01867</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data for all the final compounds and intermediates and HPLC traces for final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">NET homology data for compound <b>31aS</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_001.pdf">jm0c01867_si_001.pdf (2.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_002.csv">jm0c01867_si_002.csv (5.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_003.pdb">jm0c01867_si_003.pdb (774.11 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01867" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmen Almansa</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5665-4685" title="Orcid link">http://orcid.org/0000-0001-5665-4685</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5231333e3f333c21331225373e33307c30332031373e3d3c33"><span class="__cf_email__" data-cfemail="6d0e0c01000c031e0c2d1a08010c0f430f0c1f0e080102030c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Luis Díaz</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8812-4689" title="Orcid link">http://orcid.org/0000-0001-8812-4689</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Félix Cuevas</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gonzalo Pazos</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paula Álvarez-Bercedo</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana I. Oliva</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Ángeles Sarmentero</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Font</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agustín Jiménez-Aquino</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María Morón</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adriana Port</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosalía Pascual</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert Dordal</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Enrique Portillo-Salido</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raquel F. Reinoso</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Miguel Vela</span> - <span class="hlFld-Affiliation affiliation">ESTEVE
Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain</span>; 
    <span>Present Address:
                        WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain (J.L.D., A.P., R.P., A.D., E.P.-S., R.F.R., J.M.V., and C.A.)</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Magda Bordas, Raquel Enrech, Joan Andreu Morató, Mónica Carro, Edmundo Ortega, Manuel Merlos, Pilar Pérez, Javier Burgueño, Marta Pujol, Enrique Hernández, Javier Farré, Inés Álvarez, Xavier Monroy, Maite Serafini, Eva Ayet, and Sandra Yeste for their expert contribution to analytical, <i>in vitro</i> and <i>in vivo</i> studies and Carlos Pérez and Eduardo Villarroel for their contribution to compound management. This work was a part of activities in R&D Projects IDI20130945 and IDI20150917 supported by the Spanish Ministerio de Economía y Competitividad (MINECO), through the Centro para el Desarrollo Tecnológico Industrial (CDTI), co-financed by the European Union through the European Regional Development Fund (ERDF; Fondo Europeo de Desarrollo Regional, FEDER).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ASP<sup>+</sup></td><td class="NLM_def"><p class="first last">4-(4-(dimethylamino)styryl)-<i>N</i>-methylpyridinium iodide</p></td></tr><tr><td class="NLM_term">Ca<sub>v</sub>α2δ-1</td><td class="NLM_def"><p class="first last">α2δ-1 subunit of voltage-gated calcium channels</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">3-methylamino-1-phenylpropoxy</p></td></tr><tr><td class="NLM_term">MAT</td><td class="NLM_def"><p class="first last">3-methylamino-1-thiophenylpropoxy</p></td></tr><tr><td class="NLM_term">NE</td><td class="NLM_def"><p class="first last">norepinephrine</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine transporter</p></td></tr><tr><td class="NLM_term">NRI</td><td class="NLM_def"><p class="first last">norepinephrine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">positive ionizable</p></td></tr><tr><td class="NLM_term">rhCYP</td><td class="NLM_def"><p class="first last">recombinant human cytochrome P450</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">SNRI</td><td class="NLM_def"><p class="first last">serotonin and norepinephrine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">Teoc</td><td class="NLM_def"><p class="first last">trimethylsilylethoxycarbonyl</p></td></tr><tr><td class="NLM_term">VGCC</td><td class="NLM_def"><p class="first last">voltage-gated calcium channels</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahana, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic non-cancer pain</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2235</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60402-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2FS0140-6736%2811%2960402-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21704872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=2226-2235&author=D.+C.+Turkauthor=H.+D.+Wilsonauthor=A.+Cahana&title=Treatment+of+chronic+non-cancer+pain&doi=10.1016%2FS0140-6736%2811%2960402-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic non-cancer pain</span></div><div class="casAuthors">Turk, Dennis C.; Wilson, Hilary D.; Cahana, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9784</span>),
    <span class="NLM_cas:pages">2226-2235</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Chronic pain is a pervasive problem that affects the patient, their significant others, and society in many ways.  The past decade has seen advances in our understanding of the mechanisms underlying pain and in the availability of tech. advanced diagnostic procedures; however, the most notable therapeutic changes have not been the development of novel evidenced-based methods, but rather changing trends in applications and practices within the available clin. armamentarium.  We provide a general overview of empirical evidence for the most commonly used interventions in the management of chronic non-cancer pain, including pharmacol., interventional, phys., psychol., rehabilitative, and alternative modalities.  Overall, currently available treatments provide modest improvements in pain and min. improvements in phys. and emotional functioning.  The quality of evidence is mediocre and has not improved substantially during the past decade.  There is a crucial need for assessment of combination treatments, identification of indicators of treatment response, and assessment of the benefit of matching of treatments to patient characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxyG7QutTErVg90H21EOLACvtfcHk0lieXptPFTEwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D&md5=55b3b3e920ec253406736fcee3337754</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960402-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960402-9%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DD.%2BC.%26aulast%3DWilson%26aufirst%3DH.%2BD.%26aulast%3DCahana%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520chronic%2520non-cancer%2520pain%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D2226%26epage%3D2235%26doi%3D10.1016%2FS0140-6736%2811%2960402-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinatra, R.</span></span> <span> </span><span class="NLM_article-title">Causes and consequences of inadequate management of acute pain</span>. <i>Pain Med</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1859</span>– <span class="NLM_lpage">1871</span>, <span class="refDoi"> DOI: 10.1111/j.1526-4637.2010.00983.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1111%2Fj.1526-4637.2010.00983.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21040438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FitVCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1859-1871&author=R.+Sinatra&title=Causes+and+consequences+of+inadequate+management+of+acute+pain&doi=10.1111%2Fj.1526-4637.2010.00983.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Causes and consequences of inadequate management of acute pain</span></div><div class="casAuthors">Sinatra Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Pain medicine (Malden, Mass.)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1859-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Intense acute pain afflicts millions of patients each year.  Despite the recently increased focus on the importance of pain control, management of acute pain has remained suboptimal.  OBJECTIVE:  The objective of this study was to identify through a review of recent literature the barriers to effective treatment of acute pain and the potential consequences of inadequate pain management.  DESIGN:  A comprehensive literature review was conducted to identify articles relevant to the management of acute pain.  Information regarding the underlying causes of inadequate pain management, as well as the sequelae associated with undermanaged pain was extracted and summarized.  RESULTS:  Studies indicate that treatment of acute pain remains suboptimal due to attitudes and educational barriers on the part of both physicians and patients, as well as the intrinsic limitations of available therapies.  Inadequate management of acute pain negatively impacts numerous aspects of patient health, and may increase the risk of developing chronic pain.  Although opioids are the preferred treatment for most moderate to severe acute pain, their side effects can impede their use, and thus, their clinical effectiveness.  Analgesic regimens with an improved efficacy/tolerability balance have the potential to improve acute pain management, and thus reduce the incidence of chronic pain.  Studies examining the use of multiple analgesics with different mechanisms of action suggest that multimodal therapies may offer an improved efficacy/tolerability balance over single agent regimens.  CONCLUSIONS:  There exists a significant need for effective, well-tolerated analgesic therapies to limit the negative consequences of undermanaged acute pain.  The use of multimodal therapy has demonstrated increasing promise and is supported by current practice guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7DxO1LDDlzJSWdIdmEou5fW6udTcc2eZja1TM7QZberntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FitVCmuw%253D%253D&md5=bfa0e3889f5c268cd2326c2d03dd58b4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1526-4637.2010.00983.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1526-4637.2010.00983.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinatra%26aufirst%3DR.%26atitle%3DCauses%2520and%2520consequences%2520of%2520inadequate%2520management%2520of%2520acute%2520pain%26jtitle%3DPain%2520Med%26date%3D2010%26volume%3D11%26spage%3D1859%26epage%3D1871%26doi%3D10.1111%2Fj.1526-4637.2010.00983.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergolizzi, J. V.,  jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarida, R. J.</span></span> <span> </span><span class="NLM_article-title">The determination and application of fixed-dose analgesic combinations for treating multimodal pain</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2009.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.jpain.2009.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=20338825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFKqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=701-709&author=R.+B.+Raffaauthor=J.+V.+Pergolizziauthor=R.+J.+Tallarida&title=The+determination+and+application+of+fixed-dose+analgesic+combinations+for+treating+multimodal+pain&doi=10.1016%2Fj.jpain.2009.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The determination and application of fixed-dose analgesic combinations for treating multimodal pain</span></div><div class="casAuthors">Raffa, Robert B.; Pergolizzi, Joseph V., Jr.; Tallarida, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">701-709</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  When the pathophysiol. of a medical condition is multimodal, ie, related to multiple physiol. causes or mediated by multiple pathways, the optimal strategy can be to use a drug or a combination of drugs that contribute multiple mechanisms to the therapeutic endpoint.  In such situations, a rational multimodal approach can also result in the fewest adverse effects.  We discuss the quant. anal. of multimodal action using the treatment of pain as a practical example and give examples of its application to some widely used analgesic drugs.  Perspective: This article reviews the medical relevance of the quant. evaluation of drug combinations, using pain and combinations of analgesics as specific examples.  Such measure can help clinicians who seek to maximize therapeutic effect while simultaneously minimizing adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH7jqoFZRbiLVg90H21EOLACvtfcHk0liAWYJhCNkRGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFKqt7Y%253D&md5=31c26fefba4061e6c64a959c3bfd1e0f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2009.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2009.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26aulast%3DPergolizzi%26aufirst%3DJ.%2BV.%26aulast%3DTallarida%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520determination%2520and%2520application%2520of%2520fixed-dose%2520analgesic%2520combinations%2520for%2520treating%2520multimodal%2520pain%26jtitle%3DJ.%2520Pain%26date%3D2010%26volume%3D11%26spage%3D701%26epage%3D709%26doi%3D10.1016%2Fj.jpain.2009.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Leon-Casasola, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittenden, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manworren, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkal, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strassels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirlby, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viscusi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walco, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. L.</span></span> <span> </span><span class="NLM_article-title">Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2015.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.jpain.2015.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=26827847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A280%3ADC%252BC28nmtFegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=131-157&author=R.+Chouauthor=D.+B.+Gordonauthor=O.+A.+de+Leon-Casasolaauthor=J.+M.+Rosenbergauthor=S.+Bicklerauthor=T.+Carterauthor=L.+Cassidyauthor=E.+H.+Chittendenauthor=E.+Degenhardtauthor=S.+Griffithauthor=M.+R.+Manworrenauthor=B.+McCarbergauthor=R.+Montgomeryauthor=J.+Murphyauthor=M.+F.+Perkalauthor=S.+Sureshauthor=K.+Slukaauthor=S.+Strasselsauthor=R.+Thirlbyauthor=E.+Viscusiauthor=G.+A.+Walcoauthor=L.+Warnerauthor=S.+J.+Weismanauthor=C.+L.+Wu&title=Management+of+postoperative+pain%3A+a+clinical+practice+guideline+from+the+American+Pain+Society%2C+the+American+Society+of+Regional+Anesthesia+and+Pain+Medicine%2C+and+the+American+Society+of+Anesthesiologists%E2%80%99+Committee+on+Regional+Anesthesia%2C+Executive+Committee%2C+and+Administrative+Council&doi=10.1016%2Fj.jpain.2015.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council</span></div><div class="casAuthors">Chou Roger; Gordon Debra B; de Leon-Casasola Oscar A; Rosenberg Jack M; Bickler Stephen; Brennan Tim; Carter Todd; Cassidy Carla L; Chittenden Eva Hall; Degenhardt Ernest; Griffith Scott; Manworren Renee; McCarberg Bill; Montgomery Robert; Murphy Jamie; Wu Christopher L; Perkal Melissa F; Suresh Santhanam; Sluka Kathleen; Strassels Scott; Thirlby Richard; Viscusi Eugene; Walco Gary A; Warner Lisa; Weisman Steven J</div><div class="citationInfo"><span class="NLM_cas:title">The journal of pain : official journal of the American Pain Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Most patients who undergo surgical procedures experience acute postoperative pain, but evidence suggests that less than half report adequate postoperative pain relief.  Many preoperative, intraoperative, and postoperative interventions and management strategies are available for reducing and managing postoperative pain.  The American Pain Society, with input from the American Society of Anesthesiologists, commissioned an interdisciplinary expert panel to develop a clinical practice guideline to promote evidence-based, effective, and safer postoperative pain management in children and adults.  The guideline was subsequently approved by the American Society for Regional Anesthesia.  As part of the guideline development process, a systematic review was commissioned on various aspects related to various interventions and management strategies for postoperative pain.  After a review of the evidence, the expert panel formulated recommendations that addressed various aspects of postoperative pain management, including preoperative education, perioperative pain management planning, use of different pharmacological and nonpharmacological modalities, organizational policies, and transition to outpatient care.  The recommendations are based on the underlying premise that optimal management begins in the preoperative period with an assessment of the patient and development of a plan of care tailored to the individual and the surgical procedure involved.  The panel found that evidence supports the use of multimodal regimens in many situations, although the exact components of effective multimodal care will vary depending on the patient, setting, and surgical procedure.  Although these guidelines are based on a systematic review of the evidence on management of postoperative pain, the panel identified numerous research gaps.  Of 32 recommendations, 4 were assessed as being supported by high-quality evidence, and 11 (in the areas of patient education and perioperative planning, patient assessment, organizational structures and policies, and transitioning to outpatient care) were made on the basis of low-quality evidence.  PERSPECTIVE:  This guideline, on the basis of a systematic review of the evidence on postoperative pain management, provides recommendations developed by a multidisciplinary expert panel.  Safe and effective postoperative pain management should be on the basis of a plan of care tailored to the individual and the surgical procedure involved, and multimodal regimens are recommended in many situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb9Ea6UaRw8MkU0YCbOU3EfW6udTcc2eYtW6b5EtCdObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nmtFegsQ%253D%253D&md5=ccdf7fdf5131f709ea1c86a5e93979f5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2015.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2015.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DD.%2BB.%26aulast%3Dde%2BLeon-Casasola%26aufirst%3DO.%2BA.%26aulast%3DRosenberg%26aufirst%3DJ.%2BM.%26aulast%3DBickler%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DT.%26aulast%3DCassidy%26aufirst%3DL.%26aulast%3DChittenden%26aufirst%3DE.%2BH.%26aulast%3DDegenhardt%26aufirst%3DE.%26aulast%3DGriffith%26aufirst%3DS.%26aulast%3DManworren%26aufirst%3DM.%2BR.%26aulast%3DMcCarberg%26aufirst%3DB.%26aulast%3DMontgomery%26aufirst%3DR.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DPerkal%26aufirst%3DM.%2BF.%26aulast%3DSuresh%26aufirst%3DS.%26aulast%3DSluka%26aufirst%3DK.%26aulast%3DStrassels%26aufirst%3DS.%26aulast%3DThirlby%26aufirst%3DR.%26aulast%3DViscusi%26aufirst%3DE.%26aulast%3DWalco%26aufirst%3DG.%2BA.%26aulast%3DWarner%26aufirst%3DL.%26aulast%3DWeisman%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DC.%2BL.%26atitle%3DManagement%2520of%2520postoperative%2520pain%253A%2520a%2520clinical%2520practice%2520guideline%2520from%2520the%2520American%2520Pain%2520Society%252C%2520the%2520American%2520Society%2520of%2520Regional%2520Anesthesia%2520and%2520Pain%2520Medicine%252C%2520and%2520the%2520American%2520Society%2520of%2520Anesthesiologists%25E2%2580%2599%2520Committee%2520on%2520Regional%2520Anesthesia%252C%2520Executive%2520Committee%252C%2520and%2520Administrative%2520Council%26jtitle%3DJ.%2520Pain%26date%3D2016%26volume%3D17%26spage%3D131%26epage%3D157%26doi%3D10.1016%2Fj.jpain.2015.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backonja, M. M.</span></span> <span> </span><span class="NLM_article-title">Combination drug therapy for chronic pain: a call for more clinical studies</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.jpain.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=20851058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=157-166&author=J.+Maoauthor=M.+S.+Goldauthor=M.+M.+Backonja&title=Combination+drug+therapy+for+chronic+pain%3A+a+call+for+more+clinical+studies&doi=10.1016%2Fj.jpain.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Therapy for Chronic Pain: A Call for More Clinical Studies</span></div><div class="casAuthors">Mao, Jianren; Gold, Michael S.; Backonja, Miroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic pain is a debilitating clin. condition assocd. with a variety of disease entities including diabetic neuropathy, postherpetic neuralgia, low back pathol., fibromyalgia, and neurol. disorders.  For many general practitioners and specialists, managing chronic pain has become a daunting challenge.  As a modality of multidisciplinary chronic pain management, medications are often prescribed in combinations, an approach referred to as combination drug therapy (CDT).  However, many medications for pain therapy, including antidepressants and opioid analgesics, have significant side effects that can compd. when used in combination and impact the effectiveness of CDT.  To date, clin. practice of CDT for chronic pain has been based largely on clin. experiences.  In this article, we will focus on (1) the scientific basis and rationales for CDT, (2) current clin. data on CDT, and (3) the need for more clin. studies to establish a framework for the use of CDT.  Perspective: More preclin., clin., and translational studies are needed to improve the efficacy of combination drug therapy that is an integral part of a comprehensive approach to the management of chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDPNs-xJvEbVg90H21EOLACvtfcHk0liAWYJhCNkRGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D&md5=955711ac2946dd44adc0e8b96b6ee423</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DGold%26aufirst%3DM.%2BS.%26aulast%3DBackonja%26aufirst%3DM.%2BM.%26atitle%3DCombination%2520drug%2520therapy%2520for%2520chronic%2520pain%253A%2520a%2520call%2520for%2520more%2520clinical%2520studies%26jtitle%3DJ.%2520Pain%26date%3D2011%26volume%3D12%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.jpain.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljZuVvJbl57lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamponi, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koschak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1124%2Fpr.114.009654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=26362469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=821-870&author=G.+W.+Zamponiauthor=J.+Striessnigauthor=A.+Koschakauthor=A.+C.+Dolphin&title=The+physiology%2C+pathology%2C+and+pharmacology+of+voltage-gated+calcium+channels+and+their+future+therapeutic+potential&doi=10.1124%2Fpr.114.009654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</span></div><div class="casAuthors">Zamponi, Gerald W.; Striessnig, Joerg; Koschak, Alexandra; Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">821-870</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Voltage-gated calcium channels are required for many key functions in the body.  In this review, the different subtypes of voltage-gated calcium channels are described and their physiol. roles and pharmacol. are outlined.  We describe the current uses of drugs interacting with the different calcium channel subtypes and subunits, as well as specific areas in which there is strong potential for future drug development.  Current therapeutic agents include drugs targeting L-type CaV1.2 calcium channels, particularly 1,4-dihydropyridines, which are widely used in the treatment of hypertension.  T-type (CaV3) channels are a target of ethosuximide, widely used in absence epilepsy.  The auxiliary subunit α2δ-1 is the therapeutic target of the gabapentinoid drugs, which are of value in certain epilepsies and chronic neuropathic pain.  The limited use of intrathecal ziconotide, a peptide blocker of N-type (CaV2.2) calcium channels, as a treatment of intractable pain, gives an indication that these channels represent excellent drug targets for various pain conditions.  We describe how selectivity for different subtypes of calcium channels (e.g., CaV1.2 and CaV1.3 L-type channels) may be achieved in the future by exploiting differences between channel isoforms in terms of sequence and biophys. properties, variation in splicing in different target tissues, and differences in the properties of the target tissues themselves in terms of membrane potential or firing frequency.  Thus, use-dependent blockers of the different isoforms could selectively block calcium channels in particular pathologies, such as nociceptive neurons in pain states or in epileptic brain circuits.  Of important future potential are selective CaV1.3 blockers for neuropsychiatric diseases, neuroprotection in Parkinson's disease, and resistant hypertension.  In addn., selective or nonselective T-type channel blockers are considered potential therapeutic targets in epilepsy, pain, obesity, sleep, and anxiety.  Use-dependent N-type calcium channel blockers are likely to be of therapeutic use in chronic pain conditions.  Thus, more selective calcium channel blockers hold promise for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0k6JL9CCXi7Vg90H21EOLACvtfcHk0ljZuVvJbl57lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D&md5=1e5a19b9974b119fc2c00cfa0089e172</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009654%26sid%3Dliteratum%253Aachs%26aulast%3DZamponi%26aufirst%3DG.%2BW.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKoschak%26aufirst%3DA.%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DThe%2520physiology%252C%2520pathology%252C%2520and%2520pharmacology%2520of%2520voltage-gated%2520calcium%2520channels%2520and%2520their%2520future%2520therapeutic%2520potential%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D821%26epage%3D870%26doi%3D10.1124%2Fpr.114.009654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Minh, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wratten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.tips.2007.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=17403543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=220-228&author=A.+Daviesauthor=J.+Hendrichauthor=A.+T.+Van+Minhauthor=J.+Wrattenauthor=L.+Douglasauthor=A.+C.+Dolphin&title=Functional+biology+of+the+alpha%282%29delta+subunits+of+voltage-gated+calcium+channels&doi=10.1016%2Fj.tips.2007.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functional biology of the α2δ subunits of voltage-gated calcium channels</span></div><div class="casAuthors">Davies, Anthony; Hendrich, Jan; Minh, Alexandra Tran Van; Wratten, Jack; Douglas, Leon; Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">220-228</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In this review, we examine what is known about the mechanism of action of the auxiliary α2δ subunits of voltage-gated Ca2+ (Cav) channels.  First, to provide some background on the α2δ proteins, we discuss the genes encoding these channels, in addn. to the topol. and predicted structure of the α2δ subunits.  We then describe the effects of α2δ subunits on the biophys. properties of Cav channels and their physiol. function.  All α2δ subunits increase the d. at the plasma membrane of Ca2+ channels activated by high voltage, and we discuss what is known about the mechanism underlying this trafficking.  Finally, we consider the link between α2δ subunits and disease, both in terms of spontaneous and engineered mouse mutants that show cerebellar ataxia and spike-wave epilepsy, and in terms of neuropathic pain and the mechanism of action of the gabapentinoid drugs - small-mol. ligands of the α2δ-1 and α2δ-2 subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRvWUjqiH1nbVg90H21EOLACvtfcHk0ljZuVvJbl57lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGiurs%253D&md5=db88d5027f9e9ebd8f3f93dd06971e1b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DHendrich%26aufirst%3DJ.%26aulast%3DVan%2BMinh%26aufirst%3DA.%2BT.%26aulast%3DWratten%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DL.%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DFunctional%2520biology%2520of%2520the%2520alpha%25282%2529delta%2520subunits%2520of%2520voltage-gated%2520calcium%2520channels%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D220%26epage%3D228%26doi%3D10.1016%2Fj.tips.2007.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piechan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donevan, S.</span></span> <span> </span><span class="NLM_article-title">Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2 calcium channel subunits</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>667</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.05.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.ejphar.2011.05.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21651903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGlt7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=667&publication_year=2011&pages=80-90&author=Z.+Liauthor=C.+P.+Taylorauthor=M.+Weberauthor=J.+Piechanauthor=F.+Priorauthor=F.+Bianauthor=C.+Cuiauthor=D.+Hoffmanauthor=S.+Donevan&title=Pregabalin+is+a+potent+and+selective+ligand+for+%CE%B12%CE%B4-1+and+%CE%B12%CE%B4-2+calcium+channel+subunits&doi=10.1016%2Fj.ejphar.2011.05.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2 calcium channel subunits</span></div><div class="casAuthors">Li, Zheng; Taylor, Charles P.; Weber, Mark; Piechan, Julie; Prior, Faith; Bian, Feng; Cui, Mei; Hoffman, Diane; Donevan, Sean</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">667</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">80-90</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pregabalin, a synthetic branched chain γ-amino acid with anticonvulsant, anxiolytic, and analgesic activities, was shown to bind with high affinity to the voltage-gated Ca channel α2δ subunit.  Given the broad therapeutic utility of pregabalin, a series of expts. was undertaken to det. the potency, selectivity, and specificity of pregabalin's receptor-binding profile at α2δ-1 and α2δ-2 subunits of voltage-gated Ca channels along with 38 widely studied receptors and channels.  Receptor autoradiog. was used to assess regional-binding d. of pregabalin throughout the rat spinal cord and brain.  In addn., a series of studies using in vivo electrophysiol. recordings of γ-aminobutyric acid (GABA)A- and GABAB-evoked currents was undertaken to det. the interaction of pregabalin with GABAergic receptor subtypes.  Together, the results of these studies demonstrate potent and selective binding of pregabalin to α2δ-1 and α2δ-2 subunits in native and recombinant human and porcine systems.  Pregabalin did not interact with any of the 38 receptors and ion channels evaluated, and a variety of central nervous system (CNS)-targeted therapeutic drugs did not show activity at the α2δ subunits of voltage-gated calcium channels.  Receptor autoradiog. demonstrated extensive [3H]-pregabalin binding throughout the CNS, with high-level binding in the cortex, hippocampus, cerebellum, dorsal horn of the spinal cord, and amygdala.  Finally, receptor-binding and electrophysiol. techniques failed to show evidence of an interaction between pregabalin and GABAA or GABAB receptors.  These studies suggest that the clin. effects of pregabalin are likely due to direct and selective interactions with α2δ-1 and α2δ-2 subunits of voltage-gated calcium channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHjcEVuUlz97Vg90H21EOLACvtfcHk0lhQrAbeAf5c8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGlt7bF&md5=c53803698e6966532d1d2b7a83a3ac92</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.05.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.05.054%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTaylor%26aufirst%3DC.%2BP.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DPiechan%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DC.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DDonevan%26aufirst%3DS.%26atitle%3DPregabalin%2520is%2520a%2520potent%2520and%2520selective%2520ligand%2520for%2520%25CE%25B12%25CE%25B4-1%2520and%2520%25CE%25B12%25CE%25B4-2%2520calcium%2520channel%2520subunits%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D667%26spage%3D80%26epage%3D90%26doi%3D10.1016%2Fj.ejphar.2011.05.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perret, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z. D.</span></span> <span> </span><span class="NLM_article-title">Targeting voltage-gated calcium channels for neuropathic pain management</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2009.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.nurt.2009.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=19789072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVKqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=679-692&author=D.+Perretauthor=Z.+D.+Luo&title=Targeting+voltage-gated+calcium+channels+for+neuropathic+pain+management&doi=10.1016%2Fj.nurt.2009.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting voltage-gated calcium channels for neuropathic pain management</span></div><div class="casAuthors">Perret, Danielle; Luo, Z. David</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiol. functions.  Pathol. conditions leading to changes in their biophys. properties and expression levels may cause malfunctions of VGCC-mediated activities, resulting in disease states.  It is believed that changes in VGCC properties under pain-inducing conditions may play a causal role in the development of chronic pain, including nerve injury-induced pain or neuropathic pain.  For the past several decades, preclin. and clin. research in developing VGCC blockers or modulators for chronic pain management has been fruitful, leading to some U.S. Food and Drug Administration-approved drugs currently available for chronic pain management.  However, their efficacy in pain relief is limited in some patients, and their long-term use is limited by their side-effect profiles.  Certainly, there is room for improvement in developing more subtype-specific VGCC blockers or modulators for chronic pain conditions.  In this review, we summarized the most recent preclin. and clin. studies related to chronic pain medications acting on the VGCC.  We also included clin. trials aiming to expand the application of approved VGCC drugs to different pain states derived from various pathol. conditions, as well as drug combination therapies trying to improve the efficacies and side-effect profiles of current pain medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3B87GXsltfLVg90H21EOLACvtfcHk0lhQrAbeAf5c8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVKqu7o%253D&md5=20048c2a781a32c919b69a82536128e2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2009.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2009.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DZ.%2BD.%26atitle%3DTargeting%2520voltage-gated%2520calcium%2520channels%2520for%2520neuropathic%2520pain%2520management%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D679%26epage%3D692%26doi%3D10.1016%2Fj.nurt.2009.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cording, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiffen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R. A.</span></span> <span> </span><span class="NLM_article-title">Pregabalin for pain in fibromyalgia in adults</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">CD011790</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD011790.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2F14651858.CD011790.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=CD011790&author=S.+Derryauthor=M.+Cordingauthor=P.+J.+Wiffenauthor=S.+Lawauthor=T.+Phillipsauthor=R.+A.+Moore&title=Pregabalin+for+pain+in+fibromyalgia+in+adults&doi=10.1002%2F14651858.CD011790.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD011790.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD011790.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DDerry%26aufirst%3DS.%26aulast%3DCording%26aufirst%3DM.%26aulast%3DWiffen%26aufirst%3DP.%2BJ.%26aulast%3DLaw%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DMoore%26aufirst%3DR.%2BA.%26atitle%3DPregabalin%2520for%2520pain%2520in%2520fibromyalgia%2520in%2520adults%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2016%26volume%3D29%26spage%3DCD011790%26doi%3D10.1002%2F14651858.CD011790.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelotti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauman, E.</span></span> <span> </span><span class="NLM_article-title">Pharmacology and mechanism of action of pregabalin: The calcium channel α<sub>2</sub>-δ (alpha<sub>2</sub>–delta) subunit as a target for antiepileptic Drug Discovery</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.eplepsyres.2006.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.eplepsyres.2006.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=17126531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Grt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=137-150&author=C.+P.+Taylorauthor=T.+Angelottiauthor=E.+Fauman&title=Pharmacology+and+mechanism+of+action+of+pregabalin%3A+The+calcium+channel+%CE%B12-%CE%B4+%28alpha2%E2%80%93delta%29+subunit+as+a+target+for+antiepileptic+Drug+Discovery&doi=10.1016%2Fj.eplepsyres.2006.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery</span></div><div class="casAuthors">Taylor, Charles P.; Angelotti, Timothy; Fauman, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-150</span>CODEN:
                <span class="NLM_cas:coden">EPIRE8</span>;
        ISSN:<span class="NLM_cas:issn">0920-1211</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Pregabalin (Lyrica) is a new antiepileptic drug that is active in animal seizure models.  Pregabalin is approved in US and Europe for adjunctive therapy of partial seizures in adults, and also has been approved for the treatment of pain from diabetic neuropathy or post-herpetic neuralgia in adults.  Recently, it has been approved for treatment of anxiety disorders in Europe.  Pregabalin is structurally related to the antiepileptic drug gabapentin and the site of action of both drugs is similar, the alpha2-delta (α2-δ) protein, an auxiliary subunit of voltage-gated calcium channels.  Pregabalin subtly reduces the synaptic release of several neurotransmitters, apparently by binding to α2-δ subunits, and possibly accounting for its actions in vivo to reduce neuronal excitability and seizures.  Several studies indicate that the pharmacol. of pregabalin requires binding to α2-δ subunits, including structure-activity analyses of compds. binding to α2-δ subunits and pharmacol. in mice deficient in binding at the α2-δ Type 1 protein.  The preclin. findings to date are consistent with a mechanism that may entail redn. of abnormal neuronal excitability through reduced neurotransmitter release.  This review addresses the preclin. pharmacol. of pregabalin, and also the biol. of the high affinity binding site, and presumed site of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2zgeyDkYn7Vg90H21EOLACvtfcHk0lhQrAbeAf5c8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Grt78%253D&md5=c5a7659e6994170bced23d2064391ea8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.eplepsyres.2006.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eplepsyres.2006.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DC.%2BP.%26aulast%3DAngelotti%26aufirst%3DT.%26aulast%3DFauman%26aufirst%3DE.%26atitle%3DPharmacology%2520and%2520mechanism%2520of%2520action%2520of%2520pregabalin%253A%2520The%2520calcium%2520channel%2520%25CE%25B12-%25CE%25B4%2520%2528alpha2%25E2%2580%2593delta%2529%2520subunit%2520as%2520a%2520target%2520for%2520antiepileptic%2520Drug%2520Discovery%26jtitle%3DEpilepsy%2520Res.%26date%3D2007%26volume%3D73%26spage%3D137%26epage%3D150%26doi%3D10.1016%2Fj.eplepsyres.2006.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, M. A.</span></span> <span> </span><span class="NLM_article-title">Use of α2δ ligands for restless legs syndrome/Willis Ekbom Disease</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1007/s40263-018-0502-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1007%2Fs40263-018-0502-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=29480463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=149-159&author=M.+A.+Faulkner&title=Use+of+%CE%B12%CE%B4+ligands+for+restless+legs+syndrome%2FWillis+Ekbom+Disease&doi=10.1007%2Fs40263-018-0502-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease</span></div><div class="casAuthors">Faulkner, Michele A.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Restless legs syndrome is a common neurol. condition affecting a substantial portion of the population.  It can be an idiopathic disorder, or one that is secondary to another cause.  Given that the underlying pathophysiol. of restless legs syndrome is not well understood, several drug classes have been studied for symptom control.  While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used.  These agents have proven both efficacious and safe in a no. of clin. trials.  Addnl., compared with the dopamine agonists, they have been assocd. with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected.  Newer clin. guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfvdr1I2cK3rVg90H21EOLACvtfcHk0ljMUfTHf47-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGht7s%253D&md5=20a8603a8d381e1ec154213fa9d7bd23</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0502-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0502-z%26sid%3Dliteratum%253Aachs%26aulast%3DFaulkner%26aufirst%3DM.%2BA.%26atitle%3DUse%2520of%2520%25CE%25B12%25CE%25B4%2520ligands%2520for%2520restless%2520legs%2520syndrome%252FWillis%2520Ekbom%2520Disease%26jtitle%3DCNS%2520Drugs%26date%3D2018%26volume%3D32%26spage%3D149%26epage%3D159%26doi%3D10.1007%2Fs40263-018-0502-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span> <span> </span><span class="NLM_article-title">Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1021/jm060650z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060650z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2569-2575&author=M.+J.+Fieldauthor=Z.+Liauthor=J.+B.+Schwarz&title=Ca2%2B+channel+alpha2-delta+ligands+for+the+treatment+of+neuropathic+pain&doi=10.1021%2Fjm060650z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ Channel α2-δ Ligands for the Treatment of Neuropathic Pain</span></div><div class="casAuthors">Field, Mark J.; Li, Zheng; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2575</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Pregabalin was recently approved in the U.S. and Europe as an add- on therapy for epilepsy, as well as for the treatment of neuropathic pain.  In addn., pregabalin recently gained approval in the EU for the treatment of generalized anxiety disorder.  As a result of it's superior potency and pharmacokinetic profile compared to gabapentin, pregabalin has enjoyed rapid uptake by prescribing physicians for these conditions.  Pregabalin is thought to access the central nervous system (CNS) via the system L amino acid transporter and act via modulation of the α2-δ subunit of voltage-gated calcium channels.  Pregabalin is remarkably silent at all other known receptors (with the exception of being a substrate for the system L transmembrane amino acid transporter), and as a consequence, the α2-δ hypothesis is gaining traction as the accepted MOA of pregabalin.  Some excellent reviews categorizing the available evidence to elucidate the mechanism of gabapentin in neuropathic pain have recently appeared.  The purpose of this Miniperspective is to showcase the medicinal chem. efforts employed to obtain structurally diverse compds. with both reported affinity for the α2-δ subunit and in vivo activity in various neuropathic pain paradigms.  Expts. to suggest that α2-δ ligands act to suppress the development and maintenance of central sensitization, as well as a discussion of the implications of α2-δ subtype localization and function, will also be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzlIxj5QQMrVg90H21EOLACvtfcHk0ljMUfTHf47-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D&md5=12cbcf55d0e7524e0971c462e27a7271</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm060650z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060650z%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DCa2%252B%2520channel%2520alpha2-delta%2520ligands%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2569%26epage%3D2575%26doi%3D10.1021%2Fjm060650z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, Y.</span></span> <span> </span><span class="NLM_article-title">Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.247551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1124%2Fjpet.117.247551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=29563324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2018&pages=573-582&author=Y.+Domonauthor=N.+Arakawaauthor=T.+Inoueauthor=F.+Matsudaauthor=M.+Takahashiauthor=N.+Yamamuraauthor=K.+Kaiauthor=Y.+Kitano&title=Binding+characteristics+and+analgesic+effects+of+mirogabalin%2C+a+novel+ligand+for+the+%CE%B12%CE%B4+subunit+of+voltage-gated+calcium+channels&doi=10.1124%2Fjpet.117.247551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the a2d subunit of voltage-gated calcium channels</span></div><div class="casAuthors">Domon, Yuki; Arakawa, Naohisa; Inoue, Tatsuya; Matsuda, Fumihiko; Takahashi, Makoto; Yamamura, Naotoshi; Kai, Kiyonori; Kitano, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-582</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In the present study, we investigated the in vitro binding characteristics and in vivo analgesic effects of mirogabalin compared with those of pregabalin, a std. a2d ligand.  Mirogabalin showed potent and selective binding affinities for the a2d subunits, while having no effects on 186 off-target proteins.  Similar to pregabalin, mirogabalin did not show clear subtype selectivity (a2d-1 vs. a2d-2) or species differences (human vs. rat).  However, in contrast to pregabalin, mirogabalin showed greater binding affinities for human a2d-1, human a2d-2, rat a2d-1, and rat a2d-2 subunits; further, it had a slower dissocn. rate for the a2d-1 subunit than the a2d-2 subunit.  In safety pharmacol. evaluations, mirogabalin and pregabalin inhibited rota-rod performance and locomotor activity in rats; however, the safety indexes of mirogabalin were superior to those of pregabalin.  In conclusion, mirogabalin shows potent and selective binding affinities for the human and rat a2d subunits, and slower dissocn. rates for the a2d-1 subunit than the a2d-2 subunit.  It shows potent and long-lasting analgesic effects in rat models of neuropathic pain, and wider safety margins for side effects of the central nervous system.  These properties of mirogabalin can be assocd. with its unique binding characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpJ0JBnhkh7Vg90H21EOLACvtfcHk0ljMUfTHf47-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP&md5=e0c0b3f89de15327211551395f4db648</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.247551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.247551%26sid%3Dliteratum%253Aachs%26aulast%3DDomon%26aufirst%3DY.%26aulast%3DArakawa%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DYamamura%26aufirst%3DN.%26aulast%3DKai%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DY.%26atitle%3DBinding%2520characteristics%2520and%2520analgesic%2520effects%2520of%2520mirogabalin%252C%2520a%2520novel%2520ligand%2520for%2520the%2520%25CE%25B12%25CE%25B4%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D365%26spage%3D573%26epage%3D582%26doi%3D10.1124%2Fjpet.117.247551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Mirogabalin: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1007%2Fs40265-019-01070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=30778848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=463-468&author=E.+D.+Deeks&title=Mirogabalin%3A+First+global+approval&doi=10.1007%2Fs40265-019-01070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mirogabalin: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Mirogabalin besylate (hereafter mirogabalin) [Tarlige] is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia.  The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.  Mirogabalin has a unique binding profile and long duration of action.  The drug is approved in Japan for the treatment of PNP and is in clin. development for this indication elsewhere in Asia.  Clin. development of the drug for fibromyalgia pain was discontinued in the USA and EU after the primary endpoint was not met in phase 3 trials.  No recent reports of development have been identified for PNP in the USA or India or for fibromyalgia pain in Australia, India, New Zealand, Russia, Argentina, Belarus, Chile, Colombia, Israel, Mexico, Switzerland, Canada, Serbia or South Africa.  This article summarizes the milestones in the development of mirogabalin leading to this first approval for PNP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA8cUiDvLmPbVg90H21EOLACvtfcHk0lgn8z1wccQ0lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D&md5=9a9b9f14f0190da528f3bc9b8cf277a7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01070-8%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DMirogabalin%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D463%26epage%3D468%26doi%3D10.1007%2Fs40265-019-01070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pracitto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boueres, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezverkov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span> <span> </span><span class="NLM_article-title">N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1913</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.01.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2004.01.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15050626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXislSqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1913-1916&author=J.+Limauthor=N.+Stockauthor=R.+Pracittoauthor=J.+K.+Boueresauthor=B.+Munozauthor=A.+Chaudharyauthor=A.+M.+Santiniauthor=K.+Orrauthor=H.+Schaffhauserauthor=R.+E.+Bezverkovauthor=J.+Aiyarauthor=S.+Venkatraman&title=N-Acridin-9-yl-butane-1%2C4-diamine+derivatives%3A+high-affinity+ligands+of+the+alpha2delta+subunit+of+voltage+gated+calcium+channels&doi=10.1016%2Fj.bmcl.2004.01.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the α2δ subunit of voltage gated calcium channels</span></div><div class="casAuthors">Lim, Jongwon; Stock, Nicholas; Pracitto, Richard; Boueres, Julia K.; Munoz, Benito; Chaudhary, Ashok; Santini, Angelina M.; Orr, Karia; Schaffhauser, Herve; Bezverkov, Robert E.; Aiyar, Jayashree; Venkatraman, Shankar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1913-1916</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of N-acridin-9-yl-butane-1,4-diamines were found to be high-affinity ligands of the α2δ subunit of voltage gated calcium channels.  The SAR studies of butane-1,4-diamine side chain resulted in the identification of a compd. (IC50=9 nM), which is more potent than gabapentin (IC50=27 nM).  Partial satn. of the acridine ring was also pursued and provided a compd. with higher binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgYEoxnJrQrVg90H21EOLACvtfcHk0lgn8z1wccQ0lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXislSqur0%253D&md5=926c7235f48cf679b2ae788b38304067</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.01.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.01.087%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DStock%26aufirst%3DN.%26aulast%3DPracitto%26aufirst%3DR.%26aulast%3DBoueres%26aufirst%3DJ.%2BK.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DOrr%26aufirst%3DK.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DBezverkov%26aufirst%3DR.%2BE.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DN-Acridin-9-yl-butane-1%252C4-diamine%2520derivatives%253A%2520high-affinity%2520ligands%2520of%2520the%2520alpha2delta%2520subunit%2520of%2520voltage%2520gated%2520calcium%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1913%26epage%3D1916%26doi%3D10.1016%2Fj.bmcl.2004.01.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebsack, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pracitto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezverkov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span> <span> </span><span class="NLM_article-title">Identification and synthesis of [1,2,4]triazolo[3,4-<i>a</i>]phthalazine derivatives as high-affinity ligands to the α<sub>2</sub>δ-1 subunit of voltage gated calcium channel</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2463</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2004.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15109633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVKhtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2463-2467&author=A.+D.+Lebsackauthor=J.+Gunznerauthor=B.+Wangauthor=R.+Pracittoauthor=H.+Schaffhauserauthor=A.+Santiniauthor=J.+Aiyarauthor=R.+Bezverkovauthor=B.+Munozauthor=W.+Liuauthor=S.+Venkatraman&title=Identification+and+synthesis+of+%5B1%2C2%2C4%5Dtriazolo%5B3%2C4-a%5Dphthalazine+derivatives+as+high-affinity+ligands+to+the+%CE%B12%CE%B4-1+subunit+of+voltage+gated+calcium+channel&doi=10.1016%2Fj.bmcl.2004.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel</span></div><div class="casAuthors">Lebsack, Alec D.; Gunzner, Janet; Wang, Bowei; Pracitto, Richard; Schaffhauser, Herve; Santini, Angelina; Aiyar, Jayashree; Bezverkov, Robert; Munoz, Benito; Liu, Wensheng; Venkatraman, Shankar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2463-2467</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of [1,2,4]triazolo[3,4-a]phthalazine derivs. as high-affinity ligands to α2δ-1 subunit of voltage gated calcium channels were identified and synthesized.  Structure-activity relationship studies directed toward improving the potency and phys. properties of 6-[[[3-(5-methyl-3-isoxazolyl)-1,2,4-triazolo[3,4-a]phthalazin-6-yl]oxy]methyl]-N-(2-phenylethyl)-2-pyridinemethanamine lead to the discovery of N-[2-(3-methylphenyl)ethyl]-6-[[[3-(trifluoromethyl)-1,2,4-triazolo[3,4-a]phthalazin-6-yl]oxy]methyl]-2-pyridinemethanamine (I) (IC50=15 nM) and (αS)-α-mMethyl-N-(2-phenylethyl)-6-[[[3-(trifluoromethyl)-1,2,4-triazolo[3,4-a]phthalazin-6-yl]oxy]methyl]-2-pyridinemethanamine (II) (IC50=30 nM).  A potent and selective radioligand, [3H]-(S)-II was also synthesized to demonstrate that this ligand binds to the same site as gabapentin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJf9GjejcPx7Vg90H21EOLACvtfcHk0lhp_VrRiU-N6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVKhtr0%253D&md5=779a5a5d41bebd35a8c1f169ad418e5f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DLebsack%26aufirst%3DA.%2BD.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DPracitto%26aufirst%3DR.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DBezverkov%26aufirst%3DR.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520synthesis%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B3%252C4-a%255Dphthalazine%2520derivatives%2520as%2520high-affinity%2520ligands%2520to%2520the%2520%25CE%25B12%25CE%25B4-1%2520subunit%2520of%2520voltage%2520gated%2520calcium%2520channel%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2463%26epage%3D2467%26doi%3D10.1016%2Fj.bmcl.2004.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arruda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sablad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 6-aryl-6<i>H</i>-pyrrolo[3,4-<i>d</i>]pyridazine derivatives: high-affinity ligands to the alpha 2 delta subunit of voltage gated calcium channels</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2003.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=14980685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFelsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1295-1298&author=B.+A.+Stearnsauthor=N.+Ankerauthor=J.+M.+Arrudaauthor=B.+T.+Campbellauthor=C.+Chenauthor=M.+Cramerauthor=T.+Huauthor=X.+Jiangauthor=K.+Parkauthor=K.+K.+Renauthor=M.+Sabladauthor=A.+Santiniauthor=H.+Schaffhauserauthor=M.+O.+Urbanauthor=B.+Munoz&title=Synthesis+and+biological+evaluation+of+6-aryl-6H-pyrrolo%5B3%2C4-d%5Dpyridazine+derivatives%3A+high-affinity+ligands+to+the+alpha+2+delta+subunit+of+voltage+gated+calcium+channels&doi=10.1016%2Fj.bmcl.2003.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 6-aryl-6H-pyrrolo[3,4-d]pyridazine derivatives: high-affinity ligands to the α2δ subunit of voltage gated calcium channels</span></div><div class="casAuthors">Stearns, Brian A.; Anker, Naomi; Arruda, Jeannie M.; Campbell, Brian T.; Chen, Chixu; Cramer, Merryl; Hu, Tao; Jiang, Xiaohui; Park, Kenneth; Ren, Kun Kun; Sablad, Marciano; Santini, Angelina; Schaffhauser, Herve; Urban, Mark O.; Munoz, Benito</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1295-1298</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A novel class of 6-aryl-6H-pyrrolo[3,4-d]pyridazine ligands for the α2δ subunit of voltage-gated calcium channels has been described.  Substitutions in the aryl ring of the mol. were generally not tolerated, and resulted in diminished binding to the α2δ subunit.  Modifications to the pyridazine ring revealed numerous permissive substitutions, and detailed SAR studies were carried out in this portion of the mol.  Replacement of the pyridazine ring Me group with an aminomethyl functionality provided greatly improved potency over the initial lead.  The initial lead compd. (I) displayed good rat pharmacokinetic properties, and was shown to be efficacious in the Chung model for neuropathic pain in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8QWoFDPl0i7Vg90H21EOLACvtfcHk0lgGjV-_eHwYwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFelsr8%253D&md5=a9c9fc444f324b4707b452ffbfea6b99</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DStearns%26aufirst%3DB.%2BA.%26aulast%3DAnker%26aufirst%3DN.%26aulast%3DArruda%26aufirst%3DJ.%2BM.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCramer%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DRen%26aufirst%3DK.%2BK.%26aulast%3DSablad%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DUrban%26aufirst%3DM.%2BO.%26aulast%3DMunoz%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25206-aryl-6H-pyrrolo%255B3%252C4-d%255Dpyridazine%2520derivatives%253A%2520high-affinity%2520ligands%2520to%2520the%2520alpha%25202%2520delta%2520subunit%2520of%2520voltage%2520gated%2520calcium%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1295%26epage%3D1298%26doi%3D10.1016%2Fj.bmcl.2003.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arruda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezverkov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 6-aryl-6<i>H</i>-pyrrolo[3,4-<i>d</i>]pyridazine derivatives as high-affinity ligands of the alpha(2)delta subunit of voltage-gated calcium channels</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2031</span>– <span class="NLM_lpage">2034</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2004.02.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15080973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2031-2034&author=T.+Huauthor=B.+A.+Stearnsauthor=B.+T.+Campbellauthor=J.+M.+Arrudaauthor=C.+Chenauthor=J.+Aiyarauthor=R.+E.+Bezverkovauthor=A.+Santiniauthor=H.+Schaffhauserauthor=W.+Liuauthor=S.+Venkatramanauthor=B.+Munoz&title=Synthesis+and+biological+evaluation+of+6-aryl-6H-pyrrolo%5B3%2C4-d%5Dpyridazine+derivatives+as+high-affinity+ligands+of+the+alpha%282%29delta+subunit+of+voltage-gated+calcium+channels&doi=10.1016%2Fj.bmcl.2004.02.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 6-aryl-6H-pyrrolo[3,4-d]pyridazine derivatives as high-affinity ligands of the α2δ subunit of voltage-gated calcium channels</span></div><div class="casAuthors">Hu, Tao; Stearns, Brian A.; Campbell, Brian T.; Arruda, Jeannie M.; Chen, Chixu; Aiyar, Jayashree; Bezverkov, Robert E.; Santini, Angelina; Schaffhauser, Herve; Liu, Wensheng; Venkatraman, Shankar; Munoz, Benito</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2031-2034</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">2H-pyrrolo[3,4-c]pyridazines I (R = 4-EtOC6H4, 2-EtO-5-pyridinyl, 5-EtO-2-pyridinyl, 5-EtO-2-pyrazinyl, 4-EtO-1-pyridazinyl, 2-EtO-5-pyrimidinyl, etc.) such as II (R1 = H, MeO, Et, H2C:CH, Me, MeS, EtO, F; R2 = H, Me; R3 = H, Me, Cl, HOCH2; R4 = H, Me) are prepd. as ligands for the α2δ subunit of voltage-gated calcium channels.  Ortho-substituents capable of electron-donation increase the binding of II to the α2δ subunit of voltage-gated calcium channels; electron-withdrawing substituents in the ortho-position of II decrease binding significantly.  II (R1 = MeO; R2 = R3 = R4 = H) binds to the α2δ subunit of voltage-gated calcium channels from A710 cells with an IC50 value of 4 nM.  Testing of tritiated ligand II (R1 = TCH2TCH; R2 = R3 = R4 = H) in purified human α2δ voltage-gated calcium channel subunits indicates that II displace Gabapentin from the α2δ subunit of voltage-gated calcium channels, and thus act as Gabapentin mimics in vitro.  In the prepn. of II (R1 = Et; R2 = R3 = R4 = H), a novel metal-free hydrogenation is used using hydrazine as the reductant; the redn. is effective in other systems (no data).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Go-zcrg8e7Vg90H21EOLACvtfcHk0lgGjV-_eHwYwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVeht7s%253D&md5=80953eb8562c85bd45478aa3a7613ebe</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.070%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DT.%26aulast%3DStearns%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DArruda%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DBezverkov%26aufirst%3DR.%2BE.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DMunoz%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25206-aryl-6H-pyrrolo%255B3%252C4-d%255Dpyridazine%2520derivatives%2520as%2520high-affinity%2520ligands%2520of%2520the%2520alpha%25282%2529delta%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2031%26epage%3D2034%26doi%3D10.1016%2Fj.bmcl.2004.02.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arruda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span> <span> </span><span class="NLM_article-title">Expedited SAR study of high-affinity ligands to the α2δ subunit of voltage-gated calcium channels: generation of a focused library using a solution-phase Sn2Ar coupling methodology</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.08.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2005.08.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=16321528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlChsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=746-749&author=C.+Chenauthor=B.+Stearnsauthor=T.+Huauthor=N.+Ankerauthor=A.+Santiniauthor=J.+M.+Arrudaauthor=B.+T.+Campbellauthor=P.+Dattaauthor=J.+Aiyarauthor=B.+Munoz&title=Expedited+SAR+study+of+high-affinity+ligands+to+the+%CE%B12%CE%B4+subunit+of+voltage-gated+calcium+channels%3A+generation+of+a+focused+library+using+a+solution-phase+Sn2Ar+coupling+methodology&doi=10.1016%2Fj.bmcl.2005.08.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Expedited SAR study of high-affinity ligands to the α2δ subunit of voltage-gated calcium channels: Generation of a focused library using a solution-phase Sn2Ar coupling methodology</span></div><div class="casAuthors">Chen, Chixu; Stearns, Brian; Hu, Tao; Anker, Naomi; Santini, Angelina; Arruda, Jeannie M.; Campbell, Brian T.; Datta, Purabi; Aiyar, Jayashree; Munoz, Benitio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">746-749</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The SAR of the lead compd. 3, a novel ligand for the α2δ subunit of voltage-gated calcium channels, was rapidly explored.  Utilizing a parallel soln.-phase Sn2Ar coupling approach, a focused library was obtained.  The library was evaluated in vitro and afforded a series of analogs with improved potencies.  The SAR trends of the library are also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLH-vOOdTSDrVg90H21EOLACvtfcHk0lhDCTPTHDbTBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlChsr7M&md5=522e81f7e3680e51a301cdac7ed742c1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.08.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.08.117%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DAnker%26aufirst%3DN.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DArruda%26aufirst%3DJ.%2BM.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DDatta%26aufirst%3DP.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DMunoz%26aufirst%3DB.%26atitle%3DExpedited%2520SAR%2520study%2520of%2520high-affinity%2520ligands%2520to%2520the%2520%25CE%25B12%25CE%25B4%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%253A%2520generation%2520of%2520a%2520focused%2520library%2520using%2520a%2520solution-phase%2520Sn2Ar%2520coupling%2520methodology%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D746%26epage%3D749%26doi%3D10.1016%2Fj.bmcl.2005.08.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myatt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravi, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billinton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livermore, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douault, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowedder, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, N. M.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4683</span>– <span class="NLM_lpage">4688</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2010.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=20566291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4683-4688&author=J.+W.+Myattauthor=M.+P.+Healyauthor=G.+S.+Braviauthor=A.+Billintonauthor=C.+N.+Johnsonauthor=K.+L.+Matthewsauthor=K.+S.+Janduauthor=W.+Mengauthor=A.+Herseyauthor=D.+G.+Livermoreauthor=C.+B.+Douaultauthor=J.+Witheringtonauthor=R.+A.+Bitauthor=J.+E.+Rowedderauthor=J.+D.+Brownauthor=N.+M.+Clayton&title=Pyrazolopyridazine+alpha-2-delta-1+ligands+for+the+treatment+of+neuropathic+pain&doi=10.1016%2Fj.bmcl.2010.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain</span></div><div class="casAuthors">Myatt, James W.; Healy, Mark P.; Bravi, Gianpaolo S.; Billinton, Andrew; Johnson, Christopher N.; Matthews, Kim L.; Jandu, Karamjit S.; Meng, Wenjing; Hersey, Anne; Livermore, David G.; Douault, Clement B.; Witherington, Jason; Bit, Rino A.; Rowedder, James E.; Brown, Jason D.; Clayton, Nick M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4683-4688</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Optimization of the novel alpha-2-delta-1 ligand 4 provided compds. 37 and 38 which have improved DMPK profiles, good in vivo analgesic activity and in vitro selectivity over alpha-2-delta-2.  An inhouse P-gp prediction program and the MetaSite software package were used to help solve the specific problems of high P-gp efflux and high in vivo clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7jBsZtS9et7Vg90H21EOLACvtfcHk0lhDCTPTHDbTBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSrsr8%253D&md5=80ec48cdc22f23bb3b1297dbd3dea125</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DMyatt%26aufirst%3DJ.%2BW.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DBravi%26aufirst%3DG.%2BS.%26aulast%3DBillinton%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DJandu%26aufirst%3DK.%2BS.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLivermore%26aufirst%3DD.%2BG.%26aulast%3DDouault%26aufirst%3DC.%2BB.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DRowedder%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DJ.%2BD.%26aulast%3DClayton%26aufirst%3DN.%2BM.%26atitle%3DPyrazolopyridazine%2520alpha-2-delta-1%2520ligands%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4683%26epage%3D4688%26doi%3D10.1016%2Fj.bmcl.2010.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otsubo, N.</span>; <span class="NLM_string-name">Tsukumo, Y.</span>; <span class="NLM_string-name">Uchida, K.</span>; <span class="NLM_string-name">Matsymmoto, Y.</span>; <span class="NLM_string-name">Iida, K.</span>; <span class="NLM_string-name">Takada, H.</span>; <span class="NLM_string-name">Takizawa, F.</span>; <span class="NLM_string-name">Arai, H.</span>; <span class="NLM_string-name">Okazaki, S.</span>; <span class="NLM_string-name">Imaizumi, T.</span></span> <span> </span><span class="NLM_article-title">Pyrimidodiazepinone Derivatives</span>. <span class="NLM_patent">US20,100,190,775</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+Otsubo&author=Y.+Tsukumo&author=K.+Uchida&author=Y.+Matsymmoto&author=K.+Iida&author=H.+Takada&author=F.+Takizawa&author=H.+Arai&author=S.+Okazaki&author=T.+Imaizumi&title=Pyrimidodiazepinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOtsubo%26aufirst%3DN.%26atitle%3DPyrimidodiazepinone%2520Derivatives%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otsubo, N.</span>; <span class="NLM_string-name">Okazaki, S.</span>; <span class="NLM_string-name">Tsukumo, Y.</span>; <span class="NLM_string-name">Iida, K.</span>; <span class="NLM_string-name">Nakoji, M.</span></span> <span> </span><span class="NLM_article-title">Pyrimidodiazepinone Compounds</span>. <span class="NLM_patent">US20140171422</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=N.+Otsubo&author=S.+Okazaki&author=Y.+Tsukumo&author=K.+Iida&author=M.+Nakoji&title=Pyrimidodiazepinone+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOtsubo%26aufirst%3DN.%26atitle%3DPyrimidodiazepinone%2520Compounds%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ossipov, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussor, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span> <span> </span><span class="NLM_article-title">Central modulation of pain</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">3779</span>– <span class="NLM_lpage">3787</span>, <span class="refDoi"> DOI: 10.1172/JCI43766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1172%2FJCI43766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21041960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWgtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=3779-3787&author=M.+H.+Ossipovauthor=G.+O.+Dussorauthor=F.+Porreca&title=Central+modulation+of+pain&doi=10.1172%2FJCI43766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Central modulation of pain</span></div><div class="casAuthors">Ossipov, Michael H.; Dussor, Gregory O.; Porreca, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3779-3787</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  It has long been appreciated that the experience of pain is highly variable between individuals.  Pain results from activation of sensory receptors specialized to detect actual or impending tissue damage (i.e., nociceptors).  However, a direct correlation between activation of nociceptors and the sensory experience of pain is not always apparent.  Even in cases in which the severity of injury appears similar, individual pain experiences may vary dramatically.  Emotional state, degree of anxiety, attention and distraction, past experiences, memories, and many other factors can either enhance or diminish the pain experience.  Here, we review evidence for "top-down" modulatory circuits that profoundly change the sensory experience of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTLcjICoIRt7Vg90H21EOLACvtfcHk0lhDPRmply_2WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWgtb3J&md5=af0ad2eaafb14fb0f3e7b2235ff1a40d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1172%2FJCI43766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI43766%26sid%3Dliteratum%253Aachs%26aulast%3DOssipov%26aufirst%3DM.%2BH.%26aulast%3DDussor%26aufirst%3DG.%2BO.%26aulast%3DPorreca%26aufirst%3DF.%26atitle%3DCentral%2520modulation%2520of%2520pain%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D3779%26epage%3D3787%26doi%3D10.1172%2FJCI43766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiroki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obata, H.</span></span> <span> </span><span class="NLM_article-title">Repeated administration of amitriptyline in neuropathic pain: modulation of the noradrenergic descending inhibitory system</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1213/ANE.0000000000002352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1213%2FANE.0000000000002352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=28787345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSksr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=1281-1288&author=T.+Hirokiauthor=T.+Sutoauthor=S.+Saitoauthor=H.+Obata&title=Repeated+administration+of+amitriptyline+in+neuropathic+pain%3A+modulation+of+the+noradrenergic+descending+inhibitory+system&doi=10.1213%2FANE.0000000000002352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System</span></div><div class="casAuthors">Hiroki, Tadanao; Suto, Takashi; Saito, Shigeru; Obata, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1281-1288</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The tricyclic antidepressant amitriptyline, the serotonin and noradrenaline reuptake inhibitor duloxetine, and gabapentinoids are first-line drugs for treatment of neuropathic pain.  The analgesic effect of these drugs relates to brainstem-spinal descending noradrenergic systems.  However, amitriptyline utilizes a variety of mechanisms for analgesia in neuropathic pain, and it is unclear which mechanism is most important.  In the present study, we investigated the role of descending noradrenergic systems in the analgesic effect of these drugs for treatment of neuropathic pain.  We also examd. whether amitriptyline modifies the descending noradrenergic systems.  Methods: Seven days after L5 spinal nerve ligation (SNL), rats received N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 50 mg/kg) to degenerate noradrenergic fibers.  The rats then received 5 daily i.p. injections of amitriptyline (10 mg/kg), duloxetine (10 mg/kg), pregabalin (10 mg/kg), or gabapentin (50 mg/kg) from 21 days after SNL surgery.  Paw withdrawal thresholds were detd. to assess the effect of the drugs on hyperalgesia after SNL.  To det. whether 5 daily injections of amitriptyline activated noradrenergic neurons in the locus coeruleus (LC) and spinal cord with or without DSP-4 treatment, we performed immunohistochem. using antibodies for c-Fos and dopamine beta-hydroxylase (DβH).  Results: Five daily injections of amitriptyline, duloxetine, pregabalin, and gabapentin exerted antihyperalgesic effects in SNL rats (P < .001; estd. treatment effect of amitriptyline [99% confidence interval]: 59.9 [35.1-84.7] g).  The antihyperalgesic effects of duloxetine, pregabalin, and gabapentin were reversed by pretreatment with DSP-4 (P < .001, resp.).  However, antihyperalgesia was still obsd. after treatment of amitriptyline in SNL rats with DSP-4 pretreatment (P < .001, 59.7 [30.0-89.3] g), and this analgesic effect was not reversed by the α2-adrenoceptor antagonist idazoxan (30μg).  Addnl., 5 daily injections of amitriptyline increased the ratio of c-Fos-immunoreactive (IR) cells in noradrenergic LC neurons in SNL rats with or without DSP-4 pretreatment (P < .001, resp.).  Five daily injections of amitriptyline increased DβH-IR in the LC and the spinal dorsal horn of SNL rats (P < .001, resp.).  With DSP-4 pretreatment, DβH-IR was dramatically decreased with or without 5 daily injections of amitriptyline (P < .001).  Conclusions: Five daily injections of amitriptyline produced antihyperalgesic effects against neuropathic pain despite suppression of noradrenergic descending inhibitory systems.  Amitriptyline activated LC neurons and increased noradrenergic fibers d. in SNL rats.  These results suggest that amitriptyline could still produce analgesia under pathol. dysfunction of the descending noradrenergic system.  Amitriptyline may enhance the analgesic effect of drugs for neuropathic pain that require normal descending noradrenergic inhibition to produce analgesia, such as serotonin and noradrenaline reuptake inhibitors and gabapentinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiJQx_fnmmhrVg90H21EOLACvtfcHk0lhDPRmply_2WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSksr3E&md5=fd279a89377065235f7207e0ab279b90</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1213%2FANE.0000000000002352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252FANE.0000000000002352%26sid%3Dliteratum%253Aachs%26aulast%3DHiroki%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DObata%26aufirst%3DH.%26atitle%3DRepeated%2520administration%2520of%2520amitriptyline%2520in%2520neuropathic%2520pain%253A%2520modulation%2520of%2520the%2520noradrenergic%2520descending%2520inhibitory%2520system%26jtitle%3DAnesth.%2520Analg.%26date%3D2017%26volume%3D125%26spage%3D1281%26epage%3D1288%26doi%3D10.1213%2FANE.0000000000002352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartrick, C. T.</span></span> <span> </span><span class="NLM_article-title">Noradrenergic reuptake inhibition in the treatment of pain</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1834</span>, <span class="refDoi"> DOI: 10.1517/13543784.2012.731393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1517%2F13543784.2012.731393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=23043362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cks73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1827-1834&author=C.+T.+Hartrick&title=Noradrenergic+reuptake+inhibition+in+the+treatment+of+pain&doi=10.1517%2F13543784.2012.731393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Noradrenergic reuptake inhibition in the treatment of pain</span></div><div class="casAuthors">Hartrick, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1827-1834</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Noradrenergic reuptake inhibitors can be effective analgesics, finding application in a wide variety of clin. pain settings.  Due to a shift toward noradrenergic-mediated pain pathways following nerve injury, they are particularly well suited to the treatment of neuropathic pain.  This phenotypic shift makes neuropathic pain difficult to control with opioids alone; some noradrenergic reuptake inhibitors have demonstrated synergy with opioids.  Agents currently in early clin. trials are discussed and include both novel delivery of old drugs and the development of new drugs.  This review was limited to noradrenergic reuptake inhibitors and analgesia.  Literature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).  Topical drug delivery and the use of combinations of agents both topically and systemically are under active investigation.  The intrathecal delivery of noradrenergic reuptake inhibitors, allowing delivery directly to the central nervous system thus limiting systemic exposure, represents an exciting avenue of investigation.  Gaps in current knowledge have complicated the development of prophylactic therapies for susceptible individuals or preemptive intervention.  Disease-modifying agents and selective inhibitors would facilitate these treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27mIkUgNx3bVg90H21EOLACvtfcHk0lgOnUqAwYtrKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cks73J&md5=95310a229651b6e3ae91cc36325e92fa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.731393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.731393%26sid%3Dliteratum%253Aachs%26aulast%3DHartrick%26aufirst%3DC.%2BT.%26atitle%3DNoradrenergic%2520reuptake%2520inhibition%2520in%2520the%2520treatment%2520of%2520pain%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1827%26epage%3D1834%26doi%3D10.1517%2F13543784.2012.731393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulse, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering, A. E.</span></span> <span> </span><span class="NLM_article-title">Endogenous analgesic action of the pontospinal noradrenergic system spatially restricts and temporally delays the progression of neuropathic pain following tibial nerve injury</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1680</span>– <span class="NLM_lpage">1690</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.pain.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=23707289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=1680-1690&author=S.+W.+Hughesauthor=L.+Hickeyauthor=R.+P.+Hulseauthor=B.+M.+Lumbauthor=A.+E.+Pickering&title=Endogenous+analgesic+action+of+the+pontospinal+noradrenergic+system+spatially+restricts+and+temporally+delays+the+progression+of+neuropathic+pain+following+tibial+nerve+injury&doi=10.1016%2Fj.pain.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous analgesic action of the pontospinal noradrenergic system spatially restricts and temporally delays the progression of neuropathic pain following tibial nerve injury</span></div><div class="casAuthors">Hughes, S. W.; Hickey, L.; Hulse, R. P.; Lumb, B. M.; Pickering, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1680-1690</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pontospinal noradrenergic neurons form part of an endogenous analgesic system that suppresses acute pain, but there is conflicting evidence about its role in neuropathic pain.  We investigated the chronol. of descending noradrenergic control during the development of a neuropathic pain phenotype in rats following tibial nerve transection (TNT).  A lumbar intrathecal cannula was implanted at the time of nerve injury allowing administration of selective α-adrenoceptor (α-AR) antagonists to sequentially assay their effects upon the expression of allodynia and hyperalgesia.  Following TNT animals progressively developed mech. and cold allodynia (by day 10) and subsequently heat hypersensitivity (day 17).  Blockade of α2-AR with intrathecal yohimbine (30 μg) revealed earlier ipsilateral sensitization of all modalities while prazosin (30 μg, α1-AR) was without effect.  Established allodynia (by day 21) was partly reversed by the re-uptake inhibitor reboxetine (5 μg, i.t.) but yohimbine no longer had any sensitizing effect.  This loss of effect coincided with a redn. in the descending noradrenergic innervation of the ipsilateral lumbar dorsal horn.  Yohimbine reversibly unmasked contralateral hindlimb allodynia and hyperalgesia of all modalities and increased dorsal horn c-fos expression to an innocuous brush stimulus.  Contralateral thermal hyperalgesia was also reversibly uncovered by yohimbine administration in a contact heat ramp paradigm in anesthetized TNT rats.  Following TNT there is an engagement of inhibitory α2-AR-mediated noradrenergic tone which completely masks contralateral and transiently suppresses the development of ipsilateral sensitization.  This endogenous analgesic system plays a key role in shaping the spatial and temporal expression of the neuropathic pain phenotype after nerve injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Mc9eIKPcurVg90H21EOLACvtfcHk0lgOnUqAwYtrKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyktbs%253D&md5=9b128e9c126bb7cf9da4c7c5d11d7d1d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%2BW.%26aulast%3DHickey%26aufirst%3DL.%26aulast%3DHulse%26aufirst%3DR.%2BP.%26aulast%3DLumb%26aufirst%3DB.%2BM.%26aulast%3DPickering%26aufirst%3DA.%2BE.%26atitle%3DEndogenous%2520analgesic%2520action%2520of%2520the%2520pontospinal%2520noradrenergic%2520system%2520spatially%2520restricts%2520and%2520temporally%2520delays%2520the%2520progression%2520of%2520neuropathic%2520pain%2520following%2520tibial%2520nerve%2520injury%26jtitle%3DPain%26date%3D2013%26volume%3D154%26spage%3D1680%26epage%3D1690%26doi%3D10.1016%2Fj.pain.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span>Available
from: <a href="https://www.fda.gov/consumers/consumer-updates/living-fibromyalgia-drugs-approved-manage-pain" class="extLink">https://www.fda.gov/consumers/consumer-updates/living-fibromyalgia-drugs-approved-manage-pain</a>. (accessed February 13, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Available%0Afrom%3A+https%3A%2F%2Fwww.fda.gov%2Fconsumers%2Fconsumer-updates%2Fliving-fibromyalgia-drugs-approved-manage-pain.+%28accessed+February+13%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dvoracsko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, A.</span></span> <span> </span><span class="NLM_article-title">The design of multitarget ligands for chronic and neuropathic pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.4155%2Ffmc.15.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=26652942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2469-2483&author=S.+Dvoracskoauthor=A.+Stefanucciauthor=E.+Novellinoauthor=A.+Mollica&title=The+design+of+multitarget+ligands+for+chronic+and+neuropathic+pain&doi=10.4155%2Ffmc.15.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The design of multitarget ligands for chronic and neuropathic pain</span></div><div class="casAuthors">Dvoracsko, Szabolcs; Stefanucci, Azzurra; Novellino, Ettore; Mollica, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2469-2483</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Monodrug therapy has been used with success to fight various pathologies.  When one medicine fails, co-administration of two or more drugs at the same time may be successfully applied in the treatment of infections, hypertension, HIV and in many other fields.  Discussion: This approach has some weakness related to the pharmacokinetic of the two different substances administered, side effects, possible drug-drug interaction.  Bivalent ligand approach would maintain the strength of the multidrug therapy (synergistic effect, lower doses, and little side effects) and overcome the weakness of a co-administration.  Conclusion: In this review we have described the state-of-the-art of the multitarget approach for the control of pain.  Several approaches adopted by different research groups and future perspectives have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEdmKaU-Blf7Vg90H21EOLACvtfcHk0lg_VPK1ZQS5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K&md5=04d64c3fd3e5f442094cbd40ebf25303</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.156%26sid%3Dliteratum%253Aachs%26aulast%3DDvoracsko%26aufirst%3DS.%26aulast%3DStefanucci%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMollica%26aufirst%3DA.%26atitle%3DThe%2520design%2520of%2520multitarget%2520ligands%2520for%2520chronic%2520and%2520neuropathic%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2469%26epage%3D2483%26doi%3D10.4155%2Ffmc.15.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhosle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharambe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gairola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaneshwar, S. S.</span></span> <span> </span><span class="NLM_article-title">Mutual prodrug concept: fundamentals and applications</span>. <i>Indian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.4103/0250-474X.26654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.4103%2F0250-474X.26654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2006&pages=286-294&author=D.+Bhosleauthor=S.+Bharambeauthor=N.+Gairolaauthor=S.+S.+Dhaneshwar&title=Mutual+prodrug+concept%3A+fundamentals+and+applications&doi=10.4103%2F0250-474X.26654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Mutual prodrug concept: fundamentals and applications</span></div><div class="casAuthors">Bhosle, D.; Bharambe, S.; Gairola, Neha; Dhaneshwar, Suneela S.</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-294</span>CODEN:
                <span class="NLM_cas:coden">IJSIDW</span>;
        ISSN:<span class="NLM_cas:issn">0250-474X</span>.
    
            (<span class="NLM_cas:orgname">Indian Pharmaceutical Association</span>)
        </div><div class="casAbstract">A review.  A therapeutically significant drug may have limited utilization in clin. practice because of poor organoleptic properties, poor bioavailability, short duration of action, nonspecificity, incomplete absorption, poor aq. soly., high first-pass metab. or other adverse effects.  There is a great emphasis on research to discover methods aimed at improving their therapeutic efficacy by minimizing or eliminating these undesirable properties.  Sometimes, an adequate pharmaceutical formulation can overcome these drawbacks, but often the galenic formulation is inoperant and a chem. modification of active mol. is necessary to correct its pharmacokinetic insufficiencies.  This chem. formulation process, whose objective is to convert an interesting active mol. into a clin. acceptable drug, often involves the so-called 'Prodrug design.'.  Mutual prodrug is a type of carrier-linked prodrug, where the carrier used is another biol. active drug instead of some inert mol.  A mutual prodrug consists of two pharmacol. active agents coupled together so that each acts as a promoiety for the other agent and vice versa.  Mutual prodrug design is really no different from the general drug discovery process, in which a unique substance is obsd. to have desirable pharmacol. effects, and studies of its properties lead to the design of better drugs.  It is a very fruitful area of research, and its introduction in human therapy has given successful results in improving the clin. and therapeutic effectiveness of drugs suffering from some undesirable properties that otherwise hinder their clin. usefulness.  The present article takes a review of various applications of mutual prodrugs and the developments in this field during the last few decades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH3cW1cvTkVLVg90H21EOLACvtfcHk0lg_VPK1ZQS5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D&md5=3dcaac61d251a1027fe9d212d0aef51c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4103%2F0250-474X.26654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0250-474X.26654%26sid%3Dliteratum%253Aachs%26aulast%3DBhosle%26aufirst%3DD.%26aulast%3DBharambe%26aufirst%3DS.%26aulast%3DGairola%26aufirst%3DN.%26aulast%3DDhaneshwar%26aufirst%3DS.%2BS.%26atitle%3DMutual%2520prodrug%2520concept%253A%2520fundamentals%2520and%2520applications%26jtitle%3DIndian%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D68%26spage%3D286%26epage%3D294%26doi%3D10.4103%2F0250-474X.26654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Design strategies for bivalent ligands targeting GPCRs</span>. <i>Chem. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2Fcmdc.201100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21520422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=963-974&author=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Design+strategies+for+bivalent+ligands+targeting+GPCRs&doi=10.1002%2Fcmdc.201100101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Design Strategies for Bivalent Ligands Targeting GPCRs</span></div><div class="casAuthors">Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature.  The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity.  However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic mol. properties, such as high mol. wt. and lipophilicity.  This Minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and compn. of the spacer group.  Furthermore, this Minireview distills the mol. descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7uDrMXq0sprVg90H21EOLACvtfcHk0lg_VPK1ZQS5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D&md5=569a8a988cdd9d2daf8f492211303934</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100101%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DDesign%2520strategies%2520for%2520bivalent%2520ligands%2520targeting%2520GPCRs%26jtitle%3DChem.%2520Med.%2520Chem.%26date%3D2011%26volume%3D6%26spage%3D963%26epage%3D974%26doi%3D10.1002%2Fcmdc.201100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, F.</span>; <span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine Compounds for Treating Pain and Pain Related Conditions</span>.  <i>PCT Int. Appl</i>. <span class="NLM_patent">WO2017191304</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Cuevas&author=C.+Almansa&title=Tetrahydropyrimidodiazepine+and+tetrahydropyridodiazepine+Compounds+for+Treating+Pain+and+Pain+Related+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCuevas%26aufirst%3DF.%26atitle%3DTetrahydropyrimidodiazepine%2520and%2520tetrahydropyridodiazepine%2520Compounds%2520for%2520Treating%2520Pain%2520and%2520Pain%2520Related%2520Conditions%26jtitle%3DPCT%2520Int.%2520Appl%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span>; <span class="NLM_string-name">Cuevas, F.</span></span> <span> </span><span class="NLM_article-title">New Alcoxyamino Derivatives for Treating Pain and Pain Related Conditions</span>.  <i>PCT Int. Appl</i>. <span class="NLM_patent">WO2019081691</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Almansa&author=F.+Cuevas&title=New+Alcoxyamino+Derivatives+for+Treating+Pain+and+Pain+Related+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DNew%2520Alcoxyamino%2520Derivatives%2520for%2520Treating%2520Pain%2520and%2520Pain%2520Related%2520Conditions%26jtitle%3DPCT%2520Int.%2520Appl%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yenes, S.</span>; <span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Compounds Having Multimodal Activity Against Pain</span>. <span class="NLM_patent">WO2019002173</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Yenes&author=C.+Almansa&title=Compounds+Having+Multimodal+Activity+Against+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYenes%26aufirst%3DS.%26atitle%3DCompounds%2520Having%2520Multimodal%2520Activity%2520Against%2520Pain%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span> <span> </span><span class="NLM_article-title">Ca<sup>2+</sup> channel α<sub>2</sub>-δ ligands for the treatment of neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1021/jm060650z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060650z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2569-2575&author=M.+J.+Fieldauthor=Z.+Liauthor=J.+B.+Schwarz&title=Ca2%2B+channel+%CE%B12-%CE%B4+ligands+for+the+treatment+of+neuropathic+pain&doi=10.1021%2Fjm060650z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ Channel α2-δ Ligands for the Treatment of Neuropathic Pain</span></div><div class="casAuthors">Field, Mark J.; Li, Zheng; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2575</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Pregabalin was recently approved in the U.S. and Europe as an add- on therapy for epilepsy, as well as for the treatment of neuropathic pain.  In addn., pregabalin recently gained approval in the EU for the treatment of generalized anxiety disorder.  As a result of it's superior potency and pharmacokinetic profile compared to gabapentin, pregabalin has enjoyed rapid uptake by prescribing physicians for these conditions.  Pregabalin is thought to access the central nervous system (CNS) via the system L amino acid transporter and act via modulation of the α2-δ subunit of voltage-gated calcium channels.  Pregabalin is remarkably silent at all other known receptors (with the exception of being a substrate for the system L transmembrane amino acid transporter), and as a consequence, the α2-δ hypothesis is gaining traction as the accepted MOA of pregabalin.  Some excellent reviews categorizing the available evidence to elucidate the mechanism of gabapentin in neuropathic pain have recently appeared.  The purpose of this Miniperspective is to showcase the medicinal chem. efforts employed to obtain structurally diverse compds. with both reported affinity for the α2-δ subunit and in vivo activity in various neuropathic pain paradigms.  Expts. to suggest that α2-δ ligands act to suppress the development and maintenance of central sensitization, as well as a discussion of the implications of α2-δ subtype localization and function, will also be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzlIxj5QQMrVg90H21EOLACvtfcHk0ljSw66Q6yMVAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D&md5=12cbcf55d0e7524e0971c462e27a7271</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm060650z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060650z%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DCa2%252B%2520channel%2520%25CE%25B12-%25CE%25B4%2520ligands%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2569%26epage%3D2575%26doi%3D10.1021%2Fjm060650z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0ljSw66Q6yMVAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span>. <i>Am. Soc. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DAm.%2520Soc.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span> <span> </span><span class="NLM_article-title">High-throughput Screening of Human Cytochrome P450 inhibitors Using Fluorometric Substrates. Methodology for 25 Enzyme/Substrate Pairs</span>. In  <i>Optimization in Drug Discovery. In vitro Methods</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span>; <span class="NLM_string-name">Caldwell, G.W.</span></span>; Eds. <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, New Jersey</span>, <span class="NLM_year">2004</span>; pp.  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">230</span>;</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1385%2F1-59259-800-5%3A215" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=215-230&author=D.+M.+Stresserauthor=Z.+Yan&author=G.W.+Caldwell&title=Optimization+in+Drug+Discovery.+In+vitro+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1385%2F1-59259-800-5%3A215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1385%252F1-59259-800-5%253A215%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26atitle%3DHigh-throughput%2520Screening%2520of%2520Human%2520Cytochrome%2520P450%2520inhibitors%2520Using%2520Fluorometric%2520Substrates.%2520Methodology%2520for%252025%2520Enzyme%252FSubstrate%2520Pairs%26btitle%3DOptimization%2520in%2520Drug%2520Discovery.%2520In%2520vitro%2520Methods%26aulast%3DYan%26aufirst%3DZ.%26pub%3DHumana%2520Press%26date%3D2004%26spage%3D215%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, G. W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Cytochrome P450 inhibition in Human Liver Microsomes</span>. <i>Optim. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1385/1-59259-800-5:231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1385%2F1-59259-800-5%3A231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosF2gs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=231-244&author=Z.+Yanauthor=G.+W.+Caldwell&title=Evaluation+of+Cytochrome+P450+inhibition+in+Human+Liver+Microsomes&doi=10.1385%2F1-59259-800-5%3A231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cytochrome P450 inhibition in human liver microsomes</span></div><div class="casAuthors">Yan, Zhengyin; Caldwell, Gary W.</div><div class="citationInfo"><span class="NLM_cas:title">Optimization in Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-244</span>CODEN:
                <span class="NLM_cas:coden">69FYUI</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Evaluation of lead compds. for P 450 inhibition in human liver microsomes has been widely accepted as an in vitro approach to assess drug interaction potential.  This chapter describes a detailed traditional CYP inhibition protocol for six major isoforms: 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4.  Microsomal incubation conditions were optimized and kinetic parameters detd. to initially establish the inhibition assay.  In CYP inhibition assay, sepd. incubations were performed for individual CYPs, and resulting samples were pooled and analyzed by liq. chromatog./tandem mass spectrometry (LC-MS/MS).  It is without doubt that results from this in vitro expt. are of great value in lead optimization in drug discovery and development.  It is obvious that more efforts are still needed to establish the relevance between in vitro CYP inhibition and drug interactions in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqruqDzG1DCgbVg90H21EOLACvtfcHk0lgJ_ZNeWClDCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosF2gs70%253D&md5=9d0186de8c2b16ee1de4a00cc89613b8</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1385%2F1-59259-800-5%3A231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-800-5%253A231%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DCaldwell%26aufirst%3DG.%2BW.%26atitle%3DEvaluation%2520of%2520Cytochrome%2520P450%2520inhibition%2520in%2520Human%2520Liver%2520Microsomes%26jtitle%3DOptim.%2520Drug%2520Discovery%26date%3D2004%26spage%3D231%26epage%3D244%26doi%3D10.1385%2F1-59259-800-5%3A231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit38c"><span><span class="NLM_label">(c) </span>Drug Interaction
Studies – Study Design, Data Analysis, Implications for Dosing
and Labeling. Center for Drug Evaluation and Research (CDER), Food
and Drug Administration, September 2006 and February 2012.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drug+Interaction%0AStudies+%E2%80%93+Study+Design%2C+Data+Analysis%2C+Implications+for+Dosing%0Aand+Labeling.+Center+for+Drug+Evaluation+and+Research+%28CDER%29%2C+Food%0Aand+Drug+Administration%2C+September+2006+and+February+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitza, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G. A.</span></span> <span> </span><span class="NLM_article-title">The [<sup>3</sup>H]-dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K<sup>+</sup>]<sub>o</sub></span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2004.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.vascn.2004.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15519905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=187-199&author=G.+J.+Diazauthor=K.+Daniellauthor=S.+T.+Leitzaauthor=R.+L.+Martinauthor=Z.+Suauthor=J.+S.+McDermottauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+%5B3H%5D-dofetilide+binding+assay+is+a+predictive+screening+tool+for+hERG+blockade+and+proarrhythmia%3A+Comparison+of+intact+cell+and+membrane+preparations+and+effects+of+altering+%5BK%2B%5Do&doi=10.1016%2Fj.vascn.2004.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span></div><div class="casAuthors">Diaz, Gilbert J.; Daniell, Katina; Leitza, Sandra T.; Martin, Ruth L.; Su, Zhi; McDermott, Jeffrey S.; Cox, Bryan F.; Gintant, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization.  Drugs that block hERG have been assocd. with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes).  While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.Methods: To validate the utility of this assay as a screening tool, we performed a series of satn. and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane prepns. from HEK 293 cells stably transfected with hERG K+ channels.  The object of these expts. was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to det. whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concns. (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.Results: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block.Discussion: In conclusion, increasing K+ concns. results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates.  There are no meaningful differences between Ki values when comparing intact cell vs. membrane assay, neither are there meaningful trends with increasing [K+]o within assays.  There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concns. (R2 values of .824 and .863, resp.).  The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compds. for their potential to block the hERG K+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJEs_DWLzvI7Vg90H21EOLACvtfcHk0ljUMKpNrm-mKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D&md5=28c925ef02404c53443dc90eae961ed1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DDaniell%26aufirst%3DK.%26aulast%3DLeitza%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520%255B3H%255D-dofetilide%2520binding%2520assay%2520is%2520a%2520predictive%2520screening%2520tool%2520for%2520hERG%2520blockade%2520and%2520proarrhythmia%253A%2520Comparison%2520of%2520intact%2520cell%2520and%2520membrane%2520preparations%2520and%2520effects%2520of%2520altering%2520%255BK%252B%255Do%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2004%26volume%3D50%26spage%3D187%26epage%3D199%26doi%3D10.1016%2Fj.vascn.2004.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beedle, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span> <span> </span><span class="NLM_article-title">Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4477</span>– <span class="NLM_lpage">4480</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.08.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2003.08.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=14643350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1yru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4477-4480&author=F.+P.+Bymasterauthor=E.+E.+Beedleauthor=J.+Findlayauthor=P.+T.+Gallagherauthor=J.+H.+Krushinskiauthor=S.+Mitchellauthor=D.+W.+Robertsonauthor=D.+C.+Thompsonauthor=L.+Wallaceauthor=D.+T.+Wong&title=Duloxetine+%28Cymbalta%29%2C+a+dual+inhibitor+of+serotonin+and+norepinephrine+reuptake&doi=10.1016%2Fj.bmcl.2003.08.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake</span></div><div class="casAuthors">Bymaster, F. P.; Beedle, E. E.; Findlay, J.; Gallagher, P. T.; Krushinski, J. H.; Mitchell, S.; Robertson, D. W.; Thompson, D. C.; Wallace, L.; Wong, D. T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4477-4480</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of naphthalenyloxy-substituted amines I (n = 2 - 4, R = H; n = 1, R = H, Ph, 4-FC6H4, 2-MeOC6H4, 2-furyl, 2-thienyl, 2-thiazolyl, etc.) has been prepd., and these compds. are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake.  One member of this series, duloxetine (Cymbalta), (S)-I (n = 1; R = 2-thienyl), has proven to be effective in clin. trials for the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa_uhGtxZMM7Vg90H21EOLACvtfcHk0ljUMKpNrm-mKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1yru7s%253D&md5=13292f56b0d5282e87b0a48217b5df48</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.08.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.08.079%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DBeedle%26aufirst%3DE.%2BE.%26aulast%3DFindlay%26aufirst%3DJ.%26aulast%3DGallagher%26aufirst%3DP.%2BT.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DMitchell%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26aulast%3DThompson%26aufirst%3DD.%2BC.%26aulast%3DWallace%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DD.%2BT.%26atitle%3DDuloxetine%2520%2528Cymbalta%2529%252C%2520a%2520dual%2520inhibitor%2520of%2520serotonin%2520and%2520norepinephrine%2520reuptake%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4477%26epage%3D4480%26doi%3D10.1016%2Fj.bmcl.2003.08.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhr-Hansen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachariassen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toubro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eildal, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo̷geso̷, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang-Andersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stro̷mgaard, K.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">12137</span>– <span class="NLM_lpage">12142</span>, <span class="refDoi"> DOI: 10.1073/pnas.1103060108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1073%2Fpnas.1103060108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21730142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFyqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=12137-12142&author=J.+Andersenauthor=N.+Stuhr-Hansenauthor=L.+Zachariassenauthor=S.+Toubroauthor=S.+M.+Hansenauthor=J.+N.+Eildalauthor=A.+D.+Bondauthor=K.+P.+Bo%CC%B7geso%CC%B7author=B.+Bang-Andersenauthor=A.+S.+Kristensenauthor=K.+Stro%CC%B7mgaard&title=Molecular+determinants+for+selective+recognition+of+antidepressants+in+the+human+serotonin+and+norepinephrine+transporters&doi=10.1073%2Fpnas.1103060108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters</span></div><div class="casAuthors">Andersen, Jacob; Stuhr-Hansen, Nicolai; Zachariassen, Linda; Toubro, Soren; Hansen, Stinna M. R.; Eildal, Jonas N. N.; Bond, Andrew D.; Bogeso, Klaus P.; Bang-Andersen, Benny; Kristensen, Anders S.; Stromgaard, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">12137-12142, S12137/1-S12137/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Inhibitors of the serotonin transporter (SERT) and norepinephrine transporter (NET) are widely used in the treatment of major depressive disorder.  Although SERT/NET selectivity is a key determinant for the therapeutic properties of these drugs, the mol. determinants defining SERT/NET selectivity are poorly understood.  In this study, the structural basis for selectivity of the SERT selective inhibitor citalopram and the structurally closely related NET selective inhibitor talopram is delineated.  A systematic structure-activity relationship study allowed identification of the substituents that control activity and selectivity toward SERT and NET and revealed a common pattern showing that SERT and NET have opposite preference for the stereochem. configuration of these inhibitors.  Mutational anal. of nonconserved SERT/NET residues within the central substrate binding site was performed to det. the mol. basis for inhibitor selectivity.  Changing only five residues in NET to the complementary residues in SERT transferred a SERT-like affinity profile for R- and S-citalopram into NET, showing that the selectivity of these compds. is detd. by amino acid differences in the central binding site of the transporters.  In contrast, the activity of R- and S-talopram was largely unaffected by any mutations within the central substrate binding site of SERT and NET and in the outer vestibule of NET, suggesting that citalopram and talopram bind to distinct sites on SERT and NET.  Together, these findings provide important insight into the mol. basis for SERT/NET selectivity of antidepressants, which can be used to guide rational development of unique transporter inhibitors with fine-tuned transporter selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhxiOx9Fk-ObVg90H21EOLACvtfcHk0ljUMKpNrm-mKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFyqtb8%253D&md5=9cb2027b7ea4f4eedbe2865087cff5ce</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1103060108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1103060108%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DJ.%26aulast%3DStuhr-Hansen%26aufirst%3DN.%26aulast%3DZachariassen%26aufirst%3DL.%26aulast%3DToubro%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DS.%2BM.%26aulast%3DEildal%26aufirst%3DJ.%2BN.%26aulast%3DBond%26aufirst%3DA.%2BD.%26aulast%3DBo%25CC%25B7geso%25CC%25B7%26aufirst%3DK.%2BP.%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26aulast%3DStro%25CC%25B7mgaard%26aufirst%3DK.%26atitle%3DMolecular%2520determinants%2520for%2520selective%2520recognition%2520of%2520antidepressants%2520in%2520the%2520human%2520serotonin%2520and%2520norepinephrine%2520transporters%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D12137%26epage%3D12142%26doi%3D10.1073%2Fpnas.1103060108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goehring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penmatsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for action by diverse antidepressants on biogenic amine transporters</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1038/nature12648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1038%2Fnature12648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=24121440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSnsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=141-145&author=H.+Wangauthor=A.+Goehringauthor=K.+H.+Wangauthor=A.+Penmatsaauthor=R.+Resslerauthor=E.+Gouaux&title=Structural+basis+for+action+by+diverse+antidepressants+on+biogenic+amine+transporters&doi=10.1038%2Fnature12648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for action by diverse antidepressants on biogenic amine transporters</span></div><div class="casAuthors">Wang, Hui; Goehring, April; Wang, Kevin H.; Penmatsa, Aravind; Ressler, Ryan; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7474</span>),
    <span class="NLM_cas:pages">141-145</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The biogenic amine transporters (BATs) regulate endogenous neurotransmitter concns. and are targets for a broad range of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs).  Because eukaryotic BATs are recalcitrant to crystallog. anal., the authors' understanding of the mechanism of these inhibitors and antidepressants is limited.  LeuT is a bacterial homolog of BATs and has proven to be a valuable paradigm for understanding relationships between their structure and function.  However, because only approx. 25% of the amino acid sequence of LeuT is in common with that of BATs, and as LeuT is a promiscuous amino acid transporter, it does not recapitulate the pharmacol. properties of BATs.  Indeed, SSRIs and TCAs bind in the extracellular vestibule of LeuT and act as non-competitive inhibitors of transport.  By contrast, multiple studies demonstrate that both TCAs and SSRIs are competitive inhibitors for eukaryotic BATs and bind to the primary binding pocket.  Here the authors engineered LeuT to harbor human BAT-like pharmacol. by mutating key residues around the primary binding pocket.  The final LeuBAT mutant binds the SSRI sertraline with a binding const. of 18 nM and displays high-affinity binding to a range of SSRIs, SNRIs and a TCA.  The authors detd. 12 crystal structures of LeuBAT in complex with four classes of antidepressants.  The chem. diverse inhibitors have a remarkably similar mode of binding in which they straddle transmembrane helix (TM) 3, wedge between TM3/TM8 and TM1/TM6, and lock the transporter in a sodium- and chloride-bound outward-facing open conformation.  Together, these studies define common and simple principles for the action of SSRIs, SNRIs and TCAs on BATs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8AMnfh2-Af7Vg90H21EOLACvtfcHk0lhMS4jUHEZSyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSnsLrE&md5=26cc6cf173fdf20ec20d928d02f05193</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature12648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12648%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGoehring%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DPenmatsa%26aufirst%3DA.%26aulast%3DRessler%26aufirst%3DR.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DStructural%2520basis%2520for%2520action%2520by%2520diverse%2520antidepressants%2520on%2520biogenic%2520amine%2520transporters%26jtitle%3DNature%26date%3D2013%26volume%3D503%26spage%3D141%26epage%3D145%26doi%3D10.1038%2Fnature12648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">X-ray structures and mechanism of the human serotonin transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1038/nature17629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1038%2Fnature17629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=27049939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=334-339&author=J.+A.+Colemanauthor=E.+M.+Greenauthor=E.+Gouaux&title=X-ray+structures+and+mechanism+of+the+human+serotonin+transporter&doi=10.1038%2Fnature17629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structures and mechanism of the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Green, Evan M.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7599</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) terminates serotonergic signaling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons.  SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signaling.  Here the authors report x-ray crystallog. structures of human SERT at 3.15 Å resoln. bound to the antidepressants (S)-citalopram or paroxetine.  Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helixes 1, 3, 6, 8 and 10, directly blocking serotonin binding.  The authors further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helixes 1, 6, 10 and 11.  Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand.  These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAxl5tROCorVg90H21EOLACvtfcHk0lhMS4jUHEZSyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D&md5=e4fa11a1e5abdd7b39f44375506aa249</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnature17629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17629%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DE.%2BM.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DX-ray%2520structures%2520and%2520mechanism%2520of%2520the%2520human%2520serotonin%2520transporter%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D334%26epage%3D339%26doi%3D10.1038%2Fnature17629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razzetti, G.</span>; <span class="NLM_string-name">Allegrini, P.</span>; <span class="NLM_string-name">Pastorello, D.</span></span> <span> </span><span class="NLM_article-title">Process for the Synthesis of Pregabalin</span>. <span class="NLM_patent">US8063244B2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Razzetti&author=P.+Allegrini&author=D.+Pastorello&title=Process+for+the+Synthesis+of+Pregabalin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRazzetti%26aufirst%3DG.%26atitle%3DProcess%2520for%2520the%2520Synthesis%2520of%2520Pregabalin%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of Pan Assay Interference Compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lgyzWNNXlhGpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span>; <span class="NLM_string-name">Terricabras, E.</span>; <span class="NLM_string-name">Erra, M.</span>; <span class="NLM_string-name">Navarro, E.</span>; <span class="NLM_string-name">Fonquerna, S.</span>; <span class="NLM_string-name">Cardús, A</span>, <span class="NLM_string-name">Lozoya, M.</span></span> <span> </span><span class="NLM_article-title">Azabiphenylaminobenzoic Acid Derivatives as DHODH Inhibitors</span>. <span class="NLM_patent">WO2009021696</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+Castro&author=E.+Terricabras&author=M.+Erra&author=E.+Navarro&author=S.+Fonquerna&author=A+Card%C3%BAs&author=M.+Lozoya&title=Azabiphenylaminobenzoic+Acid+Derivatives+as+DHODH+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCastro%26aufirst%3DJ.%26atitle%3DAzabiphenylaminobenzoic%2520Acid%2520Derivatives%2520as%2520DHODH%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti–Renom, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudhan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eramian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span> <span> </span><span class="NLM_article-title">Comparative protein structure modeling using MODELLER</span>. <i>Curr. Protoc. Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5.6.1</span>– <span class="NLM_lpage">5.6.37</span>, <span class="refDoi"> DOI: 10.1002/0471140864.ps0209s50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2F0471140864.ps0209s50" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5.6.1-5.6.37&author=N.+Eswarauthor=B.+Webbauthor=M.+A.+Marti%E2%80%93Renomauthor=M.+S.+Madhusudhanauthor=D.+Eramianauthor=M.-Y.+Shenauthor=U.+Pieperauthor=A.+Sali&title=Comparative+protein+structure+modeling+using+MODELLER&doi=10.1002%2F0471140864.ps0209s50"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2F0471140864.ps0209s50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471140864.ps0209s50%26sid%3Dliteratum%253Aachs%26aulast%3DEswar%26aufirst%3DN.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DMarti%25E2%2580%2593Renom%26aufirst%3DM.%2BA.%26aulast%3DMadhusudhan%26aufirst%3DM.%2BS.%26aulast%3DEramian%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DM.-Y.%26aulast%3DPieper%26aufirst%3DU.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DComparative%2520protein%2520structure%2520modeling%2520using%2520MODELLER%26jtitle%3DCurr.%2520Protoc.%2520Protein%2520Sci.%26date%3D2007%26volume%3D50%26spage%3D5.6.1%26epage%3D5.6.37%26doi%3D10.1002%2F0471140864.ps0209s50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span>Discovery
Studio 16;
Dassault Systèmes BIOVIA: San Diego, CA, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Discovery%0AStudio+16%3B%0ADassault+Syst%C3%A8mes+BIOVIA%3A+San+Diego%2C+CA%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diller, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.</span></span> <span> </span><span class="NLM_article-title">High throughput docking for library design and library prioritization</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=11276081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2001&pages=113-124&author=D.+J.+Dillerauthor=K.+M.+Merz&title=High+throughput+docking+for+library+design+and+library+prioritization&doi=10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput docking for library design and library prioritization</span></div><div class="casAuthors">Diller, David J.; Merz, Kenneth M., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-124</span>CODEN:
                <span class="NLM_cas:coden">PSFGEY</span>;
        ISSN:<span class="NLM_cas:issn">0887-3585</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The prioritization of the screening of combinatorial libraries is an extremely important task for the rapid identification of tight binding ligands and ultimately pharmaceutical compds.  When structural information for the target is available, mol. docking is an approach that can be used for prioritization.  Here, we present the initial validation of a new rapid approach to mol. docking developed for prioritizing combinatorial libraries.  The algorithm is tested on 103 individual cases from the protein data bank and in nearly 90% of these cases docks the ligand to within 2.0 Å of the obsd. binding mode.  Because the mean CPU time is <5 s/mol, this approach can process hundreds of thousands of compds. per wk.  Furthermore, if a somewhat less thorough search is performed, the search time drops to 1 s/mol, thus allowing millions of compds. to be docked per wk and tested for potential activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRE1RQbB3WD7Vg90H21EOLACvtfcHk0lgV5V_n-XwEBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlels7c%253D&md5=a84ff9a463495594d85db465b27e9216</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0134%252820010501%252943%253A2%253C113%253A%253AAID-PROT1023%253E3.0.CO%253B2-T%26sid%3Dliteratum%253Aachs%26aulast%3DDiller%26aufirst%3DD.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26atitle%3DHigh%2520throughput%2520docking%2520for%2520library%2520design%2520and%2520library%2520prioritization%26jtitle%3DProteins%26date%3D2001%26volume%3D43%26spage%3D113%26epage%3D124%26doi%3D10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span>Schrödinger
Release
2017-4: Maestro, Schrödinger, LLC, New York, NY, 2020.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schr%C3%B6dinger%0ARelease%0A2017-4%3A+Maestro%2C+Schr%C3%B6dinger%2C+LLC%2C+New+York%2C+NY%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K. J.</span>; <span class="NLM_string-name">Chow, E.</span>; <span class="NLM_string-name">Xu, H.</span>; <span class="NLM_string-name">Dror, R. O.</span>; <span class="NLM_string-name">Eastwood, M. P.</span>; <span class="NLM_string-name">Gregersen, B. A.</span>; <span class="NLM_string-name">Klepeis, J. L.</span>; <span class="NLM_string-name">Kolossvary, I.</span>; <span class="NLM_string-name">Moraes, M. A.</span>; <span class="NLM_string-name">Sacerdoti, F. D.</span>; <span class="NLM_string-name">Salmon, J. K.</span>; <span class="NLM_string-name">Shan, Y.</span>; <span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Scalable algorithms for Molecular Dynamics Simulations on commodity clusters</span>.  <i>Proceedings of the ACM/IEEE Conference on Supercomputing (SC06)</i>; <span class="NLM_publisher-loc">Tampa, Florida</span>, <span class="NLM_year">2006</span>, November  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">17</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=11-17&author=K.+J.+Bowers&author=E.+Chow&author=H.+Xu&author=R.+O.+Dror&author=M.+P.+Eastwood&author=B.+A.+Gregersen&author=J.+L.+Klepeis&author=I.+Kolossvary&author=M.+A.+Moraes&author=F.+D.+Sacerdoti&author=J.+K.+Salmon&author=Y.+Shan&author=D.+E.+Shaw&title=Scalable+algorithms+for+Molecular+Dynamics+Simulations+on+commodity+clusters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DK.%2BJ.%26atitle%3DScalable%2520algorithms%2520for%2520Molecular%2520Dynamics%2520Simulations%2520on%2520commodity%2520clusters%26jtitle%3DProceedings%2520of%2520the%2520ACM%252FIEEE%2520Conference%2520on%2520Supercomputing%2520%2528SC06%2529%26date%3D2006%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37a','cit37b'],'ref38':['cit38a','cit38b','cit38c'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of described blockers of the Ca<sub>v</sub>α2δ-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative SSRI (fluoxetine), NRI (reboxetine and atomoxetine), and SNRI (duloxetine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Strategy for developing dual Ca<sub>v</sub>α2δ-1 and NET ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of compounds <b>15</b>, <b>16</b>, <b>17</b> and <b>23</b>.<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) for R = Me: KO<i><sup>t</sup></i>Bu, THF, rt, and 24 h; for R = Et: Et<sub>3</sub>N, ACN, 80 °C, and 48 h; (b) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100 °C, and 16 h; (c) <i>m</i>-CPBA, DCM, rt, and 1 h; (d) NHR<sub>1</sub>R<sub>2</sub>, THF, rt, and 16 h; (e) Et<sub>3</sub>N, ACN, 0 °C to rt, and 20 h; (f) NaBH(OAc)<sub>3</sub>, DCE, rt, and 1.5 h; (g) Boc<sub>2</sub>O, DCM, 0 °C to rt, and 20 h; (h) <i>m</i>-CPBA, DCM, rt, and 3.5 h; (i) EtNH<sub>2</sub>, H<sub>2</sub>O, rt, and 72 h; (j) HCl, dioxane, rt, and 16 h; and (k) Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 110 °C, and 24 h.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>31</b>–<b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, THF, rt, and 20 h; (b) methylamine, H<sub>2</sub>O, EtOH, 130 °C, and 1 h; (c) Boc<sub>2</sub>O, DCM, rt, and 2 h; (d) NaH, DMF, rt, and 3 h; (e) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 110 °C, and 16 h; (f) <i>m</i>-CPBA, DCM, rt, and 1 h; (g) ethylamine, THF, rt, and 16 h; (h) HCl, dioxane, rt, and 45 min; (i) paraformaldehyde, NaBH(OAc)<sub>3</sub>, DIPEA, AcOH, DCE, rt, and 70 h; and (j) methylamine, NaCN, EtOH, 100 °C, and 16 h.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Pyrimido[4,5-<i>e</i>][1,4]diazepin-5-one Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMA, 90 °C, and 3 h; (b) R = Boc: Boc<sub>2</sub>O, DCM, rt, and 3 h; R = Teoc: 4-nitrophenyl-(2-(trimethylsilyl)ethyl)carbonate, DIPEA, DCM, rt, and 20 h; (c) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100 °C, and 20 h; (d) R = Boc: ZnBr<sub>2</sub>, DCM, rt, 24 h; (e) R = Teoc: CsF, DMF, 90 °C, and 90 min; (f) <i>m</i>-CPBA, DCM, rt, and 1 h; (g) NHR<sub>1</sub>R<sub>2</sub>, THF, rt, and 20 h or MW at 100 °C and 30 min; (h) Pd/C, Et<sub>3</sub>SiH, THF, 0 °C to rt, and 4 h; and (i) MeMgBr, THF, 0 °C, and 1 h.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Pyridodiazepin-5(2<i>H</i>)-one Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>3</sub>N, THF, rt, and 2.5 h; (b) HCl, dioxane, rt, and 2 h; (c) CsF, Et<sub>3</sub>N, DMF, 75 °C, and 16 h; (d) EtNH<sub>2</sub>, H<sub>2</sub>O, 135 °C, MW, and 2 h; (e) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100–130 °C, and 20 h; (f) CsF, DMF, 90 °C, and 90 min or MW at 90 °C and 90 min; (g) Et<sub>3</sub>SiH, Pd/C, THF, rt, and 16 h; (h) MeB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, 130 °C, and 48 h; and (i) NaOMe, MeOH, 110 °C, MW, and 2 h.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Compounds <b>65</b>, <b>67</b>, <b>69</b>, and <b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-dimethylethane-1,2-diamine, dioxane, 100 °C, and 20 h; (b) CsF, DMF, 90 °C, and 90 min; and (c) paraformaldehyde, NaBH(OAc)<sub>3</sub>, DIPEA, AcOH, DCE, rt, 48 h.</p></p></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modification sequence from <b>6</b> to <b>16a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/medium/jm0c01867_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking of compound <b>31aS</b> in the NET homology model generated from the SERT structures l5I6X, 5I6Z, 5I71, 5I73, 5I74, and 5I75. (A) RMSD of the protein and the docked ligand in the 1 μs molecular dynamics simulations. (B) 2D representation of the interactions of <b>31aS</b> in the active site of NET. (C) Image of NET embedded in the lipid bilayer and solvated. (D) Compound <b>31aS</b> in the NET binding site; the aminoacids belonging to the different subsites have been colored in orange for subsite A, purple for B, cyan for C, and yellow for the residues belonging to the allosteric site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01867/20210218/images/large/jm0c01867_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01867&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01417" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01417" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahana, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic non-cancer pain</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2235</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60402-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2FS0140-6736%2811%2960402-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21704872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=2226-2235&author=D.+C.+Turkauthor=H.+D.+Wilsonauthor=A.+Cahana&title=Treatment+of+chronic+non-cancer+pain&doi=10.1016%2FS0140-6736%2811%2960402-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic non-cancer pain</span></div><div class="casAuthors">Turk, Dennis C.; Wilson, Hilary D.; Cahana, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9784</span>),
    <span class="NLM_cas:pages">2226-2235</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Chronic pain is a pervasive problem that affects the patient, their significant others, and society in many ways.  The past decade has seen advances in our understanding of the mechanisms underlying pain and in the availability of tech. advanced diagnostic procedures; however, the most notable therapeutic changes have not been the development of novel evidenced-based methods, but rather changing trends in applications and practices within the available clin. armamentarium.  We provide a general overview of empirical evidence for the most commonly used interventions in the management of chronic non-cancer pain, including pharmacol., interventional, phys., psychol., rehabilitative, and alternative modalities.  Overall, currently available treatments provide modest improvements in pain and min. improvements in phys. and emotional functioning.  The quality of evidence is mediocre and has not improved substantially during the past decade.  There is a crucial need for assessment of combination treatments, identification of indicators of treatment response, and assessment of the benefit of matching of treatments to patient characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxyG7QutTErVg90H21EOLACvtfcHk0lg0c2_diPtOhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejsbg%253D&md5=55b3b3e920ec253406736fcee3337754</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960402-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960402-9%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DD.%2BC.%26aulast%3DWilson%26aufirst%3DH.%2BD.%26aulast%3DCahana%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520chronic%2520non-cancer%2520pain%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D2226%26epage%3D2235%26doi%3D10.1016%2FS0140-6736%2811%2960402-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinatra, R.</span></span> <span> </span><span class="NLM_article-title">Causes and consequences of inadequate management of acute pain</span>. <i>Pain Med</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1859</span>– <span class="NLM_lpage">1871</span>, <span class="refDoi"> DOI: 10.1111/j.1526-4637.2010.00983.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1111%2Fj.1526-4637.2010.00983.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21040438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FitVCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1859-1871&author=R.+Sinatra&title=Causes+and+consequences+of+inadequate+management+of+acute+pain&doi=10.1111%2Fj.1526-4637.2010.00983.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Causes and consequences of inadequate management of acute pain</span></div><div class="casAuthors">Sinatra Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Pain medicine (Malden, Mass.)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1859-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Intense acute pain afflicts millions of patients each year.  Despite the recently increased focus on the importance of pain control, management of acute pain has remained suboptimal.  OBJECTIVE:  The objective of this study was to identify through a review of recent literature the barriers to effective treatment of acute pain and the potential consequences of inadequate pain management.  DESIGN:  A comprehensive literature review was conducted to identify articles relevant to the management of acute pain.  Information regarding the underlying causes of inadequate pain management, as well as the sequelae associated with undermanaged pain was extracted and summarized.  RESULTS:  Studies indicate that treatment of acute pain remains suboptimal due to attitudes and educational barriers on the part of both physicians and patients, as well as the intrinsic limitations of available therapies.  Inadequate management of acute pain negatively impacts numerous aspects of patient health, and may increase the risk of developing chronic pain.  Although opioids are the preferred treatment for most moderate to severe acute pain, their side effects can impede their use, and thus, their clinical effectiveness.  Analgesic regimens with an improved efficacy/tolerability balance have the potential to improve acute pain management, and thus reduce the incidence of chronic pain.  Studies examining the use of multiple analgesics with different mechanisms of action suggest that multimodal therapies may offer an improved efficacy/tolerability balance over single agent regimens.  CONCLUSIONS:  There exists a significant need for effective, well-tolerated analgesic therapies to limit the negative consequences of undermanaged acute pain.  The use of multimodal therapy has demonstrated increasing promise and is supported by current practice guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7DxO1LDDlzJSWdIdmEou5fW6udTcc2ebG92ZHTFTyErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FitVCmuw%253D%253D&md5=bfa0e3889f5c268cd2326c2d03dd58b4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1526-4637.2010.00983.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1526-4637.2010.00983.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinatra%26aufirst%3DR.%26atitle%3DCauses%2520and%2520consequences%2520of%2520inadequate%2520management%2520of%2520acute%2520pain%26jtitle%3DPain%2520Med%26date%3D2010%26volume%3D11%26spage%3D1859%26epage%3D1871%26doi%3D10.1111%2Fj.1526-4637.2010.00983.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergolizzi, J. V.,  jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarida, R. J.</span></span> <span> </span><span class="NLM_article-title">The determination and application of fixed-dose analgesic combinations for treating multimodal pain</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2009.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.jpain.2009.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=20338825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFKqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=701-709&author=R.+B.+Raffaauthor=J.+V.+Pergolizziauthor=R.+J.+Tallarida&title=The+determination+and+application+of+fixed-dose+analgesic+combinations+for+treating+multimodal+pain&doi=10.1016%2Fj.jpain.2009.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The determination and application of fixed-dose analgesic combinations for treating multimodal pain</span></div><div class="casAuthors">Raffa, Robert B.; Pergolizzi, Joseph V., Jr.; Tallarida, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">701-709</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  When the pathophysiol. of a medical condition is multimodal, ie, related to multiple physiol. causes or mediated by multiple pathways, the optimal strategy can be to use a drug or a combination of drugs that contribute multiple mechanisms to the therapeutic endpoint.  In such situations, a rational multimodal approach can also result in the fewest adverse effects.  We discuss the quant. anal. of multimodal action using the treatment of pain as a practical example and give examples of its application to some widely used analgesic drugs.  Perspective: This article reviews the medical relevance of the quant. evaluation of drug combinations, using pain and combinations of analgesics as specific examples.  Such measure can help clinicians who seek to maximize therapeutic effect while simultaneously minimizing adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH7jqoFZRbiLVg90H21EOLACvtfcHk0lg0c2_diPtOhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFKqt7Y%253D&md5=31c26fefba4061e6c64a959c3bfd1e0f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2009.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2009.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26aulast%3DPergolizzi%26aufirst%3DJ.%2BV.%26aulast%3DTallarida%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520determination%2520and%2520application%2520of%2520fixed-dose%2520analgesic%2520combinations%2520for%2520treating%2520multimodal%2520pain%26jtitle%3DJ.%2520Pain%26date%3D2010%26volume%3D11%26spage%3D701%26epage%3D709%26doi%3D10.1016%2Fj.jpain.2009.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Leon-Casasola, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittenden, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manworren, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkal, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strassels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirlby, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viscusi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walco, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. L.</span></span> <span> </span><span class="NLM_article-title">Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2015.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.jpain.2015.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=26827847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A280%3ADC%252BC28nmtFegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=131-157&author=R.+Chouauthor=D.+B.+Gordonauthor=O.+A.+de+Leon-Casasolaauthor=J.+M.+Rosenbergauthor=S.+Bicklerauthor=T.+Carterauthor=L.+Cassidyauthor=E.+H.+Chittendenauthor=E.+Degenhardtauthor=S.+Griffithauthor=M.+R.+Manworrenauthor=B.+McCarbergauthor=R.+Montgomeryauthor=J.+Murphyauthor=M.+F.+Perkalauthor=S.+Sureshauthor=K.+Slukaauthor=S.+Strasselsauthor=R.+Thirlbyauthor=E.+Viscusiauthor=G.+A.+Walcoauthor=L.+Warnerauthor=S.+J.+Weismanauthor=C.+L.+Wu&title=Management+of+postoperative+pain%3A+a+clinical+practice+guideline+from+the+American+Pain+Society%2C+the+American+Society+of+Regional+Anesthesia+and+Pain+Medicine%2C+and+the+American+Society+of+Anesthesiologists%E2%80%99+Committee+on+Regional+Anesthesia%2C+Executive+Committee%2C+and+Administrative+Council&doi=10.1016%2Fj.jpain.2015.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council</span></div><div class="casAuthors">Chou Roger; Gordon Debra B; de Leon-Casasola Oscar A; Rosenberg Jack M; Bickler Stephen; Brennan Tim; Carter Todd; Cassidy Carla L; Chittenden Eva Hall; Degenhardt Ernest; Griffith Scott; Manworren Renee; McCarberg Bill; Montgomery Robert; Murphy Jamie; Wu Christopher L; Perkal Melissa F; Suresh Santhanam; Sluka Kathleen; Strassels Scott; Thirlby Richard; Viscusi Eugene; Walco Gary A; Warner Lisa; Weisman Steven J</div><div class="citationInfo"><span class="NLM_cas:title">The journal of pain : official journal of the American Pain Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Most patients who undergo surgical procedures experience acute postoperative pain, but evidence suggests that less than half report adequate postoperative pain relief.  Many preoperative, intraoperative, and postoperative interventions and management strategies are available for reducing and managing postoperative pain.  The American Pain Society, with input from the American Society of Anesthesiologists, commissioned an interdisciplinary expert panel to develop a clinical practice guideline to promote evidence-based, effective, and safer postoperative pain management in children and adults.  The guideline was subsequently approved by the American Society for Regional Anesthesia.  As part of the guideline development process, a systematic review was commissioned on various aspects related to various interventions and management strategies for postoperative pain.  After a review of the evidence, the expert panel formulated recommendations that addressed various aspects of postoperative pain management, including preoperative education, perioperative pain management planning, use of different pharmacological and nonpharmacological modalities, organizational policies, and transition to outpatient care.  The recommendations are based on the underlying premise that optimal management begins in the preoperative period with an assessment of the patient and development of a plan of care tailored to the individual and the surgical procedure involved.  The panel found that evidence supports the use of multimodal regimens in many situations, although the exact components of effective multimodal care will vary depending on the patient, setting, and surgical procedure.  Although these guidelines are based on a systematic review of the evidence on management of postoperative pain, the panel identified numerous research gaps.  Of 32 recommendations, 4 were assessed as being supported by high-quality evidence, and 11 (in the areas of patient education and perioperative planning, patient assessment, organizational structures and policies, and transitioning to outpatient care) were made on the basis of low-quality evidence.  PERSPECTIVE:  This guideline, on the basis of a systematic review of the evidence on postoperative pain management, provides recommendations developed by a multidisciplinary expert panel.  Safe and effective postoperative pain management should be on the basis of a plan of care tailored to the individual and the surgical procedure involved, and multimodal regimens are recommended in many situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb9Ea6UaRw8MkU0YCbOU3EfW6udTcc2eZe85QFWzbIS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nmtFegsQ%253D%253D&md5=ccdf7fdf5131f709ea1c86a5e93979f5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2015.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2015.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DD.%2BB.%26aulast%3Dde%2BLeon-Casasola%26aufirst%3DO.%2BA.%26aulast%3DRosenberg%26aufirst%3DJ.%2BM.%26aulast%3DBickler%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DT.%26aulast%3DCassidy%26aufirst%3DL.%26aulast%3DChittenden%26aufirst%3DE.%2BH.%26aulast%3DDegenhardt%26aufirst%3DE.%26aulast%3DGriffith%26aufirst%3DS.%26aulast%3DManworren%26aufirst%3DM.%2BR.%26aulast%3DMcCarberg%26aufirst%3DB.%26aulast%3DMontgomery%26aufirst%3DR.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DPerkal%26aufirst%3DM.%2BF.%26aulast%3DSuresh%26aufirst%3DS.%26aulast%3DSluka%26aufirst%3DK.%26aulast%3DStrassels%26aufirst%3DS.%26aulast%3DThirlby%26aufirst%3DR.%26aulast%3DViscusi%26aufirst%3DE.%26aulast%3DWalco%26aufirst%3DG.%2BA.%26aulast%3DWarner%26aufirst%3DL.%26aulast%3DWeisman%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DC.%2BL.%26atitle%3DManagement%2520of%2520postoperative%2520pain%253A%2520a%2520clinical%2520practice%2520guideline%2520from%2520the%2520American%2520Pain%2520Society%252C%2520the%2520American%2520Society%2520of%2520Regional%2520Anesthesia%2520and%2520Pain%2520Medicine%252C%2520and%2520the%2520American%2520Society%2520of%2520Anesthesiologists%25E2%2580%2599%2520Committee%2520on%2520Regional%2520Anesthesia%252C%2520Executive%2520Committee%252C%2520and%2520Administrative%2520Council%26jtitle%3DJ.%2520Pain%26date%3D2016%26volume%3D17%26spage%3D131%26epage%3D157%26doi%3D10.1016%2Fj.jpain.2015.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backonja, M. M.</span></span> <span> </span><span class="NLM_article-title">Combination drug therapy for chronic pain: a call for more clinical studies</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.jpain.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=20851058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=157-166&author=J.+Maoauthor=M.+S.+Goldauthor=M.+M.+Backonja&title=Combination+drug+therapy+for+chronic+pain%3A+a+call+for+more+clinical+studies&doi=10.1016%2Fj.jpain.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Therapy for Chronic Pain: A Call for More Clinical Studies</span></div><div class="casAuthors">Mao, Jianren; Gold, Michael S.; Backonja, Miroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic pain is a debilitating clin. condition assocd. with a variety of disease entities including diabetic neuropathy, postherpetic neuralgia, low back pathol., fibromyalgia, and neurol. disorders.  For many general practitioners and specialists, managing chronic pain has become a daunting challenge.  As a modality of multidisciplinary chronic pain management, medications are often prescribed in combinations, an approach referred to as combination drug therapy (CDT).  However, many medications for pain therapy, including antidepressants and opioid analgesics, have significant side effects that can compd. when used in combination and impact the effectiveness of CDT.  To date, clin. practice of CDT for chronic pain has been based largely on clin. experiences.  In this article, we will focus on (1) the scientific basis and rationales for CDT, (2) current clin. data on CDT, and (3) the need for more clin. studies to establish a framework for the use of CDT.  Perspective: More preclin., clin., and translational studies are needed to improve the efficacy of combination drug therapy that is an integral part of a comprehensive approach to the management of chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDPNs-xJvEbVg90H21EOLACvtfcHk0lhNUpYcH7G1Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D&md5=955711ac2946dd44adc0e8b96b6ee423</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DGold%26aufirst%3DM.%2BS.%26aulast%3DBackonja%26aufirst%3DM.%2BM.%26atitle%3DCombination%2520drug%2520therapy%2520for%2520chronic%2520pain%253A%2520a%2520call%2520for%2520more%2520clinical%2520studies%26jtitle%3DJ.%2520Pain%26date%3D2011%26volume%3D12%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.jpain.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhNUpYcH7G1Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamponi, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koschak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1124%2Fpr.114.009654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=26362469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=821-870&author=G.+W.+Zamponiauthor=J.+Striessnigauthor=A.+Koschakauthor=A.+C.+Dolphin&title=The+physiology%2C+pathology%2C+and+pharmacology+of+voltage-gated+calcium+channels+and+their+future+therapeutic+potential&doi=10.1124%2Fpr.114.009654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</span></div><div class="casAuthors">Zamponi, Gerald W.; Striessnig, Joerg; Koschak, Alexandra; Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">821-870</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Voltage-gated calcium channels are required for many key functions in the body.  In this review, the different subtypes of voltage-gated calcium channels are described and their physiol. roles and pharmacol. are outlined.  We describe the current uses of drugs interacting with the different calcium channel subtypes and subunits, as well as specific areas in which there is strong potential for future drug development.  Current therapeutic agents include drugs targeting L-type CaV1.2 calcium channels, particularly 1,4-dihydropyridines, which are widely used in the treatment of hypertension.  T-type (CaV3) channels are a target of ethosuximide, widely used in absence epilepsy.  The auxiliary subunit α2δ-1 is the therapeutic target of the gabapentinoid drugs, which are of value in certain epilepsies and chronic neuropathic pain.  The limited use of intrathecal ziconotide, a peptide blocker of N-type (CaV2.2) calcium channels, as a treatment of intractable pain, gives an indication that these channels represent excellent drug targets for various pain conditions.  We describe how selectivity for different subtypes of calcium channels (e.g., CaV1.2 and CaV1.3 L-type channels) may be achieved in the future by exploiting differences between channel isoforms in terms of sequence and biophys. properties, variation in splicing in different target tissues, and differences in the properties of the target tissues themselves in terms of membrane potential or firing frequency.  Thus, use-dependent blockers of the different isoforms could selectively block calcium channels in particular pathologies, such as nociceptive neurons in pain states or in epileptic brain circuits.  Of important future potential are selective CaV1.3 blockers for neuropsychiatric diseases, neuroprotection in Parkinson's disease, and resistant hypertension.  In addn., selective or nonselective T-type channel blockers are considered potential therapeutic targets in epilepsy, pain, obesity, sleep, and anxiety.  Use-dependent N-type calcium channel blockers are likely to be of therapeutic use in chronic pain conditions.  Thus, more selective calcium channel blockers hold promise for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0k6JL9CCXi7Vg90H21EOLACvtfcHk0lhac8ErLY645g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D&md5=1e5a19b9974b119fc2c00cfa0089e172</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009654%26sid%3Dliteratum%253Aachs%26aulast%3DZamponi%26aufirst%3DG.%2BW.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKoschak%26aufirst%3DA.%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DThe%2520physiology%252C%2520pathology%252C%2520and%2520pharmacology%2520of%2520voltage-gated%2520calcium%2520channels%2520and%2520their%2520future%2520therapeutic%2520potential%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D821%26epage%3D870%26doi%3D10.1124%2Fpr.114.009654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Minh, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wratten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.tips.2007.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=17403543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=220-228&author=A.+Daviesauthor=J.+Hendrichauthor=A.+T.+Van+Minhauthor=J.+Wrattenauthor=L.+Douglasauthor=A.+C.+Dolphin&title=Functional+biology+of+the+alpha%282%29delta+subunits+of+voltage-gated+calcium+channels&doi=10.1016%2Fj.tips.2007.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functional biology of the α2δ subunits of voltage-gated calcium channels</span></div><div class="casAuthors">Davies, Anthony; Hendrich, Jan; Minh, Alexandra Tran Van; Wratten, Jack; Douglas, Leon; Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">220-228</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In this review, we examine what is known about the mechanism of action of the auxiliary α2δ subunits of voltage-gated Ca2+ (Cav) channels.  First, to provide some background on the α2δ proteins, we discuss the genes encoding these channels, in addn. to the topol. and predicted structure of the α2δ subunits.  We then describe the effects of α2δ subunits on the biophys. properties of Cav channels and their physiol. function.  All α2δ subunits increase the d. at the plasma membrane of Ca2+ channels activated by high voltage, and we discuss what is known about the mechanism underlying this trafficking.  Finally, we consider the link between α2δ subunits and disease, both in terms of spontaneous and engineered mouse mutants that show cerebellar ataxia and spike-wave epilepsy, and in terms of neuropathic pain and the mechanism of action of the gabapentinoid drugs - small-mol. ligands of the α2δ-1 and α2δ-2 subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRvWUjqiH1nbVg90H21EOLACvtfcHk0lhac8ErLY645g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGiurs%253D&md5=db88d5027f9e9ebd8f3f93dd06971e1b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DHendrich%26aufirst%3DJ.%26aulast%3DVan%2BMinh%26aufirst%3DA.%2BT.%26aulast%3DWratten%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DL.%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DFunctional%2520biology%2520of%2520the%2520alpha%25282%2529delta%2520subunits%2520of%2520voltage-gated%2520calcium%2520channels%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D220%26epage%3D228%26doi%3D10.1016%2Fj.tips.2007.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piechan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donevan, S.</span></span> <span> </span><span class="NLM_article-title">Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2 calcium channel subunits</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>667</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.05.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.ejphar.2011.05.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21651903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGlt7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=667&publication_year=2011&pages=80-90&author=Z.+Liauthor=C.+P.+Taylorauthor=M.+Weberauthor=J.+Piechanauthor=F.+Priorauthor=F.+Bianauthor=C.+Cuiauthor=D.+Hoffmanauthor=S.+Donevan&title=Pregabalin+is+a+potent+and+selective+ligand+for+%CE%B12%CE%B4-1+and+%CE%B12%CE%B4-2+calcium+channel+subunits&doi=10.1016%2Fj.ejphar.2011.05.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2 calcium channel subunits</span></div><div class="casAuthors">Li, Zheng; Taylor, Charles P.; Weber, Mark; Piechan, Julie; Prior, Faith; Bian, Feng; Cui, Mei; Hoffman, Diane; Donevan, Sean</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">667</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">80-90</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pregabalin, a synthetic branched chain γ-amino acid with anticonvulsant, anxiolytic, and analgesic activities, was shown to bind with high affinity to the voltage-gated Ca channel α2δ subunit.  Given the broad therapeutic utility of pregabalin, a series of expts. was undertaken to det. the potency, selectivity, and specificity of pregabalin's receptor-binding profile at α2δ-1 and α2δ-2 subunits of voltage-gated Ca channels along with 38 widely studied receptors and channels.  Receptor autoradiog. was used to assess regional-binding d. of pregabalin throughout the rat spinal cord and brain.  In addn., a series of studies using in vivo electrophysiol. recordings of γ-aminobutyric acid (GABA)A- and GABAB-evoked currents was undertaken to det. the interaction of pregabalin with GABAergic receptor subtypes.  Together, the results of these studies demonstrate potent and selective binding of pregabalin to α2δ-1 and α2δ-2 subunits in native and recombinant human and porcine systems.  Pregabalin did not interact with any of the 38 receptors and ion channels evaluated, and a variety of central nervous system (CNS)-targeted therapeutic drugs did not show activity at the α2δ subunits of voltage-gated calcium channels.  Receptor autoradiog. demonstrated extensive [3H]-pregabalin binding throughout the CNS, with high-level binding in the cortex, hippocampus, cerebellum, dorsal horn of the spinal cord, and amygdala.  Finally, receptor-binding and electrophysiol. techniques failed to show evidence of an interaction between pregabalin and GABAA or GABAB receptors.  These studies suggest that the clin. effects of pregabalin are likely due to direct and selective interactions with α2δ-1 and α2δ-2 subunits of voltage-gated calcium channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHjcEVuUlz97Vg90H21EOLACvtfcHk0lgN8uXwj4YuEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGlt7bF&md5=c53803698e6966532d1d2b7a83a3ac92</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.05.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.05.054%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTaylor%26aufirst%3DC.%2BP.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DPiechan%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DC.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DDonevan%26aufirst%3DS.%26atitle%3DPregabalin%2520is%2520a%2520potent%2520and%2520selective%2520ligand%2520for%2520%25CE%25B12%25CE%25B4-1%2520and%2520%25CE%25B12%25CE%25B4-2%2520calcium%2520channel%2520subunits%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D667%26spage%3D80%26epage%3D90%26doi%3D10.1016%2Fj.ejphar.2011.05.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perret, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z. D.</span></span> <span> </span><span class="NLM_article-title">Targeting voltage-gated calcium channels for neuropathic pain management</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2009.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.nurt.2009.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=19789072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVKqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=679-692&author=D.+Perretauthor=Z.+D.+Luo&title=Targeting+voltage-gated+calcium+channels+for+neuropathic+pain+management&doi=10.1016%2Fj.nurt.2009.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting voltage-gated calcium channels for neuropathic pain management</span></div><div class="casAuthors">Perret, Danielle; Luo, Z. David</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiol. functions.  Pathol. conditions leading to changes in their biophys. properties and expression levels may cause malfunctions of VGCC-mediated activities, resulting in disease states.  It is believed that changes in VGCC properties under pain-inducing conditions may play a causal role in the development of chronic pain, including nerve injury-induced pain or neuropathic pain.  For the past several decades, preclin. and clin. research in developing VGCC blockers or modulators for chronic pain management has been fruitful, leading to some U.S. Food and Drug Administration-approved drugs currently available for chronic pain management.  However, their efficacy in pain relief is limited in some patients, and their long-term use is limited by their side-effect profiles.  Certainly, there is room for improvement in developing more subtype-specific VGCC blockers or modulators for chronic pain conditions.  In this review, we summarized the most recent preclin. and clin. studies related to chronic pain medications acting on the VGCC.  We also included clin. trials aiming to expand the application of approved VGCC drugs to different pain states derived from various pathol. conditions, as well as drug combination therapies trying to improve the efficacies and side-effect profiles of current pain medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3B87GXsltfLVg90H21EOLACvtfcHk0lgN8uXwj4YuEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVKqu7o%253D&md5=20048c2a781a32c919b69a82536128e2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2009.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2009.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DZ.%2BD.%26atitle%3DTargeting%2520voltage-gated%2520calcium%2520channels%2520for%2520neuropathic%2520pain%2520management%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D679%26epage%3D692%26doi%3D10.1016%2Fj.nurt.2009.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cording, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiffen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R. A.</span></span> <span> </span><span class="NLM_article-title">Pregabalin for pain in fibromyalgia in adults</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">CD011790</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD011790.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2F14651858.CD011790.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=CD011790&author=S.+Derryauthor=M.+Cordingauthor=P.+J.+Wiffenauthor=S.+Lawauthor=T.+Phillipsauthor=R.+A.+Moore&title=Pregabalin+for+pain+in+fibromyalgia+in+adults&doi=10.1002%2F14651858.CD011790.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD011790.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD011790.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DDerry%26aufirst%3DS.%26aulast%3DCording%26aufirst%3DM.%26aulast%3DWiffen%26aufirst%3DP.%2BJ.%26aulast%3DLaw%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DMoore%26aufirst%3DR.%2BA.%26atitle%3DPregabalin%2520for%2520pain%2520in%2520fibromyalgia%2520in%2520adults%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2016%26volume%3D29%26spage%3DCD011790%26doi%3D10.1002%2F14651858.CD011790.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelotti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauman, E.</span></span> <span> </span><span class="NLM_article-title">Pharmacology and mechanism of action of pregabalin: The calcium channel α<sub>2</sub>-δ (alpha<sub>2</sub>–delta) subunit as a target for antiepileptic Drug Discovery</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.eplepsyres.2006.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.eplepsyres.2006.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=17126531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Grt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=137-150&author=C.+P.+Taylorauthor=T.+Angelottiauthor=E.+Fauman&title=Pharmacology+and+mechanism+of+action+of+pregabalin%3A+The+calcium+channel+%CE%B12-%CE%B4+%28alpha2%E2%80%93delta%29+subunit+as+a+target+for+antiepileptic+Drug+Discovery&doi=10.1016%2Fj.eplepsyres.2006.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery</span></div><div class="casAuthors">Taylor, Charles P.; Angelotti, Timothy; Fauman, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-150</span>CODEN:
                <span class="NLM_cas:coden">EPIRE8</span>;
        ISSN:<span class="NLM_cas:issn">0920-1211</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Pregabalin (Lyrica) is a new antiepileptic drug that is active in animal seizure models.  Pregabalin is approved in US and Europe for adjunctive therapy of partial seizures in adults, and also has been approved for the treatment of pain from diabetic neuropathy or post-herpetic neuralgia in adults.  Recently, it has been approved for treatment of anxiety disorders in Europe.  Pregabalin is structurally related to the antiepileptic drug gabapentin and the site of action of both drugs is similar, the alpha2-delta (α2-δ) protein, an auxiliary subunit of voltage-gated calcium channels.  Pregabalin subtly reduces the synaptic release of several neurotransmitters, apparently by binding to α2-δ subunits, and possibly accounting for its actions in vivo to reduce neuronal excitability and seizures.  Several studies indicate that the pharmacol. of pregabalin requires binding to α2-δ subunits, including structure-activity analyses of compds. binding to α2-δ subunits and pharmacol. in mice deficient in binding at the α2-δ Type 1 protein.  The preclin. findings to date are consistent with a mechanism that may entail redn. of abnormal neuronal excitability through reduced neurotransmitter release.  This review addresses the preclin. pharmacol. of pregabalin, and also the biol. of the high affinity binding site, and presumed site of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2zgeyDkYn7Vg90H21EOLACvtfcHk0lgwY8iVy-lzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Grt78%253D&md5=c5a7659e6994170bced23d2064391ea8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.eplepsyres.2006.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eplepsyres.2006.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DC.%2BP.%26aulast%3DAngelotti%26aufirst%3DT.%26aulast%3DFauman%26aufirst%3DE.%26atitle%3DPharmacology%2520and%2520mechanism%2520of%2520action%2520of%2520pregabalin%253A%2520The%2520calcium%2520channel%2520%25CE%25B12-%25CE%25B4%2520%2528alpha2%25E2%2580%2593delta%2529%2520subunit%2520as%2520a%2520target%2520for%2520antiepileptic%2520Drug%2520Discovery%26jtitle%3DEpilepsy%2520Res.%26date%3D2007%26volume%3D73%26spage%3D137%26epage%3D150%26doi%3D10.1016%2Fj.eplepsyres.2006.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, M. A.</span></span> <span> </span><span class="NLM_article-title">Use of α2δ ligands for restless legs syndrome/Willis Ekbom Disease</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1007/s40263-018-0502-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1007%2Fs40263-018-0502-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=29480463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=149-159&author=M.+A.+Faulkner&title=Use+of+%CE%B12%CE%B4+ligands+for+restless+legs+syndrome%2FWillis+Ekbom+Disease&doi=10.1007%2Fs40263-018-0502-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease</span></div><div class="casAuthors">Faulkner, Michele A.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Restless legs syndrome is a common neurol. condition affecting a substantial portion of the population.  It can be an idiopathic disorder, or one that is secondary to another cause.  Given that the underlying pathophysiol. of restless legs syndrome is not well understood, several drug classes have been studied for symptom control.  While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used.  These agents have proven both efficacious and safe in a no. of clin. trials.  Addnl., compared with the dopamine agonists, they have been assocd. with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected.  Newer clin. guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfvdr1I2cK3rVg90H21EOLACvtfcHk0lgwY8iVy-lzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGht7s%253D&md5=20a8603a8d381e1ec154213fa9d7bd23</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0502-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0502-z%26sid%3Dliteratum%253Aachs%26aulast%3DFaulkner%26aufirst%3DM.%2BA.%26atitle%3DUse%2520of%2520%25CE%25B12%25CE%25B4%2520ligands%2520for%2520restless%2520legs%2520syndrome%252FWillis%2520Ekbom%2520Disease%26jtitle%3DCNS%2520Drugs%26date%3D2018%26volume%3D32%26spage%3D149%26epage%3D159%26doi%3D10.1007%2Fs40263-018-0502-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span> <span> </span><span class="NLM_article-title">Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1021/jm060650z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060650z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2569-2575&author=M.+J.+Fieldauthor=Z.+Liauthor=J.+B.+Schwarz&title=Ca2%2B+channel+alpha2-delta+ligands+for+the+treatment+of+neuropathic+pain&doi=10.1021%2Fjm060650z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ Channel α2-δ Ligands for the Treatment of Neuropathic Pain</span></div><div class="casAuthors">Field, Mark J.; Li, Zheng; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2575</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Pregabalin was recently approved in the U.S. and Europe as an add- on therapy for epilepsy, as well as for the treatment of neuropathic pain.  In addn., pregabalin recently gained approval in the EU for the treatment of generalized anxiety disorder.  As a result of it's superior potency and pharmacokinetic profile compared to gabapentin, pregabalin has enjoyed rapid uptake by prescribing physicians for these conditions.  Pregabalin is thought to access the central nervous system (CNS) via the system L amino acid transporter and act via modulation of the α2-δ subunit of voltage-gated calcium channels.  Pregabalin is remarkably silent at all other known receptors (with the exception of being a substrate for the system L transmembrane amino acid transporter), and as a consequence, the α2-δ hypothesis is gaining traction as the accepted MOA of pregabalin.  Some excellent reviews categorizing the available evidence to elucidate the mechanism of gabapentin in neuropathic pain have recently appeared.  The purpose of this Miniperspective is to showcase the medicinal chem. efforts employed to obtain structurally diverse compds. with both reported affinity for the α2-δ subunit and in vivo activity in various neuropathic pain paradigms.  Expts. to suggest that α2-δ ligands act to suppress the development and maintenance of central sensitization, as well as a discussion of the implications of α2-δ subtype localization and function, will also be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzlIxj5QQMrVg90H21EOLACvtfcHk0lgwY8iVy-lzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D&md5=12cbcf55d0e7524e0971c462e27a7271</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm060650z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060650z%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DCa2%252B%2520channel%2520alpha2-delta%2520ligands%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2569%26epage%3D2575%26doi%3D10.1021%2Fjm060650z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, Y.</span></span> <span> </span><span class="NLM_article-title">Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.247551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1124%2Fjpet.117.247551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=29563324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2018&pages=573-582&author=Y.+Domonauthor=N.+Arakawaauthor=T.+Inoueauthor=F.+Matsudaauthor=M.+Takahashiauthor=N.+Yamamuraauthor=K.+Kaiauthor=Y.+Kitano&title=Binding+characteristics+and+analgesic+effects+of+mirogabalin%2C+a+novel+ligand+for+the+%CE%B12%CE%B4+subunit+of+voltage-gated+calcium+channels&doi=10.1124%2Fjpet.117.247551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the a2d subunit of voltage-gated calcium channels</span></div><div class="casAuthors">Domon, Yuki; Arakawa, Naohisa; Inoue, Tatsuya; Matsuda, Fumihiko; Takahashi, Makoto; Yamamura, Naotoshi; Kai, Kiyonori; Kitano, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-582</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In the present study, we investigated the in vitro binding characteristics and in vivo analgesic effects of mirogabalin compared with those of pregabalin, a std. a2d ligand.  Mirogabalin showed potent and selective binding affinities for the a2d subunits, while having no effects on 186 off-target proteins.  Similar to pregabalin, mirogabalin did not show clear subtype selectivity (a2d-1 vs. a2d-2) or species differences (human vs. rat).  However, in contrast to pregabalin, mirogabalin showed greater binding affinities for human a2d-1, human a2d-2, rat a2d-1, and rat a2d-2 subunits; further, it had a slower dissocn. rate for the a2d-1 subunit than the a2d-2 subunit.  In safety pharmacol. evaluations, mirogabalin and pregabalin inhibited rota-rod performance and locomotor activity in rats; however, the safety indexes of mirogabalin were superior to those of pregabalin.  In conclusion, mirogabalin shows potent and selective binding affinities for the human and rat a2d subunits, and slower dissocn. rates for the a2d-1 subunit than the a2d-2 subunit.  It shows potent and long-lasting analgesic effects in rat models of neuropathic pain, and wider safety margins for side effects of the central nervous system.  These properties of mirogabalin can be assocd. with its unique binding characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpJ0JBnhkh7Vg90H21EOLACvtfcHk0lgSyxzixDQp1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP&md5=e0c0b3f89de15327211551395f4db648</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.247551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.247551%26sid%3Dliteratum%253Aachs%26aulast%3DDomon%26aufirst%3DY.%26aulast%3DArakawa%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DYamamura%26aufirst%3DN.%26aulast%3DKai%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DY.%26atitle%3DBinding%2520characteristics%2520and%2520analgesic%2520effects%2520of%2520mirogabalin%252C%2520a%2520novel%2520ligand%2520for%2520the%2520%25CE%25B12%25CE%25B4%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D365%26spage%3D573%26epage%3D582%26doi%3D10.1124%2Fjpet.117.247551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Mirogabalin: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1007%2Fs40265-019-01070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=30778848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=463-468&author=E.+D.+Deeks&title=Mirogabalin%3A+First+global+approval&doi=10.1007%2Fs40265-019-01070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mirogabalin: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Mirogabalin besylate (hereafter mirogabalin) [Tarlige] is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia.  The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.  Mirogabalin has a unique binding profile and long duration of action.  The drug is approved in Japan for the treatment of PNP and is in clin. development for this indication elsewhere in Asia.  Clin. development of the drug for fibromyalgia pain was discontinued in the USA and EU after the primary endpoint was not met in phase 3 trials.  No recent reports of development have been identified for PNP in the USA or India or for fibromyalgia pain in Australia, India, New Zealand, Russia, Argentina, Belarus, Chile, Colombia, Israel, Mexico, Switzerland, Canada, Serbia or South Africa.  This article summarizes the milestones in the development of mirogabalin leading to this first approval for PNP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA8cUiDvLmPbVg90H21EOLACvtfcHk0lgSyxzixDQp1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D&md5=9a9b9f14f0190da528f3bc9b8cf277a7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01070-8%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DMirogabalin%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D463%26epage%3D468%26doi%3D10.1007%2Fs40265-019-01070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pracitto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boueres, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezverkov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span> <span> </span><span class="NLM_article-title">N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1913</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.01.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2004.01.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15050626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXislSqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1913-1916&author=J.+Limauthor=N.+Stockauthor=R.+Pracittoauthor=J.+K.+Boueresauthor=B.+Munozauthor=A.+Chaudharyauthor=A.+M.+Santiniauthor=K.+Orrauthor=H.+Schaffhauserauthor=R.+E.+Bezverkovauthor=J.+Aiyarauthor=S.+Venkatraman&title=N-Acridin-9-yl-butane-1%2C4-diamine+derivatives%3A+high-affinity+ligands+of+the+alpha2delta+subunit+of+voltage+gated+calcium+channels&doi=10.1016%2Fj.bmcl.2004.01.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the α2δ subunit of voltage gated calcium channels</span></div><div class="casAuthors">Lim, Jongwon; Stock, Nicholas; Pracitto, Richard; Boueres, Julia K.; Munoz, Benito; Chaudhary, Ashok; Santini, Angelina M.; Orr, Karia; Schaffhauser, Herve; Bezverkov, Robert E.; Aiyar, Jayashree; Venkatraman, Shankar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1913-1916</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of N-acridin-9-yl-butane-1,4-diamines were found to be high-affinity ligands of the α2δ subunit of voltage gated calcium channels.  The SAR studies of butane-1,4-diamine side chain resulted in the identification of a compd. (IC50=9 nM), which is more potent than gabapentin (IC50=27 nM).  Partial satn. of the acridine ring was also pursued and provided a compd. with higher binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgYEoxnJrQrVg90H21EOLACvtfcHk0lhYVXebyTFt5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXislSqur0%253D&md5=926c7235f48cf679b2ae788b38304067</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.01.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.01.087%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DStock%26aufirst%3DN.%26aulast%3DPracitto%26aufirst%3DR.%26aulast%3DBoueres%26aufirst%3DJ.%2BK.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DOrr%26aufirst%3DK.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DBezverkov%26aufirst%3DR.%2BE.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DN-Acridin-9-yl-butane-1%252C4-diamine%2520derivatives%253A%2520high-affinity%2520ligands%2520of%2520the%2520alpha2delta%2520subunit%2520of%2520voltage%2520gated%2520calcium%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1913%26epage%3D1916%26doi%3D10.1016%2Fj.bmcl.2004.01.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebsack, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pracitto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezverkov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span> <span> </span><span class="NLM_article-title">Identification and synthesis of [1,2,4]triazolo[3,4-<i>a</i>]phthalazine derivatives as high-affinity ligands to the α<sub>2</sub>δ-1 subunit of voltage gated calcium channel</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2463</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2004.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15109633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVKhtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2463-2467&author=A.+D.+Lebsackauthor=J.+Gunznerauthor=B.+Wangauthor=R.+Pracittoauthor=H.+Schaffhauserauthor=A.+Santiniauthor=J.+Aiyarauthor=R.+Bezverkovauthor=B.+Munozauthor=W.+Liuauthor=S.+Venkatraman&title=Identification+and+synthesis+of+%5B1%2C2%2C4%5Dtriazolo%5B3%2C4-a%5Dphthalazine+derivatives+as+high-affinity+ligands+to+the+%CE%B12%CE%B4-1+subunit+of+voltage+gated+calcium+channel&doi=10.1016%2Fj.bmcl.2004.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel</span></div><div class="casAuthors">Lebsack, Alec D.; Gunzner, Janet; Wang, Bowei; Pracitto, Richard; Schaffhauser, Herve; Santini, Angelina; Aiyar, Jayashree; Bezverkov, Robert; Munoz, Benito; Liu, Wensheng; Venkatraman, Shankar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2463-2467</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of [1,2,4]triazolo[3,4-a]phthalazine derivs. as high-affinity ligands to α2δ-1 subunit of voltage gated calcium channels were identified and synthesized.  Structure-activity relationship studies directed toward improving the potency and phys. properties of 6-[[[3-(5-methyl-3-isoxazolyl)-1,2,4-triazolo[3,4-a]phthalazin-6-yl]oxy]methyl]-N-(2-phenylethyl)-2-pyridinemethanamine lead to the discovery of N-[2-(3-methylphenyl)ethyl]-6-[[[3-(trifluoromethyl)-1,2,4-triazolo[3,4-a]phthalazin-6-yl]oxy]methyl]-2-pyridinemethanamine (I) (IC50=15 nM) and (αS)-α-mMethyl-N-(2-phenylethyl)-6-[[[3-(trifluoromethyl)-1,2,4-triazolo[3,4-a]phthalazin-6-yl]oxy]methyl]-2-pyridinemethanamine (II) (IC50=30 nM).  A potent and selective radioligand, [3H]-(S)-II was also synthesized to demonstrate that this ligand binds to the same site as gabapentin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJf9GjejcPx7Vg90H21EOLACvtfcHk0lhYVXebyTFt5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVKhtr0%253D&md5=779a5a5d41bebd35a8c1f169ad418e5f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DLebsack%26aufirst%3DA.%2BD.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DPracitto%26aufirst%3DR.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DBezverkov%26aufirst%3DR.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520synthesis%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B3%252C4-a%255Dphthalazine%2520derivatives%2520as%2520high-affinity%2520ligands%2520to%2520the%2520%25CE%25B12%25CE%25B4-1%2520subunit%2520of%2520voltage%2520gated%2520calcium%2520channel%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2463%26epage%3D2467%26doi%3D10.1016%2Fj.bmcl.2004.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arruda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sablad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 6-aryl-6<i>H</i>-pyrrolo[3,4-<i>d</i>]pyridazine derivatives: high-affinity ligands to the alpha 2 delta subunit of voltage gated calcium channels</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2003.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=14980685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFelsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1295-1298&author=B.+A.+Stearnsauthor=N.+Ankerauthor=J.+M.+Arrudaauthor=B.+T.+Campbellauthor=C.+Chenauthor=M.+Cramerauthor=T.+Huauthor=X.+Jiangauthor=K.+Parkauthor=K.+K.+Renauthor=M.+Sabladauthor=A.+Santiniauthor=H.+Schaffhauserauthor=M.+O.+Urbanauthor=B.+Munoz&title=Synthesis+and+biological+evaluation+of+6-aryl-6H-pyrrolo%5B3%2C4-d%5Dpyridazine+derivatives%3A+high-affinity+ligands+to+the+alpha+2+delta+subunit+of+voltage+gated+calcium+channels&doi=10.1016%2Fj.bmcl.2003.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 6-aryl-6H-pyrrolo[3,4-d]pyridazine derivatives: high-affinity ligands to the α2δ subunit of voltage gated calcium channels</span></div><div class="casAuthors">Stearns, Brian A.; Anker, Naomi; Arruda, Jeannie M.; Campbell, Brian T.; Chen, Chixu; Cramer, Merryl; Hu, Tao; Jiang, Xiaohui; Park, Kenneth; Ren, Kun Kun; Sablad, Marciano; Santini, Angelina; Schaffhauser, Herve; Urban, Mark O.; Munoz, Benito</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1295-1298</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A novel class of 6-aryl-6H-pyrrolo[3,4-d]pyridazine ligands for the α2δ subunit of voltage-gated calcium channels has been described.  Substitutions in the aryl ring of the mol. were generally not tolerated, and resulted in diminished binding to the α2δ subunit.  Modifications to the pyridazine ring revealed numerous permissive substitutions, and detailed SAR studies were carried out in this portion of the mol.  Replacement of the pyridazine ring Me group with an aminomethyl functionality provided greatly improved potency over the initial lead.  The initial lead compd. (I) displayed good rat pharmacokinetic properties, and was shown to be efficacious in the Chung model for neuropathic pain in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8QWoFDPl0i7Vg90H21EOLACvtfcHk0lgoQdD05g-NNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFelsr8%253D&md5=a9c9fc444f324b4707b452ffbfea6b99</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DStearns%26aufirst%3DB.%2BA.%26aulast%3DAnker%26aufirst%3DN.%26aulast%3DArruda%26aufirst%3DJ.%2BM.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCramer%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DRen%26aufirst%3DK.%2BK.%26aulast%3DSablad%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DUrban%26aufirst%3DM.%2BO.%26aulast%3DMunoz%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25206-aryl-6H-pyrrolo%255B3%252C4-d%255Dpyridazine%2520derivatives%253A%2520high-affinity%2520ligands%2520to%2520the%2520alpha%25202%2520delta%2520subunit%2520of%2520voltage%2520gated%2520calcium%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1295%26epage%3D1298%26doi%3D10.1016%2Fj.bmcl.2003.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arruda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezverkov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 6-aryl-6<i>H</i>-pyrrolo[3,4-<i>d</i>]pyridazine derivatives as high-affinity ligands of the alpha(2)delta subunit of voltage-gated calcium channels</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2031</span>– <span class="NLM_lpage">2034</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2004.02.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15080973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2031-2034&author=T.+Huauthor=B.+A.+Stearnsauthor=B.+T.+Campbellauthor=J.+M.+Arrudaauthor=C.+Chenauthor=J.+Aiyarauthor=R.+E.+Bezverkovauthor=A.+Santiniauthor=H.+Schaffhauserauthor=W.+Liuauthor=S.+Venkatramanauthor=B.+Munoz&title=Synthesis+and+biological+evaluation+of+6-aryl-6H-pyrrolo%5B3%2C4-d%5Dpyridazine+derivatives+as+high-affinity+ligands+of+the+alpha%282%29delta+subunit+of+voltage-gated+calcium+channels&doi=10.1016%2Fj.bmcl.2004.02.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 6-aryl-6H-pyrrolo[3,4-d]pyridazine derivatives as high-affinity ligands of the α2δ subunit of voltage-gated calcium channels</span></div><div class="casAuthors">Hu, Tao; Stearns, Brian A.; Campbell, Brian T.; Arruda, Jeannie M.; Chen, Chixu; Aiyar, Jayashree; Bezverkov, Robert E.; Santini, Angelina; Schaffhauser, Herve; Liu, Wensheng; Venkatraman, Shankar; Munoz, Benito</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2031-2034</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">2H-pyrrolo[3,4-c]pyridazines I (R = 4-EtOC6H4, 2-EtO-5-pyridinyl, 5-EtO-2-pyridinyl, 5-EtO-2-pyrazinyl, 4-EtO-1-pyridazinyl, 2-EtO-5-pyrimidinyl, etc.) such as II (R1 = H, MeO, Et, H2C:CH, Me, MeS, EtO, F; R2 = H, Me; R3 = H, Me, Cl, HOCH2; R4 = H, Me) are prepd. as ligands for the α2δ subunit of voltage-gated calcium channels.  Ortho-substituents capable of electron-donation increase the binding of II to the α2δ subunit of voltage-gated calcium channels; electron-withdrawing substituents in the ortho-position of II decrease binding significantly.  II (R1 = MeO; R2 = R3 = R4 = H) binds to the α2δ subunit of voltage-gated calcium channels from A710 cells with an IC50 value of 4 nM.  Testing of tritiated ligand II (R1 = TCH2TCH; R2 = R3 = R4 = H) in purified human α2δ voltage-gated calcium channel subunits indicates that II displace Gabapentin from the α2δ subunit of voltage-gated calcium channels, and thus act as Gabapentin mimics in vitro.  In the prepn. of II (R1 = Et; R2 = R3 = R4 = H), a novel metal-free hydrogenation is used using hydrazine as the reductant; the redn. is effective in other systems (no data).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Go-zcrg8e7Vg90H21EOLACvtfcHk0ljyqFGFbTSUpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVeht7s%253D&md5=80953eb8562c85bd45478aa3a7613ebe</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.070%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DT.%26aulast%3DStearns%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DArruda%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DBezverkov%26aufirst%3DR.%2BE.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DMunoz%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25206-aryl-6H-pyrrolo%255B3%252C4-d%255Dpyridazine%2520derivatives%2520as%2520high-affinity%2520ligands%2520of%2520the%2520alpha%25282%2529delta%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2031%26epage%3D2034%26doi%3D10.1016%2Fj.bmcl.2004.02.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arruda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span> <span> </span><span class="NLM_article-title">Expedited SAR study of high-affinity ligands to the α2δ subunit of voltage-gated calcium channels: generation of a focused library using a solution-phase Sn2Ar coupling methodology</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.08.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2005.08.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=16321528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlChsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=746-749&author=C.+Chenauthor=B.+Stearnsauthor=T.+Huauthor=N.+Ankerauthor=A.+Santiniauthor=J.+M.+Arrudaauthor=B.+T.+Campbellauthor=P.+Dattaauthor=J.+Aiyarauthor=B.+Munoz&title=Expedited+SAR+study+of+high-affinity+ligands+to+the+%CE%B12%CE%B4+subunit+of+voltage-gated+calcium+channels%3A+generation+of+a+focused+library+using+a+solution-phase+Sn2Ar+coupling+methodology&doi=10.1016%2Fj.bmcl.2005.08.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Expedited SAR study of high-affinity ligands to the α2δ subunit of voltage-gated calcium channels: Generation of a focused library using a solution-phase Sn2Ar coupling methodology</span></div><div class="casAuthors">Chen, Chixu; Stearns, Brian; Hu, Tao; Anker, Naomi; Santini, Angelina; Arruda, Jeannie M.; Campbell, Brian T.; Datta, Purabi; Aiyar, Jayashree; Munoz, Benitio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">746-749</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The SAR of the lead compd. 3, a novel ligand for the α2δ subunit of voltage-gated calcium channels, was rapidly explored.  Utilizing a parallel soln.-phase Sn2Ar coupling approach, a focused library was obtained.  The library was evaluated in vitro and afforded a series of analogs with improved potencies.  The SAR trends of the library are also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLH-vOOdTSDrVg90H21EOLACvtfcHk0ljyqFGFbTSUpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlChsr7M&md5=522e81f7e3680e51a301cdac7ed742c1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.08.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.08.117%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DAnker%26aufirst%3DN.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DArruda%26aufirst%3DJ.%2BM.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DDatta%26aufirst%3DP.%26aulast%3DAiyar%26aufirst%3DJ.%26aulast%3DMunoz%26aufirst%3DB.%26atitle%3DExpedited%2520SAR%2520study%2520of%2520high-affinity%2520ligands%2520to%2520the%2520%25CE%25B12%25CE%25B4%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%253A%2520generation%2520of%2520a%2520focused%2520library%2520using%2520a%2520solution-phase%2520Sn2Ar%2520coupling%2520methodology%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D746%26epage%3D749%26doi%3D10.1016%2Fj.bmcl.2005.08.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myatt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravi, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billinton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livermore, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douault, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowedder, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, N. M.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4683</span>– <span class="NLM_lpage">4688</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2010.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=20566291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4683-4688&author=J.+W.+Myattauthor=M.+P.+Healyauthor=G.+S.+Braviauthor=A.+Billintonauthor=C.+N.+Johnsonauthor=K.+L.+Matthewsauthor=K.+S.+Janduauthor=W.+Mengauthor=A.+Herseyauthor=D.+G.+Livermoreauthor=C.+B.+Douaultauthor=J.+Witheringtonauthor=R.+A.+Bitauthor=J.+E.+Rowedderauthor=J.+D.+Brownauthor=N.+M.+Clayton&title=Pyrazolopyridazine+alpha-2-delta-1+ligands+for+the+treatment+of+neuropathic+pain&doi=10.1016%2Fj.bmcl.2010.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain</span></div><div class="casAuthors">Myatt, James W.; Healy, Mark P.; Bravi, Gianpaolo S.; Billinton, Andrew; Johnson, Christopher N.; Matthews, Kim L.; Jandu, Karamjit S.; Meng, Wenjing; Hersey, Anne; Livermore, David G.; Douault, Clement B.; Witherington, Jason; Bit, Rino A.; Rowedder, James E.; Brown, Jason D.; Clayton, Nick M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4683-4688</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Optimization of the novel alpha-2-delta-1 ligand 4 provided compds. 37 and 38 which have improved DMPK profiles, good in vivo analgesic activity and in vitro selectivity over alpha-2-delta-2.  An inhouse P-gp prediction program and the MetaSite software package were used to help solve the specific problems of high P-gp efflux and high in vivo clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7jBsZtS9et7Vg90H21EOLACvtfcHk0lgII6cgFYtcIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSrsr8%253D&md5=80ec48cdc22f23bb3b1297dbd3dea125</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DMyatt%26aufirst%3DJ.%2BW.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DBravi%26aufirst%3DG.%2BS.%26aulast%3DBillinton%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DJandu%26aufirst%3DK.%2BS.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLivermore%26aufirst%3DD.%2BG.%26aulast%3DDouault%26aufirst%3DC.%2BB.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DRowedder%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DJ.%2BD.%26aulast%3DClayton%26aufirst%3DN.%2BM.%26atitle%3DPyrazolopyridazine%2520alpha-2-delta-1%2520ligands%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4683%26epage%3D4688%26doi%3D10.1016%2Fj.bmcl.2010.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otsubo, N.</span>; <span class="NLM_string-name">Tsukumo, Y.</span>; <span class="NLM_string-name">Uchida, K.</span>; <span class="NLM_string-name">Matsymmoto, Y.</span>; <span class="NLM_string-name">Iida, K.</span>; <span class="NLM_string-name">Takada, H.</span>; <span class="NLM_string-name">Takizawa, F.</span>; <span class="NLM_string-name">Arai, H.</span>; <span class="NLM_string-name">Okazaki, S.</span>; <span class="NLM_string-name">Imaizumi, T.</span></span> <span> </span><span class="NLM_article-title">Pyrimidodiazepinone Derivatives</span>. <span class="NLM_patent">US20,100,190,775</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+Otsubo&author=Y.+Tsukumo&author=K.+Uchida&author=Y.+Matsymmoto&author=K.+Iida&author=H.+Takada&author=F.+Takizawa&author=H.+Arai&author=S.+Okazaki&author=T.+Imaizumi&title=Pyrimidodiazepinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOtsubo%26aufirst%3DN.%26atitle%3DPyrimidodiazepinone%2520Derivatives%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otsubo, N.</span>; <span class="NLM_string-name">Okazaki, S.</span>; <span class="NLM_string-name">Tsukumo, Y.</span>; <span class="NLM_string-name">Iida, K.</span>; <span class="NLM_string-name">Nakoji, M.</span></span> <span> </span><span class="NLM_article-title">Pyrimidodiazepinone Compounds</span>. <span class="NLM_patent">US20140171422</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=N.+Otsubo&author=S.+Okazaki&author=Y.+Tsukumo&author=K.+Iida&author=M.+Nakoji&title=Pyrimidodiazepinone+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOtsubo%26aufirst%3DN.%26atitle%3DPyrimidodiazepinone%2520Compounds%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ossipov, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussor, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span> <span> </span><span class="NLM_article-title">Central modulation of pain</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">3779</span>– <span class="NLM_lpage">3787</span>, <span class="refDoi"> DOI: 10.1172/JCI43766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1172%2FJCI43766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21041960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWgtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=3779-3787&author=M.+H.+Ossipovauthor=G.+O.+Dussorauthor=F.+Porreca&title=Central+modulation+of+pain&doi=10.1172%2FJCI43766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Central modulation of pain</span></div><div class="casAuthors">Ossipov, Michael H.; Dussor, Gregory O.; Porreca, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3779-3787</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  It has long been appreciated that the experience of pain is highly variable between individuals.  Pain results from activation of sensory receptors specialized to detect actual or impending tissue damage (i.e., nociceptors).  However, a direct correlation between activation of nociceptors and the sensory experience of pain is not always apparent.  Even in cases in which the severity of injury appears similar, individual pain experiences may vary dramatically.  Emotional state, degree of anxiety, attention and distraction, past experiences, memories, and many other factors can either enhance or diminish the pain experience.  Here, we review evidence for "top-down" modulatory circuits that profoundly change the sensory experience of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTLcjICoIRt7Vg90H21EOLACvtfcHk0lgII6cgFYtcIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWgtb3J&md5=af0ad2eaafb14fb0f3e7b2235ff1a40d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1172%2FJCI43766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI43766%26sid%3Dliteratum%253Aachs%26aulast%3DOssipov%26aufirst%3DM.%2BH.%26aulast%3DDussor%26aufirst%3DG.%2BO.%26aulast%3DPorreca%26aufirst%3DF.%26atitle%3DCentral%2520modulation%2520of%2520pain%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D3779%26epage%3D3787%26doi%3D10.1172%2FJCI43766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiroki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obata, H.</span></span> <span> </span><span class="NLM_article-title">Repeated administration of amitriptyline in neuropathic pain: modulation of the noradrenergic descending inhibitory system</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1213/ANE.0000000000002352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1213%2FANE.0000000000002352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=28787345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSksr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=1281-1288&author=T.+Hirokiauthor=T.+Sutoauthor=S.+Saitoauthor=H.+Obata&title=Repeated+administration+of+amitriptyline+in+neuropathic+pain%3A+modulation+of+the+noradrenergic+descending+inhibitory+system&doi=10.1213%2FANE.0000000000002352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System</span></div><div class="casAuthors">Hiroki, Tadanao; Suto, Takashi; Saito, Shigeru; Obata, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1281-1288</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The tricyclic antidepressant amitriptyline, the serotonin and noradrenaline reuptake inhibitor duloxetine, and gabapentinoids are first-line drugs for treatment of neuropathic pain.  The analgesic effect of these drugs relates to brainstem-spinal descending noradrenergic systems.  However, amitriptyline utilizes a variety of mechanisms for analgesia in neuropathic pain, and it is unclear which mechanism is most important.  In the present study, we investigated the role of descending noradrenergic systems in the analgesic effect of these drugs for treatment of neuropathic pain.  We also examd. whether amitriptyline modifies the descending noradrenergic systems.  Methods: Seven days after L5 spinal nerve ligation (SNL), rats received N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 50 mg/kg) to degenerate noradrenergic fibers.  The rats then received 5 daily i.p. injections of amitriptyline (10 mg/kg), duloxetine (10 mg/kg), pregabalin (10 mg/kg), or gabapentin (50 mg/kg) from 21 days after SNL surgery.  Paw withdrawal thresholds were detd. to assess the effect of the drugs on hyperalgesia after SNL.  To det. whether 5 daily injections of amitriptyline activated noradrenergic neurons in the locus coeruleus (LC) and spinal cord with or without DSP-4 treatment, we performed immunohistochem. using antibodies for c-Fos and dopamine beta-hydroxylase (DβH).  Results: Five daily injections of amitriptyline, duloxetine, pregabalin, and gabapentin exerted antihyperalgesic effects in SNL rats (P < .001; estd. treatment effect of amitriptyline [99% confidence interval]: 59.9 [35.1-84.7] g).  The antihyperalgesic effects of duloxetine, pregabalin, and gabapentin were reversed by pretreatment with DSP-4 (P < .001, resp.).  However, antihyperalgesia was still obsd. after treatment of amitriptyline in SNL rats with DSP-4 pretreatment (P < .001, 59.7 [30.0-89.3] g), and this analgesic effect was not reversed by the α2-adrenoceptor antagonist idazoxan (30μg).  Addnl., 5 daily injections of amitriptyline increased the ratio of c-Fos-immunoreactive (IR) cells in noradrenergic LC neurons in SNL rats with or without DSP-4 pretreatment (P < .001, resp.).  Five daily injections of amitriptyline increased DβH-IR in the LC and the spinal dorsal horn of SNL rats (P < .001, resp.).  With DSP-4 pretreatment, DβH-IR was dramatically decreased with or without 5 daily injections of amitriptyline (P < .001).  Conclusions: Five daily injections of amitriptyline produced antihyperalgesic effects against neuropathic pain despite suppression of noradrenergic descending inhibitory systems.  Amitriptyline activated LC neurons and increased noradrenergic fibers d. in SNL rats.  These results suggest that amitriptyline could still produce analgesia under pathol. dysfunction of the descending noradrenergic system.  Amitriptyline may enhance the analgesic effect of drugs for neuropathic pain that require normal descending noradrenergic inhibition to produce analgesia, such as serotonin and noradrenaline reuptake inhibitors and gabapentinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiJQx_fnmmhrVg90H21EOLACvtfcHk0lgII6cgFYtcIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSksr3E&md5=fd279a89377065235f7207e0ab279b90</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1213%2FANE.0000000000002352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252FANE.0000000000002352%26sid%3Dliteratum%253Aachs%26aulast%3DHiroki%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DObata%26aufirst%3DH.%26atitle%3DRepeated%2520administration%2520of%2520amitriptyline%2520in%2520neuropathic%2520pain%253A%2520modulation%2520of%2520the%2520noradrenergic%2520descending%2520inhibitory%2520system%26jtitle%3DAnesth.%2520Analg.%26date%3D2017%26volume%3D125%26spage%3D1281%26epage%3D1288%26doi%3D10.1213%2FANE.0000000000002352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartrick, C. T.</span></span> <span> </span><span class="NLM_article-title">Noradrenergic reuptake inhibition in the treatment of pain</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1834</span>, <span class="refDoi"> DOI: 10.1517/13543784.2012.731393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1517%2F13543784.2012.731393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=23043362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cks73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1827-1834&author=C.+T.+Hartrick&title=Noradrenergic+reuptake+inhibition+in+the+treatment+of+pain&doi=10.1517%2F13543784.2012.731393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Noradrenergic reuptake inhibition in the treatment of pain</span></div><div class="casAuthors">Hartrick, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1827-1834</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Noradrenergic reuptake inhibitors can be effective analgesics, finding application in a wide variety of clin. pain settings.  Due to a shift toward noradrenergic-mediated pain pathways following nerve injury, they are particularly well suited to the treatment of neuropathic pain.  This phenotypic shift makes neuropathic pain difficult to control with opioids alone; some noradrenergic reuptake inhibitors have demonstrated synergy with opioids.  Agents currently in early clin. trials are discussed and include both novel delivery of old drugs and the development of new drugs.  This review was limited to noradrenergic reuptake inhibitors and analgesia.  Literature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).  Topical drug delivery and the use of combinations of agents both topically and systemically are under active investigation.  The intrathecal delivery of noradrenergic reuptake inhibitors, allowing delivery directly to the central nervous system thus limiting systemic exposure, represents an exciting avenue of investigation.  Gaps in current knowledge have complicated the development of prophylactic therapies for susceptible individuals or preemptive intervention.  Disease-modifying agents and selective inhibitors would facilitate these treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27mIkUgNx3bVg90H21EOLACvtfcHk0lgDTk-uJQEyZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cks73J&md5=95310a229651b6e3ae91cc36325e92fa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.731393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.731393%26sid%3Dliteratum%253Aachs%26aulast%3DHartrick%26aufirst%3DC.%2BT.%26atitle%3DNoradrenergic%2520reuptake%2520inhibition%2520in%2520the%2520treatment%2520of%2520pain%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1827%26epage%3D1834%26doi%3D10.1517%2F13543784.2012.731393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulse, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering, A. E.</span></span> <span> </span><span class="NLM_article-title">Endogenous analgesic action of the pontospinal noradrenergic system spatially restricts and temporally delays the progression of neuropathic pain following tibial nerve injury</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1680</span>– <span class="NLM_lpage">1690</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.pain.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=23707289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=1680-1690&author=S.+W.+Hughesauthor=L.+Hickeyauthor=R.+P.+Hulseauthor=B.+M.+Lumbauthor=A.+E.+Pickering&title=Endogenous+analgesic+action+of+the+pontospinal+noradrenergic+system+spatially+restricts+and+temporally+delays+the+progression+of+neuropathic+pain+following+tibial+nerve+injury&doi=10.1016%2Fj.pain.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous analgesic action of the pontospinal noradrenergic system spatially restricts and temporally delays the progression of neuropathic pain following tibial nerve injury</span></div><div class="casAuthors">Hughes, S. W.; Hickey, L.; Hulse, R. P.; Lumb, B. M.; Pickering, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1680-1690</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pontospinal noradrenergic neurons form part of an endogenous analgesic system that suppresses acute pain, but there is conflicting evidence about its role in neuropathic pain.  We investigated the chronol. of descending noradrenergic control during the development of a neuropathic pain phenotype in rats following tibial nerve transection (TNT).  A lumbar intrathecal cannula was implanted at the time of nerve injury allowing administration of selective α-adrenoceptor (α-AR) antagonists to sequentially assay their effects upon the expression of allodynia and hyperalgesia.  Following TNT animals progressively developed mech. and cold allodynia (by day 10) and subsequently heat hypersensitivity (day 17).  Blockade of α2-AR with intrathecal yohimbine (30 μg) revealed earlier ipsilateral sensitization of all modalities while prazosin (30 μg, α1-AR) was without effect.  Established allodynia (by day 21) was partly reversed by the re-uptake inhibitor reboxetine (5 μg, i.t.) but yohimbine no longer had any sensitizing effect.  This loss of effect coincided with a redn. in the descending noradrenergic innervation of the ipsilateral lumbar dorsal horn.  Yohimbine reversibly unmasked contralateral hindlimb allodynia and hyperalgesia of all modalities and increased dorsal horn c-fos expression to an innocuous brush stimulus.  Contralateral thermal hyperalgesia was also reversibly uncovered by yohimbine administration in a contact heat ramp paradigm in anesthetized TNT rats.  Following TNT there is an engagement of inhibitory α2-AR-mediated noradrenergic tone which completely masks contralateral and transiently suppresses the development of ipsilateral sensitization.  This endogenous analgesic system plays a key role in shaping the spatial and temporal expression of the neuropathic pain phenotype after nerve injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Mc9eIKPcurVg90H21EOLACvtfcHk0lgDTk-uJQEyZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyktbs%253D&md5=9b128e9c126bb7cf9da4c7c5d11d7d1d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%2BW.%26aulast%3DHickey%26aufirst%3DL.%26aulast%3DHulse%26aufirst%3DR.%2BP.%26aulast%3DLumb%26aufirst%3DB.%2BM.%26aulast%3DPickering%26aufirst%3DA.%2BE.%26atitle%3DEndogenous%2520analgesic%2520action%2520of%2520the%2520pontospinal%2520noradrenergic%2520system%2520spatially%2520restricts%2520and%2520temporally%2520delays%2520the%2520progression%2520of%2520neuropathic%2520pain%2520following%2520tibial%2520nerve%2520injury%26jtitle%3DPain%26date%3D2013%26volume%3D154%26spage%3D1680%26epage%3D1690%26doi%3D10.1016%2Fj.pain.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span>Available
from: <a href="https://www.fda.gov/consumers/consumer-updates/living-fibromyalgia-drugs-approved-manage-pain" class="extLink">https://www.fda.gov/consumers/consumer-updates/living-fibromyalgia-drugs-approved-manage-pain</a>. (accessed February 13, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Available%0Afrom%3A+https%3A%2F%2Fwww.fda.gov%2Fconsumers%2Fconsumer-updates%2Fliving-fibromyalgia-drugs-approved-manage-pain.+%28accessed+February+13%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dvoracsko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, A.</span></span> <span> </span><span class="NLM_article-title">The design of multitarget ligands for chronic and neuropathic pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.4155%2Ffmc.15.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=26652942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2469-2483&author=S.+Dvoracskoauthor=A.+Stefanucciauthor=E.+Novellinoauthor=A.+Mollica&title=The+design+of+multitarget+ligands+for+chronic+and+neuropathic+pain&doi=10.4155%2Ffmc.15.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The design of multitarget ligands for chronic and neuropathic pain</span></div><div class="casAuthors">Dvoracsko, Szabolcs; Stefanucci, Azzurra; Novellino, Ettore; Mollica, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2469-2483</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Monodrug therapy has been used with success to fight various pathologies.  When one medicine fails, co-administration of two or more drugs at the same time may be successfully applied in the treatment of infections, hypertension, HIV and in many other fields.  Discussion: This approach has some weakness related to the pharmacokinetic of the two different substances administered, side effects, possible drug-drug interaction.  Bivalent ligand approach would maintain the strength of the multidrug therapy (synergistic effect, lower doses, and little side effects) and overcome the weakness of a co-administration.  Conclusion: In this review we have described the state-of-the-art of the multitarget approach for the control of pain.  Several approaches adopted by different research groups and future perspectives have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEdmKaU-Blf7Vg90H21EOLACvtfcHk0lgDTk-uJQEyZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtL7K&md5=04d64c3fd3e5f442094cbd40ebf25303</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.156%26sid%3Dliteratum%253Aachs%26aulast%3DDvoracsko%26aufirst%3DS.%26aulast%3DStefanucci%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMollica%26aufirst%3DA.%26atitle%3DThe%2520design%2520of%2520multitarget%2520ligands%2520for%2520chronic%2520and%2520neuropathic%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2469%26epage%3D2483%26doi%3D10.4155%2Ffmc.15.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhosle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharambe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gairola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaneshwar, S. S.</span></span> <span> </span><span class="NLM_article-title">Mutual prodrug concept: fundamentals and applications</span>. <i>Indian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.4103/0250-474X.26654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.4103%2F0250-474X.26654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2006&pages=286-294&author=D.+Bhosleauthor=S.+Bharambeauthor=N.+Gairolaauthor=S.+S.+Dhaneshwar&title=Mutual+prodrug+concept%3A+fundamentals+and+applications&doi=10.4103%2F0250-474X.26654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Mutual prodrug concept: fundamentals and applications</span></div><div class="casAuthors">Bhosle, D.; Bharambe, S.; Gairola, Neha; Dhaneshwar, Suneela S.</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-294</span>CODEN:
                <span class="NLM_cas:coden">IJSIDW</span>;
        ISSN:<span class="NLM_cas:issn">0250-474X</span>.
    
            (<span class="NLM_cas:orgname">Indian Pharmaceutical Association</span>)
        </div><div class="casAbstract">A review.  A therapeutically significant drug may have limited utilization in clin. practice because of poor organoleptic properties, poor bioavailability, short duration of action, nonspecificity, incomplete absorption, poor aq. soly., high first-pass metab. or other adverse effects.  There is a great emphasis on research to discover methods aimed at improving their therapeutic efficacy by minimizing or eliminating these undesirable properties.  Sometimes, an adequate pharmaceutical formulation can overcome these drawbacks, but often the galenic formulation is inoperant and a chem. modification of active mol. is necessary to correct its pharmacokinetic insufficiencies.  This chem. formulation process, whose objective is to convert an interesting active mol. into a clin. acceptable drug, often involves the so-called 'Prodrug design.'.  Mutual prodrug is a type of carrier-linked prodrug, where the carrier used is another biol. active drug instead of some inert mol.  A mutual prodrug consists of two pharmacol. active agents coupled together so that each acts as a promoiety for the other agent and vice versa.  Mutual prodrug design is really no different from the general drug discovery process, in which a unique substance is obsd. to have desirable pharmacol. effects, and studies of its properties lead to the design of better drugs.  It is a very fruitful area of research, and its introduction in human therapy has given successful results in improving the clin. and therapeutic effectiveness of drugs suffering from some undesirable properties that otherwise hinder their clin. usefulness.  The present article takes a review of various applications of mutual prodrugs and the developments in this field during the last few decades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH3cW1cvTkVLVg90H21EOLACvtfcHk0lgwUvUxA6GzNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFOnt7k%253D&md5=3dcaac61d251a1027fe9d212d0aef51c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4103%2F0250-474X.26654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0250-474X.26654%26sid%3Dliteratum%253Aachs%26aulast%3DBhosle%26aufirst%3DD.%26aulast%3DBharambe%26aufirst%3DS.%26aulast%3DGairola%26aufirst%3DN.%26aulast%3DDhaneshwar%26aufirst%3DS.%2BS.%26atitle%3DMutual%2520prodrug%2520concept%253A%2520fundamentals%2520and%2520applications%26jtitle%3DIndian%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D68%26spage%3D286%26epage%3D294%26doi%3D10.4103%2F0250-474X.26654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Design strategies for bivalent ligands targeting GPCRs</span>. <i>Chem. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2Fcmdc.201100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21520422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=963-974&author=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Design+strategies+for+bivalent+ligands+targeting+GPCRs&doi=10.1002%2Fcmdc.201100101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Design Strategies for Bivalent Ligands Targeting GPCRs</span></div><div class="casAuthors">Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature.  The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity.  However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic mol. properties, such as high mol. wt. and lipophilicity.  This Minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and compn. of the spacer group.  Furthermore, this Minireview distills the mol. descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7uDrMXq0sprVg90H21EOLACvtfcHk0lgwUvUxA6GzNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D&md5=569a8a988cdd9d2daf8f492211303934</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100101%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DDesign%2520strategies%2520for%2520bivalent%2520ligands%2520targeting%2520GPCRs%26jtitle%3DChem.%2520Med.%2520Chem.%26date%3D2011%26volume%3D6%26spage%3D963%26epage%3D974%26doi%3D10.1002%2Fcmdc.201100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, F.</span>; <span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine Compounds for Treating Pain and Pain Related Conditions</span>.  <i>PCT Int. Appl</i>. <span class="NLM_patent">WO2017191304</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Cuevas&author=C.+Almansa&title=Tetrahydropyrimidodiazepine+and+tetrahydropyridodiazepine+Compounds+for+Treating+Pain+and+Pain+Related+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCuevas%26aufirst%3DF.%26atitle%3DTetrahydropyrimidodiazepine%2520and%2520tetrahydropyridodiazepine%2520Compounds%2520for%2520Treating%2520Pain%2520and%2520Pain%2520Related%2520Conditions%26jtitle%3DPCT%2520Int.%2520Appl%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span>; <span class="NLM_string-name">Cuevas, F.</span></span> <span> </span><span class="NLM_article-title">New Alcoxyamino Derivatives for Treating Pain and Pain Related Conditions</span>.  <i>PCT Int. Appl</i>. <span class="NLM_patent">WO2019081691</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Almansa&author=F.+Cuevas&title=New+Alcoxyamino+Derivatives+for+Treating+Pain+and+Pain+Related+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DNew%2520Alcoxyamino%2520Derivatives%2520for%2520Treating%2520Pain%2520and%2520Pain%2520Related%2520Conditions%26jtitle%3DPCT%2520Int.%2520Appl%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yenes, S.</span>; <span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Compounds Having Multimodal Activity Against Pain</span>. <span class="NLM_patent">WO2019002173</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Yenes&author=C.+Almansa&title=Compounds+Having+Multimodal+Activity+Against+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYenes%26aufirst%3DS.%26atitle%3DCompounds%2520Having%2520Multimodal%2520Activity%2520Against%2520Pain%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span> <span> </span><span class="NLM_article-title">Ca<sup>2+</sup> channel α<sub>2</sub>-δ ligands for the treatment of neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1021/jm060650z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060650z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2569-2575&author=M.+J.+Fieldauthor=Z.+Liauthor=J.+B.+Schwarz&title=Ca2%2B+channel+%CE%B12-%CE%B4+ligands+for+the+treatment+of+neuropathic+pain&doi=10.1021%2Fjm060650z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ Channel α2-δ Ligands for the Treatment of Neuropathic Pain</span></div><div class="casAuthors">Field, Mark J.; Li, Zheng; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2575</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Pregabalin was recently approved in the U.S. and Europe as an add- on therapy for epilepsy, as well as for the treatment of neuropathic pain.  In addn., pregabalin recently gained approval in the EU for the treatment of generalized anxiety disorder.  As a result of it's superior potency and pharmacokinetic profile compared to gabapentin, pregabalin has enjoyed rapid uptake by prescribing physicians for these conditions.  Pregabalin is thought to access the central nervous system (CNS) via the system L amino acid transporter and act via modulation of the α2-δ subunit of voltage-gated calcium channels.  Pregabalin is remarkably silent at all other known receptors (with the exception of being a substrate for the system L transmembrane amino acid transporter), and as a consequence, the α2-δ hypothesis is gaining traction as the accepted MOA of pregabalin.  Some excellent reviews categorizing the available evidence to elucidate the mechanism of gabapentin in neuropathic pain have recently appeared.  The purpose of this Miniperspective is to showcase the medicinal chem. efforts employed to obtain structurally diverse compds. with both reported affinity for the α2-δ subunit and in vivo activity in various neuropathic pain paradigms.  Expts. to suggest that α2-δ ligands act to suppress the development and maintenance of central sensitization, as well as a discussion of the implications of α2-δ subtype localization and function, will also be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzlIxj5QQMrVg90H21EOLACvtfcHk0lgwUvUxA6GzNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVKqsbc%253D&md5=12cbcf55d0e7524e0971c462e27a7271</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm060650z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060650z%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DCa2%252B%2520channel%2520%25CE%25B12-%25CE%25B4%2520ligands%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2569%26epage%3D2575%26doi%3D10.1021%2Fjm060650z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0li_1QsfkFYZpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span>. <i>Am. Soc. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DAm.%2520Soc.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span> <span> </span><span class="NLM_article-title">High-throughput Screening of Human Cytochrome P450 inhibitors Using Fluorometric Substrates. Methodology for 25 Enzyme/Substrate Pairs</span>. In  <i>Optimization in Drug Discovery. In vitro Methods</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span>; <span class="NLM_string-name">Caldwell, G.W.</span></span>; Eds. <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, New Jersey</span>, <span class="NLM_year">2004</span>; pp.  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">230</span>;</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1385%2F1-59259-800-5%3A215" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=215-230&author=D.+M.+Stresserauthor=Z.+Yan&author=G.W.+Caldwell&title=Optimization+in+Drug+Discovery.+In+vitro+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1385%2F1-59259-800-5%3A215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1385%252F1-59259-800-5%253A215%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26atitle%3DHigh-throughput%2520Screening%2520of%2520Human%2520Cytochrome%2520P450%2520inhibitors%2520Using%2520Fluorometric%2520Substrates.%2520Methodology%2520for%252025%2520Enzyme%252FSubstrate%2520Pairs%26btitle%3DOptimization%2520in%2520Drug%2520Discovery.%2520In%2520vitro%2520Methods%26aulast%3DYan%26aufirst%3DZ.%26pub%3DHumana%2520Press%26date%3D2004%26spage%3D215%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, G. W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Cytochrome P450 inhibition in Human Liver Microsomes</span>. <i>Optim. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1385/1-59259-800-5:231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1385%2F1-59259-800-5%3A231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosF2gs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=231-244&author=Z.+Yanauthor=G.+W.+Caldwell&title=Evaluation+of+Cytochrome+P450+inhibition+in+Human+Liver+Microsomes&doi=10.1385%2F1-59259-800-5%3A231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cytochrome P450 inhibition in human liver microsomes</span></div><div class="casAuthors">Yan, Zhengyin; Caldwell, Gary W.</div><div class="citationInfo"><span class="NLM_cas:title">Optimization in Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-244</span>CODEN:
                <span class="NLM_cas:coden">69FYUI</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Evaluation of lead compds. for P 450 inhibition in human liver microsomes has been widely accepted as an in vitro approach to assess drug interaction potential.  This chapter describes a detailed traditional CYP inhibition protocol for six major isoforms: 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4.  Microsomal incubation conditions were optimized and kinetic parameters detd. to initially establish the inhibition assay.  In CYP inhibition assay, sepd. incubations were performed for individual CYPs, and resulting samples were pooled and analyzed by liq. chromatog./tandem mass spectrometry (LC-MS/MS).  It is without doubt that results from this in vitro expt. are of great value in lead optimization in drug discovery and development.  It is obvious that more efforts are still needed to establish the relevance between in vitro CYP inhibition and drug interactions in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqruqDzG1DCgbVg90H21EOLACvtfcHk0li_1QsfkFYZpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosF2gs70%253D&md5=9d0186de8c2b16ee1de4a00cc89613b8</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1385%2F1-59259-800-5%3A231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-800-5%253A231%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DCaldwell%26aufirst%3DG.%2BW.%26atitle%3DEvaluation%2520of%2520Cytochrome%2520P450%2520inhibition%2520in%2520Human%2520Liver%2520Microsomes%26jtitle%3DOptim.%2520Drug%2520Discovery%26date%3D2004%26spage%3D231%26epage%3D244%26doi%3D10.1385%2F1-59259-800-5%3A231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit38c"><span><span class="NLM_label">(c) </span>Drug Interaction
Studies – Study Design, Data Analysis, Implications for Dosing
and Labeling. Center for Drug Evaluation and Research (CDER), Food
and Drug Administration, September 2006 and February 2012.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drug+Interaction%0AStudies+%E2%80%93+Study+Design%2C+Data+Analysis%2C+Implications+for+Dosing%0Aand+Labeling.+Center+for+Drug+Evaluation+and+Research+%28CDER%29%2C+Food%0Aand+Drug+Administration%2C+September+2006+and+February+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitza, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G. A.</span></span> <span> </span><span class="NLM_article-title">The [<sup>3</sup>H]-dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K<sup>+</sup>]<sub>o</sub></span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2004.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.vascn.2004.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=15519905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=187-199&author=G.+J.+Diazauthor=K.+Daniellauthor=S.+T.+Leitzaauthor=R.+L.+Martinauthor=Z.+Suauthor=J.+S.+McDermottauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+%5B3H%5D-dofetilide+binding+assay+is+a+predictive+screening+tool+for+hERG+blockade+and+proarrhythmia%3A+Comparison+of+intact+cell+and+membrane+preparations+and+effects+of+altering+%5BK%2B%5Do&doi=10.1016%2Fj.vascn.2004.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span></div><div class="casAuthors">Diaz, Gilbert J.; Daniell, Katina; Leitza, Sandra T.; Martin, Ruth L.; Su, Zhi; McDermott, Jeffrey S.; Cox, Bryan F.; Gintant, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization.  Drugs that block hERG have been assocd. with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes).  While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.Methods: To validate the utility of this assay as a screening tool, we performed a series of satn. and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane prepns. from HEK 293 cells stably transfected with hERG K+ channels.  The object of these expts. was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to det. whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concns. (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.Results: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block.Discussion: In conclusion, increasing K+ concns. results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates.  There are no meaningful differences between Ki values when comparing intact cell vs. membrane assay, neither are there meaningful trends with increasing [K+]o within assays.  There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concns. (R2 values of .824 and .863, resp.).  The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compds. for their potential to block the hERG K+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJEs_DWLzvI7Vg90H21EOLACvtfcHk0li5fPlRCTOwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D&md5=28c925ef02404c53443dc90eae961ed1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DDaniell%26aufirst%3DK.%26aulast%3DLeitza%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520%255B3H%255D-dofetilide%2520binding%2520assay%2520is%2520a%2520predictive%2520screening%2520tool%2520for%2520hERG%2520blockade%2520and%2520proarrhythmia%253A%2520Comparison%2520of%2520intact%2520cell%2520and%2520membrane%2520preparations%2520and%2520effects%2520of%2520altering%2520%255BK%252B%255Do%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2004%26volume%3D50%26spage%3D187%26epage%3D199%26doi%3D10.1016%2Fj.vascn.2004.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beedle, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span> <span> </span><span class="NLM_article-title">Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4477</span>– <span class="NLM_lpage">4480</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.08.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1016%2Fj.bmcl.2003.08.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=14643350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1yru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4477-4480&author=F.+P.+Bymasterauthor=E.+E.+Beedleauthor=J.+Findlayauthor=P.+T.+Gallagherauthor=J.+H.+Krushinskiauthor=S.+Mitchellauthor=D.+W.+Robertsonauthor=D.+C.+Thompsonauthor=L.+Wallaceauthor=D.+T.+Wong&title=Duloxetine+%28Cymbalta%29%2C+a+dual+inhibitor+of+serotonin+and+norepinephrine+reuptake&doi=10.1016%2Fj.bmcl.2003.08.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake</span></div><div class="casAuthors">Bymaster, F. P.; Beedle, E. E.; Findlay, J.; Gallagher, P. T.; Krushinski, J. H.; Mitchell, S.; Robertson, D. W.; Thompson, D. C.; Wallace, L.; Wong, D. T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4477-4480</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of naphthalenyloxy-substituted amines I (n = 2 - 4, R = H; n = 1, R = H, Ph, 4-FC6H4, 2-MeOC6H4, 2-furyl, 2-thienyl, 2-thiazolyl, etc.) has been prepd., and these compds. are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake.  One member of this series, duloxetine (Cymbalta), (S)-I (n = 1; R = 2-thienyl), has proven to be effective in clin. trials for the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa_uhGtxZMM7Vg90H21EOLACvtfcHk0li5fPlRCTOwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1yru7s%253D&md5=13292f56b0d5282e87b0a48217b5df48</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.08.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.08.079%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DBeedle%26aufirst%3DE.%2BE.%26aulast%3DFindlay%26aufirst%3DJ.%26aulast%3DGallagher%26aufirst%3DP.%2BT.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DMitchell%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26aulast%3DThompson%26aufirst%3DD.%2BC.%26aulast%3DWallace%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DD.%2BT.%26atitle%3DDuloxetine%2520%2528Cymbalta%2529%252C%2520a%2520dual%2520inhibitor%2520of%2520serotonin%2520and%2520norepinephrine%2520reuptake%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4477%26epage%3D4480%26doi%3D10.1016%2Fj.bmcl.2003.08.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhr-Hansen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachariassen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toubro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eildal, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo̷geso̷, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang-Andersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stro̷mgaard, K.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">12137</span>– <span class="NLM_lpage">12142</span>, <span class="refDoi"> DOI: 10.1073/pnas.1103060108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1073%2Fpnas.1103060108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=21730142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFyqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=12137-12142&author=J.+Andersenauthor=N.+Stuhr-Hansenauthor=L.+Zachariassenauthor=S.+Toubroauthor=S.+M.+Hansenauthor=J.+N.+Eildalauthor=A.+D.+Bondauthor=K.+P.+Bo%CC%B7geso%CC%B7author=B.+Bang-Andersenauthor=A.+S.+Kristensenauthor=K.+Stro%CC%B7mgaard&title=Molecular+determinants+for+selective+recognition+of+antidepressants+in+the+human+serotonin+and+norepinephrine+transporters&doi=10.1073%2Fpnas.1103060108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters</span></div><div class="casAuthors">Andersen, Jacob; Stuhr-Hansen, Nicolai; Zachariassen, Linda; Toubro, Soren; Hansen, Stinna M. R.; Eildal, Jonas N. N.; Bond, Andrew D.; Bogeso, Klaus P.; Bang-Andersen, Benny; Kristensen, Anders S.; Stromgaard, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">12137-12142, S12137/1-S12137/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Inhibitors of the serotonin transporter (SERT) and norepinephrine transporter (NET) are widely used in the treatment of major depressive disorder.  Although SERT/NET selectivity is a key determinant for the therapeutic properties of these drugs, the mol. determinants defining SERT/NET selectivity are poorly understood.  In this study, the structural basis for selectivity of the SERT selective inhibitor citalopram and the structurally closely related NET selective inhibitor talopram is delineated.  A systematic structure-activity relationship study allowed identification of the substituents that control activity and selectivity toward SERT and NET and revealed a common pattern showing that SERT and NET have opposite preference for the stereochem. configuration of these inhibitors.  Mutational anal. of nonconserved SERT/NET residues within the central substrate binding site was performed to det. the mol. basis for inhibitor selectivity.  Changing only five residues in NET to the complementary residues in SERT transferred a SERT-like affinity profile for R- and S-citalopram into NET, showing that the selectivity of these compds. is detd. by amino acid differences in the central binding site of the transporters.  In contrast, the activity of R- and S-talopram was largely unaffected by any mutations within the central substrate binding site of SERT and NET and in the outer vestibule of NET, suggesting that citalopram and talopram bind to distinct sites on SERT and NET.  Together, these findings provide important insight into the mol. basis for SERT/NET selectivity of antidepressants, which can be used to guide rational development of unique transporter inhibitors with fine-tuned transporter selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhxiOx9Fk-ObVg90H21EOLACvtfcHk0li5fPlRCTOwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFyqtb8%253D&md5=9cb2027b7ea4f4eedbe2865087cff5ce</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1103060108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1103060108%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DJ.%26aulast%3DStuhr-Hansen%26aufirst%3DN.%26aulast%3DZachariassen%26aufirst%3DL.%26aulast%3DToubro%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DS.%2BM.%26aulast%3DEildal%26aufirst%3DJ.%2BN.%26aulast%3DBond%26aufirst%3DA.%2BD.%26aulast%3DBo%25CC%25B7geso%25CC%25B7%26aufirst%3DK.%2BP.%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26aulast%3DStro%25CC%25B7mgaard%26aufirst%3DK.%26atitle%3DMolecular%2520determinants%2520for%2520selective%2520recognition%2520of%2520antidepressants%2520in%2520the%2520human%2520serotonin%2520and%2520norepinephrine%2520transporters%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D12137%26epage%3D12142%26doi%3D10.1073%2Fpnas.1103060108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goehring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penmatsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for action by diverse antidepressants on biogenic amine transporters</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1038/nature12648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1038%2Fnature12648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=24121440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSnsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=141-145&author=H.+Wangauthor=A.+Goehringauthor=K.+H.+Wangauthor=A.+Penmatsaauthor=R.+Resslerauthor=E.+Gouaux&title=Structural+basis+for+action+by+diverse+antidepressants+on+biogenic+amine+transporters&doi=10.1038%2Fnature12648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for action by diverse antidepressants on biogenic amine transporters</span></div><div class="casAuthors">Wang, Hui; Goehring, April; Wang, Kevin H.; Penmatsa, Aravind; Ressler, Ryan; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7474</span>),
    <span class="NLM_cas:pages">141-145</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The biogenic amine transporters (BATs) regulate endogenous neurotransmitter concns. and are targets for a broad range of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs).  Because eukaryotic BATs are recalcitrant to crystallog. anal., the authors' understanding of the mechanism of these inhibitors and antidepressants is limited.  LeuT is a bacterial homolog of BATs and has proven to be a valuable paradigm for understanding relationships between their structure and function.  However, because only approx. 25% of the amino acid sequence of LeuT is in common with that of BATs, and as LeuT is a promiscuous amino acid transporter, it does not recapitulate the pharmacol. properties of BATs.  Indeed, SSRIs and TCAs bind in the extracellular vestibule of LeuT and act as non-competitive inhibitors of transport.  By contrast, multiple studies demonstrate that both TCAs and SSRIs are competitive inhibitors for eukaryotic BATs and bind to the primary binding pocket.  Here the authors engineered LeuT to harbor human BAT-like pharmacol. by mutating key residues around the primary binding pocket.  The final LeuBAT mutant binds the SSRI sertraline with a binding const. of 18 nM and displays high-affinity binding to a range of SSRIs, SNRIs and a TCA.  The authors detd. 12 crystal structures of LeuBAT in complex with four classes of antidepressants.  The chem. diverse inhibitors have a remarkably similar mode of binding in which they straddle transmembrane helix (TM) 3, wedge between TM3/TM8 and TM1/TM6, and lock the transporter in a sodium- and chloride-bound outward-facing open conformation.  Together, these studies define common and simple principles for the action of SSRIs, SNRIs and TCAs on BATs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8AMnfh2-Af7Vg90H21EOLACvtfcHk0lhp79V_1-ZUdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSnsLrE&md5=26cc6cf173fdf20ec20d928d02f05193</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature12648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12648%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGoehring%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DPenmatsa%26aufirst%3DA.%26aulast%3DRessler%26aufirst%3DR.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DStructural%2520basis%2520for%2520action%2520by%2520diverse%2520antidepressants%2520on%2520biogenic%2520amine%2520transporters%26jtitle%3DNature%26date%3D2013%26volume%3D503%26spage%3D141%26epage%3D145%26doi%3D10.1038%2Fnature12648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">X-ray structures and mechanism of the human serotonin transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1038/nature17629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1038%2Fnature17629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=27049939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=334-339&author=J.+A.+Colemanauthor=E.+M.+Greenauthor=E.+Gouaux&title=X-ray+structures+and+mechanism+of+the+human+serotonin+transporter&doi=10.1038%2Fnature17629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structures and mechanism of the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Green, Evan M.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7599</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) terminates serotonergic signaling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons.  SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signaling.  Here the authors report x-ray crystallog. structures of human SERT at 3.15 Å resoln. bound to the antidepressants (S)-citalopram or paroxetine.  Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helixes 1, 3, 6, 8 and 10, directly blocking serotonin binding.  The authors further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helixes 1, 6, 10 and 11.  Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand.  These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAxl5tROCorVg90H21EOLACvtfcHk0lhp79V_1-ZUdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D&md5=e4fa11a1e5abdd7b39f44375506aa249</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnature17629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17629%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DE.%2BM.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DX-ray%2520structures%2520and%2520mechanism%2520of%2520the%2520human%2520serotonin%2520transporter%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D334%26epage%3D339%26doi%3D10.1038%2Fnature17629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razzetti, G.</span>; <span class="NLM_string-name">Allegrini, P.</span>; <span class="NLM_string-name">Pastorello, D.</span></span> <span> </span><span class="NLM_article-title">Process for the Synthesis of Pregabalin</span>. <span class="NLM_patent">US8063244B2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Razzetti&author=P.+Allegrini&author=D.+Pastorello&title=Process+for+the+Synthesis+of+Pregabalin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRazzetti%26aufirst%3DG.%26atitle%3DProcess%2520for%2520the%2520Synthesis%2520of%2520Pregabalin%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of Pan Assay Interference Compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lhp79V_1-ZUdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span>; <span class="NLM_string-name">Terricabras, E.</span>; <span class="NLM_string-name">Erra, M.</span>; <span class="NLM_string-name">Navarro, E.</span>; <span class="NLM_string-name">Fonquerna, S.</span>; <span class="NLM_string-name">Cardús, A</span>, <span class="NLM_string-name">Lozoya, M.</span></span> <span> </span><span class="NLM_article-title">Azabiphenylaminobenzoic Acid Derivatives as DHODH Inhibitors</span>. <span class="NLM_patent">WO2009021696</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+Castro&author=E.+Terricabras&author=M.+Erra&author=E.+Navarro&author=S.+Fonquerna&author=A+Card%C3%BAs&author=M.+Lozoya&title=Azabiphenylaminobenzoic+Acid+Derivatives+as+DHODH+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCastro%26aufirst%3DJ.%26atitle%3DAzabiphenylaminobenzoic%2520Acid%2520Derivatives%2520as%2520DHODH%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti–Renom, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudhan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eramian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span> <span> </span><span class="NLM_article-title">Comparative protein structure modeling using MODELLER</span>. <i>Curr. Protoc. Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5.6.1</span>– <span class="NLM_lpage">5.6.37</span>, <span class="refDoi"> DOI: 10.1002/0471140864.ps0209s50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2F0471140864.ps0209s50" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5.6.1-5.6.37&author=N.+Eswarauthor=B.+Webbauthor=M.+A.+Marti%E2%80%93Renomauthor=M.+S.+Madhusudhanauthor=D.+Eramianauthor=M.-Y.+Shenauthor=U.+Pieperauthor=A.+Sali&title=Comparative+protein+structure+modeling+using+MODELLER&doi=10.1002%2F0471140864.ps0209s50"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2F0471140864.ps0209s50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471140864.ps0209s50%26sid%3Dliteratum%253Aachs%26aulast%3DEswar%26aufirst%3DN.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DMarti%25E2%2580%2593Renom%26aufirst%3DM.%2BA.%26aulast%3DMadhusudhan%26aufirst%3DM.%2BS.%26aulast%3DEramian%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DM.-Y.%26aulast%3DPieper%26aufirst%3DU.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DComparative%2520protein%2520structure%2520modeling%2520using%2520MODELLER%26jtitle%3DCurr.%2520Protoc.%2520Protein%2520Sci.%26date%3D2007%26volume%3D50%26spage%3D5.6.1%26epage%3D5.6.37%26doi%3D10.1002%2F0471140864.ps0209s50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span>Discovery
Studio 16;
Dassault Systèmes BIOVIA: San Diego, CA, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Discovery%0AStudio+16%3B%0ADassault+Syst%C3%A8mes+BIOVIA%3A+San+Diego%2C+CA%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diller, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.</span></span> <span> </span><span class="NLM_article-title">High throughput docking for library design and library prioritization</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=11276081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2001&pages=113-124&author=D.+J.+Dillerauthor=K.+M.+Merz&title=High+throughput+docking+for+library+design+and+library+prioritization&doi=10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput docking for library design and library prioritization</span></div><div class="casAuthors">Diller, David J.; Merz, Kenneth M., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-124</span>CODEN:
                <span class="NLM_cas:coden">PSFGEY</span>;
        ISSN:<span class="NLM_cas:issn">0887-3585</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The prioritization of the screening of combinatorial libraries is an extremely important task for the rapid identification of tight binding ligands and ultimately pharmaceutical compds.  When structural information for the target is available, mol. docking is an approach that can be used for prioritization.  Here, we present the initial validation of a new rapid approach to mol. docking developed for prioritizing combinatorial libraries.  The algorithm is tested on 103 individual cases from the protein data bank and in nearly 90% of these cases docks the ligand to within 2.0 Å of the obsd. binding mode.  Because the mean CPU time is <5 s/mol, this approach can process hundreds of thousands of compds. per wk.  Furthermore, if a somewhat less thorough search is performed, the search time drops to 1 s/mol, thus allowing millions of compds. to be docked per wk and tested for potential activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRE1RQbB3WD7Vg90H21EOLACvtfcHk0lgaAEjN6s2wpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlels7c%253D&md5=a84ff9a463495594d85db465b27e9216</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0134%252820010501%252943%253A2%253C113%253A%253AAID-PROT1023%253E3.0.CO%253B2-T%26sid%3Dliteratum%253Aachs%26aulast%3DDiller%26aufirst%3DD.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26atitle%3DHigh%2520throughput%2520docking%2520for%2520library%2520design%2520and%2520library%2520prioritization%26jtitle%3DProteins%26date%3D2001%26volume%3D43%26spage%3D113%26epage%3D124%26doi%3D10.1002%2F1097-0134%2820010501%2943%3A2%3C113%3A%3AAID-PROT1023%3E3.0.CO%3B2-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span>Schrödinger
Release
2017-4: Maestro, Schrödinger, LLC, New York, NY, 2020.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schr%C3%B6dinger%0ARelease%0A2017-4%3A+Maestro%2C+Schr%C3%B6dinger%2C+LLC%2C+New+York%2C+NY%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K. J.</span>; <span class="NLM_string-name">Chow, E.</span>; <span class="NLM_string-name">Xu, H.</span>; <span class="NLM_string-name">Dror, R. O.</span>; <span class="NLM_string-name">Eastwood, M. P.</span>; <span class="NLM_string-name">Gregersen, B. A.</span>; <span class="NLM_string-name">Klepeis, J. L.</span>; <span class="NLM_string-name">Kolossvary, I.</span>; <span class="NLM_string-name">Moraes, M. A.</span>; <span class="NLM_string-name">Sacerdoti, F. D.</span>; <span class="NLM_string-name">Salmon, J. K.</span>; <span class="NLM_string-name">Shan, Y.</span>; <span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Scalable algorithms for Molecular Dynamics Simulations on commodity clusters</span>.  <i>Proceedings of the ACM/IEEE Conference on Supercomputing (SC06)</i>; <span class="NLM_publisher-loc">Tampa, Florida</span>, <span class="NLM_year">2006</span>, November  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">17</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=11-17&author=K.+J.+Bowers&author=E.+Chow&author=H.+Xu&author=R.+O.+Dror&author=M.+P.+Eastwood&author=B.+A.+Gregersen&author=J.+L.+Klepeis&author=I.+Kolossvary&author=M.+A.+Moraes&author=F.+D.+Sacerdoti&author=J.+K.+Salmon&author=Y.+Shan&author=D.+E.+Shaw&title=Scalable+algorithms+for+Molecular+Dynamics+Simulations+on+commodity+clusters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DK.%2BJ.%26atitle%3DScalable%2520algorithms%2520for%2520Molecular%2520Dynamics%2520Simulations%2520on%2520commodity%2520clusters%26jtitle%3DProceedings%2520of%2520the%2520ACM%252FIEEE%2520Conference%2520on%2520Supercomputing%2520%2528SC06%2529%26date%3D2006%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i59"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01867">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_04772"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01867?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01867</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data for all the final compounds and intermediates and HPLC traces for final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_002.csv">CSV</a>)</p></li><li><p class="inline">NET homology data for compound <b>31aS</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_001.pdf">jm0c01867_si_001.pdf (2.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_002.csv">jm0c01867_si_002.csv (5.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01867/suppl_file/jm0c01867_si_003.pdb">jm0c01867_si_003.pdb (774.11 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01867%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01867" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679aa3f34f213c64","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
